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Bryostatin 1 is a complex natural product that was originally isolated by Pettit 
from the bryozoan Bugula neritina. Its intriguing structural complexity and remarkable 
biological profile against several human diseases such as cancer, Alzheimer’s disease, 
HIV, and stroke have put bryostatin 1 in the forefront of research. The mechanism by 
which bryostatin mediates these effects are thought to be related to its ability to activate 
the protein kinase C (PKC) family of signaling enzymes. However, bryostatin is unique 
compared to most other known PKC activators such as the phorbol esters, as it is not a 
tumor promoter. The reasons behind bryostatin’s distinct biological profile remain 
unknown and are of great interest for the development new drug leads that target PKC. 
The work presented in this dissertation deals with the synthesis and biological 
evaluation of bryostatin 1 analogues modified in the northern hemisphere of the 
molecule. Specifically, the role of various substituents in the A and B ring region has 
been investigated by synthesizing Merle 30, 32, 34, and 38. This study suggested that 
these functional groups do not by themselves serve as functional switches between the 
PMA versus bryostatin 1-like activity of bryostatin analogues. Analogues with more 
polar groups in the A, B ring region tend to behave like bryostatin 1 as opposed to PMA. 
However, analogues with similar polarity in the northern hemisphere to that of bryostatin 
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CHAPTER 1 
 
STUDIES ON THE EFFECT OF THE C9 HYDROXY GROUP AND  
THE C8 GEM-DIMETHYL GROUP ON THE BIOLOGICAL  
PROFILE OF BRYOSTATIN 1  
 
Introduction 
Marine microbiology has recently become a popular area of research in pursuit of 
developing new drug candidates against various human ailments. In that context, marine 
bacterial species have gained tremendous attention due to their amazing ability to 
produce various small molecule natural products with varying degrees of structural 
complexities.1 One of the examples of such biologically interesting natural products 
isolated from the marine environment is bryostatin 1. Bryostatin 1 is the most extensively 
studied member of some 20 structurally related polyketide macrolide natural products. In 
1970, George Pettit and coworkers found that extracts from the marine bryozoan Bugula 
neritina from the Gulf of Mexico demonstrated antineoplastic properties.2 The original 
source of these agents was later found to be the bacterial endosymbiont Candidatus 
endobugula sertula.3 To date, 19 other members of the bryostatin family of natural 
products have been isolated.4 It was not until several years later in 1982 that the structure 
of bryostatin 1 was elucidated by pioneering work of the Pettit group.5 The same group in 
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1991 confirmed the absolute configuration of bryostatins using heavy atom dispersion 
effects in the X-ray structure of a p-bromobenzoate derivative of bryostatin 2.6 It was 
suggested that bryostatin acts as a deterrent against marine predators like fish and other 
organisms in protecting bryozoans; in return, the symbiotic bacteria gets a suitable 
environment to grow.7 The structures of bryostatins 1-20 are summarized in Figure 1.1. 
 
Structural features of the bryostatins 
Structural complexities of the bryostatins have inspired organic chemists since 
their discovery. All the members of the bryostatin family are characterized by 20-
membered macrolactones in which there are three highly substituted pyran rings 
embedded within the macrocycle; these are referred to as the A-, B-, and C-rings. The 
pyran rings are linked by a C16-C17 (E)-disubstituted olefin, gem-dimethyl functionality 
at C18, and a methylene bridge at C10. All the members also have a pair of geminal 
dimethyls at C8 and C18, as well as an exocyclic enoate at C13 and C21 in common. 
Besides their structural differences at C7 and C20, bryostatins 3, 19, and 20 have a fused 
butenolide to the C-ring. Bryostatins 10, 11, 13, 18, and 20 are all missing C20 
substitution and bryostatins 16 and 17 have a simplified C-ring in the form of a glycal. 
Bryostatins 17 and 18 have opposite methyl enoate geometry in the C-ring. Interestingly, 
neristatin 1, although not included in the bryostatin family, has striking similarity in 
structure with the members in the family.8 The crystal structure of bryostatin 1 solved by 
the Clardy group indicated the presence of an intramolecular transannular hydrogen-
bonding network between the C19 hydroxyl hydrogen atom and the C3 hydroxyl oxygen 
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Biological activities of bryostatins 
Initial reports on antineoplastic and cytostatic properties 
In 1970, Pettit and coworkers reported that they had observed 168-200% life 
extension using the extracts from the bryozoan Bugula neritina in murine P388 
lymphocytic leukemia (PS system) cell lines as developed by the NIH.2 Later in 1978, the 
same group reported that bryostatin 1 had shown 52-96% life extension at 10-70 
µg/(kg/injection dose) levels and an ED50 of 0.89 µg/mL against the murine P388 
lymphocytic leukemia (PS system) in vitro cell line.9 In 1983, the authors reported high 
potency of bryostatin 1 in the form of 34-51% life extension at 37.5-150 µg/kg for L1210 
lymphocytic leukemia cell lines and 40-48% life extension at 5-20 µg/kg for M5076 
ovarian carcinoma cells and 20-65% curative response in the tumor regression model at 
20-40 µg/kg for the same cell line.4a Bryostatin 2 was found to show 60% increase in life 
span at 30 µg/kg for the P388 cell line.4b Bryostatin 3 was also found to strongly inhibit 
growth of P388 cells in the form of 63% life extension at 30 µg/kg.4a Bryostatin 4 showed 
62% increase in life extension at 46 µg/kg with pronounced cell growth (P388 cell line 
ED50 of 10-3-10-4 µg/mL).4c Similarly various other members of the bryostatin family also 
showed antineoplastic properties, as tabulated in Table 1.10 Researchers from the Johns 
Hopkins Oncology Center found that maximum inhibition of leukemic growth in acute 
nonlymphocytic leukemia (ANLL) cells occurred at concentrations as low as 10-9 to 10-7 
mol/L bryostatin 1.11 Bryostatin 1 was also shown to have some growth inhibitory effect 
on the MCF-7 human breast cancer cells at relatively higher concentration of 100 nM.12 
DNA synthesis in the human lung cancer cell line A549 suffered 75% inhibition at 10 nM 




Table 1.1. ED50 values and life span extension data with various bryostatins 
Compounds ED50 (PS leukemia) Life span extensiona 
Bryostatin 1 10-4 µg/mL 52-96% at 10-70 µg/kg (P388) 
  34-51% at 37.5-150 µg/kg (L1210) 
  31-68% at 5-40 µg/kg (M531) 
Bryostatin 2 10-4 µg/mL 60% at 30 µg/kg (P388) 
Bryostatin 3  63% at 30 µg/kg (P388) 
Bryostatin 4 10-3-10-4 µg/mL 62% at 46 µg/kg (P388) 
Bryostatin 5 1.3 × 10-3-2.6 × 10-4 µg/mL 88% at 185 µg/kg (P388) 
Bryostatin 6 1.0 × 10-5 µg/mL 82% at 185 µg/kg (P388) 
Bryostatin 7 2.6 × 10-5 µg/mL 77% at 92 µg/kg (P388) 
Bryostatin 8  74% at 110 µg/kg (P388) 
Bryostatin 9 1.2 × 10-3 µg/mL 40% at 80 µg/kg (P388) 
Bryostatin 10 2.6 × 10-4 µg/mL 34% at 10 µg/kg (P388) 
Bryostatin 11 1.8 × 10-5 µg/mL 64% at 92.5 µg/kg (P388) 
Bryostatin 12 0.014 µg/mL 47-68% at 30-50 µg/kg (P388) 
Bryostatin 13 0.0054 µg/mL  







against solid tumor cell lines, including M5076 reticulum cell sarcoma and B-16 
melanoma, stimulated its development in the treatment of human cancers.14 Additionally, 
bryostatin 1 was also found to reverse multidrug resistance in various cancer cell lines.15    
 
Effects on hematopoiesis  
 Bryostatin 1 was found to stimulate blast forming unit-erythrocyte (BFU-E) 
granulocyte-macrophage colony forming unit (CFU-GM) in a concentration-dependent 
fashion, especially in the presence of interleukin 6 (IL-6) or granulocyte colony-
stimulating factor (G-CSF).16 Bryostatin 1 was also found to modulate the proliferation 
and lineage commitment of CD34+ cells in the presence of interleukin 3 (IL-3) or 
granulocyte-macrophage colony-stimulating factor (GM-CSF), resulting in an increase in 
macrophage/neutrophil colonies and a decrease in eosinophilic ones.17 However, single 
cell cultures of CD34+ cells were not stimulated by bryostatin 1 alone and later it was 
postulated that accessory cells such as T cells, stimulated by bryostatin 1, produce GM-
CSF and/or IL-3 and mediates the process.18 In another study with a bryostatin 1 sample 
supplied by Dr. G. R. Pettit, it was revealed that bryostatin 1 could, mediated by the 
secretion of tumor necrosis factor α (TNFα) by CD14+ cells, inhibit unpurified bone 
marrow progenitor cell colony formation.19  
 
Effects on immune functions    
 Initial studies with bryostatins revealed that they could increase cytotoxic T-cell 
proliferation and function via enhancing the functions of interleukins IL-2 and IL-4. IL-2 
receptor expression on CD4+ and CD8+ cells was triggered by bryostatin 1.20 
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Additionally, when lymphocytes obtained from tumor-draining lymph nodes in MCA-
105 tumor-bearing mice were incubated with the combination of bryostatin 1 and a 
calcium ionophore, followed by IL-2, these cells exhibited significant expansion in vitro 
and showed antitumor activity when injected back into the tumor-bearing mice.21 An in 
vitro linear relationship between the concentration of bryostatin 1 and the reduction of 
time to platelet activation, maximal rate of aggregation, and stimulated platelet ATP 
release was also observed.22 Bryostatin 1 was also found to activate monocytes in vitro.23 
Recent studies of bryostatin 1 have shown dual actions of bryostatin 1: inhibiting acute 
HIV-1 infection as well as reactivating latent HIV, without bystander T-cell activation or 
cytotoxicity.24 These results bring bryostatin 1 to the long queue of promising leads 
against HIV along with highly active antiretroviral treatment (HAART). 
 
Effects on cellular differentiation 
 Cellular differentiation of human promyelocytic leukemia cells (HL-60) is 
associated with a reduction in proliferation. Interestingly, bryostatin 1 was found to 
induce monocytic differentiation of HL-60 cells at nanomolar concentrations.25 
Bryostatin 1 was also found to stimulate differentiation in other promyelocytic leukemia 
cell lines, NB4 and acute myeloid leukemia (AML) cells, such as the myelomonocytic 
cell line U937.26  
 
Synergistic effects with other anticancer agents 
 Although bryostatin 1 showed promising antitumor activities as a single agent, the 
most exciting in vitro findings are related to its ability to sensitize to other anticancer 
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agents. Pre-incubation of AML blast cells with bryostatin 1 increases arabinofuranosyl 
cytidine (Ara-C)-induced apoptosis, which is likely the result of increased intracellular 
accumulation of a toxic metabolite 1-β-D-arabinofuranosylcytosine 5’-triphosphate (Ara-
CTP) (Table 1.2).27 WSU-CLL (now considered as pre-B cell leukemia REH cells28) 
severe combined immunodeficiency (SCID) mouse xenografts had an increase in tumor 
cell apoptosis using 2-chlorodeoxyadenosine (2-CDA) after pretreatment with bryostatin 
1.29 Bryostatin 1 enhanced the cytotoxic effects of taxol on U937 human leukemia cells, 
cisplatin on cervical carcinoma HeLa cells, and vincristine on WSU-DLCL2 B-cell non-
Hodgkin lymphoma cells.30 The combination of bryostatin 1 and vincristine eliminated 
tumor completely in 2 of 5 SCID mouse Waldenstrom’s macroglobulinaemia xenografts 
model while either agent alone could not cure any tumor.31 Additionally, bryostatin 1 
synergistically inhibited growth of murine leukemia P388 and showed synergism with  
 
Table 1.2. Synergism of bryostatin 1 with other anticancer agents in vitro32 
Tumor type (cell line) Anticancer agents 
AML Cytarabine (Ara-C) 
CLL (WSU-CLL)a 2-chlorodeoxyadenosine (2-CDA) 
Leukemia (U937) Paclitaxel 
NHL (WSU-DLCL2) Vincristine 
Cervix (HeLa) Cisplatin 
Waldenstrom’s Vincristine 
Breast Tamoxifen 
anow considered as pre-B cell leukemia REH cells28 
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auristatin PE and dolastatin 10 in WSU-CLL (now considered as pre-B cell leukemia 
REH cells28) cells.33 While bryostatin 1 showed some protective effects against radiation 
on CFU-GM cells, it was also shown to sensitize HL-60 cells to radiation without DNA 
fragmentation or increase in apoptosis.34 
 
Activities on central nervous system (CNS) functions 
 Daniel Alkon’s laboratory at the Blanchette Rockefeller Neurosciences Institute 
recently found that bryostatin 1 enhanced learning and memory, and showed 
antidepressant activity in Hermissenda and rat models.35 Bryostatin 1 was found to 
activate α-secretase at subnanomolar concentrations, thereby enhancing the secretion of 
α-secretase product soluble amyloid precursor protein (sAPP)α in fibroblasts from 
Alzheimer’s disease (AD) patients, and to reduce brain Aβ40 and Aβ42 accumulation in 
AD double-transgenic mice.36 Additionally, bryostatin 1 showed neuroprotective activity 
by rescuing ischemia-induced deficits in synaptogenesis.37    
 
Clinical trials with bryostatin 1 
Promising initial reports on bryostatin 1 inspired the entry of the marine natural 
product to clinical trials. Phase 1 studies of bryostatin 1 used as a single agent were not 
very encouraging and showed many side effects such as myalgia, nausea, anorexia, etc.38 
Interestingly, myelosuppression, a common toxicity associated with many conventional 
cytotoxic drugs, is not a side effect of bryostatin 1. This inspired bryostatin’s use in 
combination with other anticancer agents. Phase 1 trials in combination with paclitaxel 
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and cisplatin showed mild or no cases of myalgia. Dose-limiting toxicities included cases 
of tachyarrhythmia, neutropenia, nausea, and anorexia.39  
These promising results in phase 1 trials inspired phase 2 trials of bryostatin 1 as 
combined agents in chemotherapy against various cancers. Phase 2 clinical trials of 
bryostatin 1 in combination with vincristine, AraC, fludarabine, gemcitabine, and 
temsirolimus gave some promising results along with some inconsistent ones. Myalgia 
turned out to be a major issue in many cases.40 
Although continued clinical development of bryostatin 1 as an anticancer agent 
seems remote at this stage, renewed enthusiasm mounted due to its promising activities 
against Alzheimer’s disease. Recently, the National Health Institute (NIH) has approved 
a phase 1 clinical trial against AD.41 
 
Mechanism of action 
 The remarkable biological activities of bryostatins and more specifically 
bryostatin 1 has been attributed to the fact that bryostatin binds to protein kinase C (PKC) 
with subnanomolar affinity.42 A brief discussion on PKC follows next. 
 
Protein kinase C (PKC) enzyme 
 Nishizuka and coworkers first discovered the enzyme protein kinase C (PKC) as a 
proteolytically activated protein kinase in 1977.43 PKC is a group of serine/threonine 
kinases (PKC isozymes) that regulate a variety of cellular processes of signal 
transduction, including proliferation, apoptosis, differentiation, motility, adhesion, 
inflammation, etc.44 There is a substantial amount of evidence linking PKC to 
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tumorigenesis.45 However, studying the effects of PKC regulation or misregulation on 
these processes is impeded by the fact that each isozyme plays distinctive role in these 
processes in a cell-type-dependent manner.46 In order to understand various PKC 
functions, it is important to identify the structural features and the various structural 
changes that occur during PKC activation.47 
 PKC isozymes can be grouped into three subclasses, namely conventional or 
classical PKCs (cPKCs), novel PKCs (nPKCs), and atypical PKCs (aPKCs), on the basis 
of the structural composition of the regulatory domain (Figure 1.2). This composition, in 
turn, determines cofactor-dependence of the isozymes. The membrane-targeting module  
 
 
Figure 1.2. Primary structures of cPKCs, nPKCs, and aPKCs. 
 
All the kinases have a conserved kinase core (colored green) and vary in the nature of the 
regulatory domain. The kinase cores contain activation loops; turn motifs, and 
hydrophobic motifs. The regulatory domains contain a pseudosubstrate in all kinases. 
They differ mainly in the composition of membrane targeting modules. (Please see text 
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is made of C1 and C2 domains. 
The cysteine (Cys)-rich C1 domain is present in all PKC isozymes. It has a 
binding site for the endogenous ligand, diacylglycerol (DAG). cPKCs and nPKCs have 
two repetitive C1 domains, but evidence suggests that only one is engaged in ligand 
binding in vivo. For certain isozymes, like PKCδ, it is the C1B domain that binds to DAG 
or other ligands. For others, such as PKCα, the C1A and C1B domains have equal roles 
in targeting PKC to membranes. For aPKCs, the C1 domain ligand-binding pocket is 
impaired and cannot bind to DAG. As the C1 domain is found in many nonkinase 
enzymes (such as RasGRP1, Munc13-1, etc.), PKCs are not unique in responding to 
DAG and other C1 domain-binding ligands.48 
 The C2 domain is present in both conventional and novel PKCs. In cPKCs, this 
domain serves the purpose of a membrane-targeting module that binds anionic 
phospholipids in a Ca2+-dependent manner. Novel PKCs lack the key residues involved 
in binding Ca2+ and, as a result, they do not bind Ca2+ or phosphatidylserine (PS, a 
phospholipid component). Atypical PKCs do not have the C2 domain; instead, they have 
a protein-protein interaction PB1 domain. All the PKCs contain a pseudosubstrate 
sequence that binds to the substrate-binding pocket of PKCs while at rest in an inactive 
conformation.47a 
 The catalytic domain consists of the kinase core and is highly conserved across all 
the kinases. The ATP- and substrate-binding site is located in this portion. This portion 
also contains the activation loop, the turn motif, and the hydrophobic motif. 
 Various experiments revealed that newly synthesized PKC associates with a 
membrane compartment in the cell and remains in an open conformation, in which the 
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autoinhibitory pseudosubstrate is not bound to the substrate-binding cavity.49 This species 
of PKC is tethered at the membrane by multiple weak interactions that comprise of weak 
interaction of the C1 and C2 domain to anionic lipids and interaction of the basic 
pseudosubstrate with anionic lipids.50 In this open conformation, the unphosphorylated 
hydrophobic motif near the C-terminus provides a docking site for 3-phosphoinositide-
dependent protein kinase-1 (PDK-1).51 PDK-1 phosphorylates the activation loop present 
nearby on the kinase core and is released from the docking site. The activation loop 
phosphorylates the turn motif and the hydrophobic motif via an intramolecular 
autophosphorylation mechanism in the case of cPKCs.52 Phosphorylation of the C-
terminal sites results in various conformational changes, thereby locking PKC into a 
thermally stable conformation. Several reports suggest that phosphorylation of the C-
terminus frees the substrate-binding cavity to bind the pseudosubstrate.53 This forces 
PKC to adopt a closed conformation, to lose its primary membrane anchor, and localize 
to the cytosol. This species of PKC is known as the mature species. Various signaling 
pathways elevate Ca2+ levels inside the cell, thereby enabling the C2 domain to bind to 
Ca2+ in cytosolic PKC.54 Next, diffusion-controlled collisions with the membrane enable 
the C2 domain to bind to the membrane in a weak interaction. The tethered PKC then 
finds the membrane-bound ligand DAG and binds to it via a high-affinity interaction with 
the C1 domain.55 The energy released in the process is used to undock the 
pseudosubstrate from the substrate-binding cavity. In this open conformation, mature 
PKC binds substrates and effects postphosphorylation downstream signaling. As the 
nPKCs do not bind to Ca2+, their rate of translocation to the membrane is an order lower 
than the cPKCs and depends on the decreased probability of finding DAG. Although 
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PKCs at this stage are highly sensitive towards dephosphorylation, molecular chaperone 
Hsp70 enables the rephosphorylation of PKCs.56 In the absence of such a process, 
dephosphorylated PKC localizes to the detergent-insoluble fraction of cells, where it is 
eventually proteolysed via various pathways (Figure 1.3). 
 
PKC as potential therapeutic target 
 Since their discovery more than 35 years ago, an enormous amount of research 
work implicated PKC in almost every cellular process of signal transduction.45 PKC 
isoforms are now believed to have both positive and negative influences on proliferation. 
PKCα, the most studied PKC isoform, can be antiproliferative as well as pro-
proliferative.57 PKCδ was found to influence cell cycle progression by preventing cells 
from entering S-phase and M-phase. However, it also activated the MAPK pathway, 
thereby having proliferative effects.45 PKCβ and PKCε were found to play crucial roles in 
differentiation.58 PKC can regulate the transport of integrins to and from the plasma 
membrane and the presence of integrins at the cell surface is key to proper cell adhesion. 
Both PKCα and PKCε associate with integrins.59 PKC isoforms can also phosphorylate 
myristoylated alanine-rich C-kinase substrate (MARCKS). Consequently, this protein 
loses its membrane-binding ability and dissociates from the plasma membrane. This can, 
in turn, facilitate dissociation of the actin cytoskeleton from plasma membrane.60 Several 
PKC isoforms (PKCδ, ε, θ, and ζ) are substrates for the enzymes that execute programed 
cell death, known as caspases. Caspases cleave PKCs in the hinge region and release a 
constitutively active catalytic domain, which has pro-apoptotic activity.61 Formation of β-


























The amyloidogenic Aβ fragment results from β-secretase-mediated cleavage of amyloid 
precursor protein (APP) to generate an NH2 terminus and a further cleavage by γ-
secretase to generate Aβ peptide that can oligomerize to generate plaques. On the other 
hand, α-secretase-mediated cleavage of APP at a different site generates soluble APP 
(sAPP), which is considered to be nontoxic. PKC isozymes α, ε, and possibly other 
isozymes can activate the α-secretase-mediated cleavage of sAPP directly or indirectly 
through phosphorylation of extracellular-signal-regulated kinase (ERK1/2). Evidence 
suggests that sAPP production by α-secretase competitively reduces Aβ production by the 
β- and γ-secretases.63 Although PKC is involved in many cellular functions, the 
mechanisms of actions depend on specific context, isoform types, and cell types. To 
understand the mechanisms in greater detail, it is important to find out the various factors 
that determine PKC actions.  
 
Phorbol esters as potent PKC modulators 
Various natural products can be used as tools for identifying molecular targets and 
this information can lead to the development of various lead compounds for fighting 
human ailments. The phorbol esters are one of the prime examples of this idea, especially 
regarding PKC (Figure 1.4). Phorbol esters were isolated and identified from croton oil, 
the seed oil from Croton tiglium.64 The croton oil was known as an irritant and later 
found to promote tumor formation in the two-stage model of mouse skin 
carcinogenesis.65 Phorbol 12-myristate 13-acetate (PMA) was found to be the most potent 
of all the compounds isolated but was too lipophilic for target identification. A designed 




Figure 1.4. Molecular structures of various phorbol related compounds 
 
and characterization of a specific receptor for the phorbol esters, thanks to the Blumberg 
group.66 Later in a hallmark work by Nishizuka, et al., it was established that PKC was 
indeed the molecular target for phorbol esters.67 Around the same time, in a further 
enlightening work by Kraft, et al., translocation of PKC by phorbol esters was found to 
depend on lipophilicity of those esters.68 All these results and the research that followed 
since then have firmly put phorbol esters into a pharmacological context. However, as 
mentioned earlier, PKC is not the sole target for DAG/ phorbol esters and at least 20 
different C1 domain-containing transducing proteins bind with DAG/ phorbol esters and 
result in an extensive network of downstream signaling. The outstanding questions that 







































































pathways chosen by cells. Are there any ways for the small molecules (DAG, phorbol 
esters) to differentiate between various target proteins and their signaling pathways? 
A step towards answering these questions was provided by Hecker and 
coworkers, who demonstrated that different phorbol derivatives could induce different 
patterns of biological response. This indicated that it would be possible to structurally 
manipulate the ligands to affect subpathways of response.69 It was further shown by 
Blumberg, et al. that prostratin, although a phorbol ester, is not a tumor-promoter and 
inhibited PMA-induced tumor promotion in CD-1 mouse skin.70  
 
Differential effects of bryostatin 1 and phorbol esters 
Bryostatin 1 was initially shown to be a potent PKC ligand and had similar effects 
to those of the phorbol esters.42, 71 Later, it was found that in some instances, bryostatin 1 
failed to induce a typical phorbol ester-like response and more importantly blocked 
phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.72 
This antagonism was found to be the general trend for bryostatin 1 rather than an 
exception. Bryostatin 1 lifted the phorbol ester-induced blockage of differentiation in 
hexamethylene bisacetamide-treated Friend erythroleukemia cells.73 Bryostatin 1 was 
also found to restore cell-cell communication that was blocked by phorbol esters.74 In a 
very important observation, Blumberg’s laboratory found that bryostatin 1 failed to 
function as a tumor promoter in mouse skin and indeed inhibited tumor promotion by 
phorbol ester.75  
 Another aspect of mechanistic difference between bryostatin 1 and PMA was 
observed in studies on the downregulation of PKC isoforms. PMA and bryostatin 1 both 
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caused dose-dependent downregulation of PKCα but for PKCδ, PMA and bryostatin 1 
had differential effects. PMA downregulated PKCδ but bryostatin 1 afforded a biphasic 
pattern, with maximal downregulation at low doses and protection of PKCδ from 
downregulation at higher doses.76 This effect appeared to have a direct correlation with 
the observation from Blumberg laboratory that suppression of PKCδ expression with 
siRNA rendered the proliferative response insensitive to bryostatin 1 and overexpression 
of PKCδ inhibited cell growth in HOP92 cells. These results are consistent with the usual 
antiproliferative effect of PKCδ.77 
 Mechanistic differences between bryostatin 1 and PMA were also observed in the 
studies of translocation patterns of PKCδ. PMA induces translocation initially to the 
plasma membrane and subsequently to the internal membranes and the nuclear 
membrane. Bryostatin 1, on the other hand, induces translocation directly to these 
internal membranes, with little or no translocation to the plasma membrane.78 
 
Nature of interactions between ligands and C1 domain 
 Various NMR studies on the structure of DAG-responsive C1 domains along with 
a crystal structure of phorbol ester bound to C1B domain of PKCδ have revealed a 
detailed picture of how the C1 domain functions as a hydrophobic switch.79 The phorbol 
ester binds to the hydrophilic cleft formed by the pulled apart strands of a β-sheet at the 
top of the C1B domain. The surface surrounding this cleft is hydrophobic and phorbol 
ester, upon binding, completes the hydrophobic surface. This, in turn, favors binding of 
the C1 domain – phorbol ester complex into the lipid membrane. The C1 domain does not 
change conformation significantly upon phorbol ester binding and this rules out any 
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allosteric regulation for its mode of action. Instead, the binding changes the association 
preference of the hydrophobic face of the C1 domain. For various ligands, the coverage 
of the hydrophilic cleft of the C1 domain could be similar (discussed more later). 
However, the diverse forms of hydrophobic side chains projecting from the ligand can be 
of special significance. As mentioned earlier, different acyl substituents on the phorbol 
ester can lead to very different biological responses (prostratin versus PMA). As 
mentioned earlier, the C1 domain binds to the plasma membrane and then finds its ligand 
DAG. However, this binding is an equilibrium process and the association with the ligand 
stabilizes the binding, making the rate of dissociation slower and shifting the equilibrium 
towards binding to the membrane. This process, expectedly, can be regulated by the 
ligands like phorbol esters. For relatively hydrophilic ligands, their increased presence in 
the cytosol may implicate a prior binding to the C1 domain.80  
Additionally, the actual binding of ligand with the C1 domain is measured in the 
presence of phospholipid, which forms the ternary complex of ligand – C1 domain – 
lipid. Therefore, the interaction with lipid also needs to be considered while investigating 
the biological profile of the ligands.  
Finally, an interesting observation made by the Blumberg group needs to be 
mentioned at this point. Tumor promoters like PMA and the indole alkaloids like 
indolactam and octylindolactam were selectively dependent on the C1B domain of PKCδ 
in mouse 3T3 cells, whereas compounds that were not tumor promoters such as 
prostratin, mezerein, or 12-deoxyphorbol 13-phenylacetate, bryostatin 1 bound to both 




Proposed pharmacophoric elements of bryostatins 
 Early structure and activity relationship studies on bryostatin were achieved 
through a collaborative effort between the Pettit, Blumberg, and Wender groups.82 
Comparison of the binding affinities of bryostatins 1-10, 16, 17, and 18 gave insight into 
the structural features responsible for binding. Varying ester functional groups on the C7 
and the C20 did not change the binding affinities significantly (Figure 1.5). Similarly, 
epoxidation of the C13-C30 olefin of bryostatin 4 did not reduce the binding affinity; 
neither did the reduction of the C13-C30 bond and the unsaturated side chain at C20 of 
bryostatin 2.82a In contrast, bryostatin 2 derivatives in which both the C13-C30 and C21-
C34 olefinic bonds are hydrogenated showed marked reduction in binding affinities 
(Figure 1.5).4g, 82a Elimination of the C19 hydroxyl group as found in bryostatin 16 and 
17 eliminates significant binding ability. Inversion of stereochemistry at C26 also 
reduced the binding affinity to some extent. Finally, acetylation of the C26 hydroxyl 
group reduced the binding affinity dramatically.82b Wender concluded from these 
observations that C4-C16 domains of bryostatins are less significant than the 
corresponding C19-C26 domains in terms of binding. 
 These observations were combined with an already developed computational and 
structure-activity relationship study related to phorbol compounds and DAG analogues.83 
Structure-activity and computational studies of phorbol derivatives indicated that the 
long-chain esters on C12 or C13 hydroxyl groups and hydroxyl groups at C4, C9, and 
C20 are necessary for binding. The spatial coordinates of the heteroatoms in phorbol 
conformers and (S)-1,2-diacyl-sn-glycerol conformers showed good correlation. For 

















































Ki = 1.35 ± 0.17 nM  
Ki = 5.86 ± 1.13 nM
Ki = 2.75 ± 0.05 nM                
Ki = 1.30 ± 0.19 nM
Ki = 1.04 ± 0.10 nM
Ki = 1.18 ± 0.29 nM
Ki = 0.84 ± 0.07 nM
Ki = 1.72 ± 0.10 nM
Ki = 1.31 ± 0.00 nM
Ki = 3.36 ± 0.06 nM
Ki = 118 ± 2       nM
Ki = 188 ± 7       nM
Ki = 4.82 ± 0.06 nM
(13, 30, 2', 3', 4', 5'-hexahydro)-bryostatin 2






























(13, 30, 21, 34, 2', 3', 4', 5'-octahydro)-bryostatin 2


































































































C19, C26 hydroxyl groups, and C1 carbonyl oxygen (Figure 1.6a). Although bryostatin 1 
does not have hydrophobic esters in similar position to that of phorbol esters, the largely 
lipophilic body of the molecule can be expected to occupy the top surface of the 
hydrophilic cleft in the C1 domain.82b Although this above hypothesis conforms to most 
of the observations, it does not necessarily correlate with the reality. In 1995, when a 
crystal structure of phorbol 13-acetate bound to C1B domain of PKCδ was published, it 
was found that 9-OH in the phorbol ester has no interaction with the C1 domain even 
though it was assumed to be one of the pharmacophore.79c This striking inconsistency 
could be due to the lipid-ligand interaction near the membrane.80 Nonetheless, Wender 
went on to propose that the northern hemisphere of bryostatin 1 (A- and B-rings) serves 
as a spacer domain and rigidifies the orientation for the pharmacophores (C1, C19, and 
C26) while binding to the C1 domain.84 
 A series of analogues prepared by Wender and coworkers were used to study the 
role of the C3 hydroxyl group. From solution NMR studies and crystallographic data, the 
C3 hydroxyl group is known to participate in an intramolecular hydrogen-bonding 
network with the C19-OH and the oxygen atoms of the A- and B-rings. NMR solution 
structure analysis and computational studies for these analogues revealed that the C3-epi 
analogue and the C3-deoxy analogue both had very different conformations compared to 
bryostatin 1 and C3 failed to form a hydrogen-bonding network with the C19-OH and the 
A- and B-ring pyran oxygen atoms. Although direct binding to the protein was not ruled 
out, the diminished binding affinity (285 nM and 297 nM versus 3.4 nM, Figure 1.6c) 
was considered to be the result of the absence of the transannular hydrogen-bonding 





(b)     (c)  
 
Figure 1.6. Pharmacophoric comparison of the PKC activators phorbol, bryostatin, and 
DAG, hydrogen bonding interactions, and role of C3 hydroxyl moiety 
 
(a) Computation studies showed that the spatial coordinates of the three heteroatoms 
correlated with each other very closely. (b) The crystal structure of bryostatin 1 
(BOKKIV) shows transannular hydrogen-bonding interactions (in blue lines) between 
C19 hemiketal hydrogen and C3 hydroxyl oxygen, C3 hydroxyl hydrogen and A- and B-
pyran ring oxygen atoms. (c) Structures of analogues for studying the role of C3 hydroxyl 





















































R = (S)-OH; Ki = 3.4 nM
    = (R)-OH; Ki = 285 nM
    = H; Ki = 297 nM
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 Identifying and understanding the mechanisms accountable for heterogeneous 
PKC responses are highly important not only to predict the actual biological 
consequences of PKC activation but also to identify useful and selective modulators of 
the PKC enzyme pathway.  
 
Chemical syntheses of bryostatins 
 Against the backdrop of the intense engagement of the scientific community in 
studying the unique biological profiles of bryostatins, it is not surprising to see chemists 
engaging in finding out efficient ways to prepare molecules of this class in the laboratory. 
Additionally, in practice, chemical synthesis seems to be the only viable solution for 
supplying adequate amount of bryostatins for further biological characterization. Isolation 
of these molecules from their natural sources proved to be a daunting task. For example, 
some 13000 kg of wet bryozoans were needed to isolate 18 g of bryostatin 1, the most 
studied member of the family.86 A continuous effort in this direction seems detrimental to 
the marine ecology. Aquaculture studies of Bugula neritina at a company called 
CalBioMarine under the supervision of National Cancer Institute failed to sustainably 
produce bryostatin in desirable amounts. Although Haygood groups’ efforts enabled the 
identification of the gene cluster bryA responsible for the production of bryostatin 1 in the 
marine microbe, expression of the gene was not possible in the laboratory.87 
 Many synthetic research groups have been involved in the total syntheses of 
bryostatins. Masamune was the first one to synthesize a member of the bryostatin family, 
bryostatin 7.88 Later, Evans89 (bryostatin 2), Yamamura90 (bryostatin 3), and Trost91 
(bryostatin 16) have demonstrated elegant synthetic routes to access these natural 
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products. In addition, Hale92 (formal synthesis of bryostatin 7), Trost93 (C20-epi-
bryostatin 7), and Thomas94 (20-deoxybryostatin) reported several synthetic routes for the 
related compounds. Recently, our group reported the first total synthesis of bryostatin 1.95 
Subsequently, Wender and Krische group reported the total syntheses of bryostatin 9 and 
bryostatin 7, respectively.96 
 
Keck’s analogue design 
 Although various total syntheses of bryostatins have been reported since 1990, a 
more practical strategy towards the preparation of bryostatins is to make analogues, 
which may retain bryostatins’ unique biological profile but shorten the synthetic route to 
provide relevant quantities of materials for further biological characterization.  
 
Pyran annulation or Keck Yu annulation 
 Our synthetic strategy towards bryostatin 1 was first realized from the 
development of the pyran annulation reaction in our group (Figure 1.7).97 In this process, 
an aldehyde and a β-hydroxyallylsilane can be coupled together in the presence of 
trimethylsilyl triflate to diastereoselectively produce 2,6-cis-disubstituted-4-
methylenetetrahydropyran. A similar reaction was also developed independently by 
Chan-Mo Yu’s group and hence, this reaction is now broadly known as the Keck Yu 
annulation.96b, 98 Additionally, Marko reported similar reactions based on Sakurai Prins-
type cyclization strategy, which he called “the intramolecular silyl-modified Sakurai 
(ISMS) reaction”.99     




Figure 1.7. Retrosynthetic strategy and transition state of Keck Yu annulation 
 
1.4 occurs rapidly at -78 oC, possibly via a chair-like transition state 1.2, which also 
explains the high diastereoselectivity (Figure 1.7). Et2O was found to be the best solvent 
and TMSOTf was the most suitable Lewis acid for this reaction.100  
 
Keck’s initial analogues of Merle series  
 Our group utilized the powerful pyran annulation reaction as a tool in the 
preparation of all the analogues. These analogues were given permanent identifiers as 
Merle numbers. Figure 1.8 shows the utilization of the key reaction in the preparation of 
some of the early members of the Merle series, Merle 23 and 28.101 Additionally, Figure 
1.9 depicts several other analogues prepared in our group prior to 2010.102   
 
Biological studies of Merle 21-28 
 The biological studies with the Merle series of compounds have been performed 
in the laboratory of our collaborator, Dr. Peter Blumberg, at the National Cancer Institute. 
The goal of the collaboration is to identify the structural features which are required for 
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Figure 1.9. Structures and binding affinities of Keck analogues of Merle series prepared 

























1.11 R = Ph, Merle 21













































1.15 Merle 26 1.16 Merle 27
Merle 21, Ki = 0.70 ± 0.01 nM
Merle 22, Ki = 1.05 ± 0.04 nM
Merle 23, Ki = 0.70 ± 0.06 nM
Merle 24, Ki = 37.7 ± 0.5   nM
Merle 25, Ki = 47.1 ± 4.2   nM
Merle 26, Ki = 13.0 ± 3.8   nM
Merle 27, Ki = 3.00 ± 0.6   nM
Merle 28, Ki = 0.52 ± 0.06 nM
PKCα Binding affinities of analogues
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both PKC binding and also for biological function as a bryostatin 1 mimic. Among the 
PKC binding agents, only the bryostatins are known to act as functional antagonists of a 
subset of PMA-induced biological responses. Conversely, for those responses induced 
both by the bryostatins and phorbol esters, the greater selectivity of the bryostatins and 
their weak activity as tumor promoters make them attractive PKC agonists.103 Therefore, 
our biological studies began with comparing binding affinities between bryostatin 1, 
phorbol ester, and the analogues. Additionally, as the high binding affinity of a ligand 
does not necessarily reflect anything about its biological function, specific cell lines were 
chosen to examine the subset of responses where bryostatin 1 and phorbol ester show 
functional antagonism. 
 
Binding affinities of Merle 21-28 
 The inhibitory dissociation constant (Ki, which indicates binding affinity) of each 
analogue ligand was determined by the ability of the ligand to displace bound [20-
3H]phorbol 12,13-dibutyrate ([3H]PDBu) from mouse recombinant isozyme PKCα in the 
presence of calcium and phosphatidylserine, using a polyethylene glycol precipitation 
assay previously described by Blumberg and Lewin.104 Merle 21, 22, and 23 lacked the 
polar functional groups in the northern hemisphere of bryostatin 1 along with the C8-
gem-dimethyl group. However, all of them were found to bind to PKCα with affinities 
(0.70 nM to 1.05 nM, Figure 1.9) similar to that of bryostatin 1 (0.48 ± 0.03 nM). 
Additionally, this indicated that subtle changes in the ester functional group at C20 did 
not change the binding affinity substantially. Merle 24 and 25 both lack the C21 
carbomethoxyenoate functional group. While Merle 25 has the right stereochemical 
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configuration at C20, Merle 24 has the opposite stereochemistry at C20. Interestingly, 
these analogues showed marked decrease in binding affinity (37 nM & 47 nM), which 
indicated that the C21 carbomethoxyenoate group plays a role in determining the binding 
affinity. This also showed that Wender’s hypothesis on pharmacophores on bryostatin 1 
was not a full description of the way bryostatin binds to PKC. In Merle 26 and 27, the 
analogues have the C7 acetate and the C7 2,4,6-trichlorobenzoate groups. These 
analogues also bound to PKCα, but with slightly diminished potency compared to 
bryostatin 1. Merle 28, on the other hand, retained the functional groups of the bryostatin 
1 A-ring and lacked only the C30 carbomethoxy. As expected, Merle 28 bound to PKCα 
tightly (Figure 1.9). 
 
Investigation of biological functions of Merle 21-28 
 All these analogues were screened for function by examination of attachment and 
proliferation of U937 leukemia cells.105 In this assay, phorbol esters inhibit proliferation 
and induce attachment. Bryostatin 1 has little effect but blocks the effect of the phorbol 
ester. Figure 1.10 shows the results with the analogue Merle 23. Merle 21 and 22 showed 
almost identical results and therefore are not displayed here. Merle 23 showed almost 
identical behavior in a dose-dependent manner to that of the tumor-promoting phorbol 
ester PMA and distinctly differed from bryostatin 1.101a When used in combination with 
PMA, bryostatin 1 blocked the responses of the phorbol ester. Merle 23, on the other 
hand, could not block the responses of PMA. This path-breaking result showed that 
Wender’s hypothesis of the northern hemisphere of bryostatin 1 as a spacer domain is 




Figure 1.10. Attachment and proliferation assays on U937 leukemia cells 
 
similar to the nontumor-promoter bryostatin 1.     
Additionally, Blumberg and coworkers examined Merle 21, 22, and 23 on the 
human erythroleukemia cell line K562. In these cells, similarly to U937 cells, Merle 23 
behaved like PMA for inhibiting cell growth in a dose-dependent manner (Figure 
1.11).102c However, in contrast to U937 and K562 cells, human prostate cells LNCaP 
were different. Blumberg observed Merle 23 resembled bryostatin 1 and not PMA in 
these cells. Merle 23 did not inhibit growth and did not induce apoptosis like bryostatin 1. 
It also had similar bryostatin-like effect on TNFα secretion and cell cycle analysis studies 
(Figure 1.12).106  
Blumberg also reported that the above-mentioned pattern of behavior of Merle 23 
relative to PMA and bryostatin 1 depended very much on the specific conditions. It was 
found that protease inhibitors like lactacystin and MG-132 shifted the response of the 
LNCaP cells to Merle 23 from bryostatin-like to PMA-like. These findings led to the 




Figure 1.11. Proliferation assay on K562 erythroleukemia cells 
 
type and can be modulated by other agents like lactacystin and MG-132. Blumberg also 
noticed that for a number of downstream responses in LNCaP cells, Merle 23 showed a 
duration of response intermediate between those of bryostatin 1 and PMA, with a little 
more PMA-like character. Additionally, for translocation studies with overexpressed 
GFP-PKCδ, Merle 23 resembled bryostatin 1, whereas for endogenous PKCδ, Merle 23 
was unique and translocated PKCδ to the cytoplasm as well as to the plasma membrane, 
unlike both phorbol ester and bryostatin.107 The authors concluded that Merle 23 could 
not be simply considered to be somewhere in the spectrum of activity between bryostatin 
1 and PMA. Instead, Merle 23 should be considered as a unique compound with its own 
effects. 
 Merle 26 and 27, which reintroduced C7 acetate and 2,4,6-trichlorobenzoyl 
groups on Merle 23, still behaved PMA-like on U937 attachment and proliferation 
assays. These studies along with the diminished potency of these analogues compared to 





Figure 1.12. Similarity between bryostatin 1 and Merle 23 in LNCaP cells  
   
not the critical determinant for antagonism of PMA-induced biological responses. 
Complete restoration of polar functional groups on the A-ring as well as C8-gem-
dimethyl group on Merle 28 shifted the properties towards bryostatin-type responses. 
While this reinforced the evidence against the hypothesis of A- and B-rings as “spacer 
domain”, it also proved that the C30 carbomethoxy group is not essential and that the A-
ring functional groups are critical to obtain bryostatin-like biological responses (Figure 
1.13). In a more recent work in collaboration with our group, Blumberg group reported 
that the origin of the unusual pattern of responses in LNCaP cells compared to U937 cells  
Inhibition	  of	  cell	  growth	  




Figure 1.13. Attachment and proliferation assays on U937 cells with Merle 27 and 28 
 
possibly lie downstream of the transcriptional regulation by various Merle compounds.108 
 
Synthesis of C9-deoxy bryostatin 1 or Merle 30 
 So far we had discovered that the C7 acetate and C30 carbomethoxy groups alone 
do not play the critical roles towards bryostatin-like activities. In the backdrop of these 
outcomes of our biological studies with the analogues, we decided to further investigate 
the structure-activity relationships. In line with that, we planned to delete the C9 hydroxy 
group from the A-ring of bryostatin 1. This C9 hydroxy group is not an ordinary hydroxy 
functionality. It is in fact a part of the hemiketal group, the other oxygen being part of the 
A-ring as well. Hemiketals are known to be chemically labile under acidic conditions. 
Protonation of the hydroxy group can trigger the lone pairs of the other oxygen atom to 
form an oxocarbenium ion by eliminating a water molecule. This reactive intermediate 
can then be attacked by nucleophiles such as other water molecules, thiols, or alcohols. 
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We hypothesized that a similar event in the surrounding cellular environment could 
perhaps be responsible for bryostatin’s special activities.  
 
Computational studies of Merle 30 by Megan L. Peach      
 Etai and coworkers carried out a computational study of bryostatin 1-bound PKC 
where they found four intermolecular hydrogen bonds. In this model, bryostatin fits well 
into the same cavity where phorbol ester was found to bind in a crystal structure. The 
four hydrogen bonds are found to form with the C26-OH to both the NH of Thr242 and 
the carbonyl of Leu251, the C35 carbonyl to the NH of Gly253, and the C9-OH to the 
carbonyl of Met239.109 
 Our collaborator, Dr. Megan Peach, performed a conformational search of 
bryostatin 1 in implicit water and octanol solvents. The global energy-minimum 
conformation found in both solvents matched with the crystal5 and NMR110 
conformations. The four lowest energy conformations are characterized by their 
intramolecular hydrogen-bonding network between the C3-OH group and the pyran 
oxygen atoms of the A- and B-rings, and another hydrogen-bonding between the proton 
of the C9-OH and the oxygen atom of the C3-OH group. Corresponding C9-deoxy 
bryostatin conformations were then built by simply replacing the C9-OH with a hydrogen 
atom. These conformations of bryostatin 1 and Merle 30 were docked into the crystal 
structure of the C1B domain of PKCδ (Figure 1.14). The docking studies revealed that 
bryostatin 1 or Merle 30 did not undergo any conformational change upon binding to the 
C1 domain. In both the compounds, the C26 OH formed similar hydrogen-binding 





Figure 1.14. Bryostatin 1 (A) and Merle 30 (B) docked into the C1B domain of PKCδ 
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observation was in the fact that the ester oxygen atom adjacent to C1 appeared to make 
weak hydrogen-bonding interaction with NH of Gln 257. The methoxy carbonyl group at 
C34 extends over the edge of the binding site and hydrogen bonds to the backbone 
Gly253 NH. Bryostatin also forms a hydrogen-bonding with C9 OH to Met239, which 
Merle 30 cannot form. This hydrogen-bonding is also absent in phorbol esters. These 
results from the computational studies supported our hypothesis that a C9-OH could be 
essential for bryostatin-like activity.    
 
Retrosynthesis of Merle 30 
 The retrosynthetic analysis of the C9-deoxy bryostatin 1 (Merle 30) is outlined in 
Figure 1.15. We envisaged that Merle 30 could arise from late stage deletion of the C9 
hydroxy group in the ketone intermediate 1.18. The macrolactone was disconnected at C1 
ester bond keeping a Yamaguchi macrolactonization reaction in mind. The unsaturated 
ester functionalities on C13, C20, and C21 would also be installed late onto the 
macrolactone core of Merle 30. The B-ring pyran of the ketone 1.18 was disconnected at 
C11-C12 and C11-O (B-ring pyran oxygen) bonds complying with our pyran annulation 
strategy to yield synthetic equivalents in the form of the C-ring β-hydroxyallyl silane 
1.19 and the A-ring aldehyde 1.20. The highly convergent union of these two equally 
complex intermediates with four stereocenters each would not only construct the B-ring 
pyran but would also install the desired stereocenter at C11. The A-ring aldehyde 1.20 
could be obtained from the open chain intermediate 1.21 through a cleavage of the olefin 
at C9 followed by a ketalization (Figure 1.16). We envisioned that the installation of the 




         
  
 



















































Figure 1.16. Retrosynthetic analysis for the A-ring 
 
stannane 1.22 onto the aldehyde 1.23. The stannane 1.22 could arise from 3,3-dimethyl 
acrylate. The aldehyde 1.23 could eventually be obtained from another chelation-
controlled Mukaiyama aldol addition of the thioketene acetal 1.26 with the aldehyde 
1.25. Thus, we were left with one stereocenter at C5, which could be set using the Keck 
catalytic asymmetric allylation (CAA). This stereocenter at C5 could allow us to 
introduce the stereocenters at C3 and C7. The stereocenter at C7 would then eventually 



























































synthetic methodology efficiently to introduce all the 4 stereocenters in the A-ring from a 
single chiral source of (S)-BINOL. 
 The C-ring β-hydroxyallyl silane was disconnected at C14-C15 to give the α,β-
unsaturated aldehyde 1.27 and the trimethylsilylmethallyl tributylstannane 1.28 (Figure 
1.17). We envisaged that a CAA reaction would install the desired stereocenter at C15. 
The aldehyde 1.27 could arise from a Horner-Wadsworth-Emmons olefination of an 
aldehyde derived from ozonolytic cleavage of the olefin 1.29. The gem-dimethyl group at 
C18 was envisioned to arise from a prenylation of an aldehyde 1.30. The aldehyde 1.30 
could be installed using a hydroformylation reaction of the olefin 1.31. The olefin 1.31 
was disconnected at the C23-C24 bond, followed by another disconnection at the C24-
C25 bond. Two consecutive chelation-controlled additions of allylstannane to the 






























































Synthesis of A-ring aldehyde 1.20 
 Dr. Dennie Welch, a former group member, originally developed the synthesis of 
the A-ring aldehyde 1.20.111 The synthesis began with the monoprotection of 
commercially available and cheap 1,3-propanediol 1.33 (Figure 1.18). Using 1 equivalent 
of tert-butyldimethylchlorosilane and an excess of the diol, the monoprotected alcohol 
1.34 was obtained in high yield. Swern oxidation of the resulting alcohol gave the 
monoprotected aldehyde 1.35 in near quantitative yield.112 The next step in the synthesis 
let us introduce the first stereocenter at C5 using CAA with allyltributyl stannane 1.36 
and (S)-BITIP as the catalyst with high yield (99%) and excellent enantioselectivity (98% 
ee).113 Scale up of this reaction to 65 grams proceeded well without any significant loss in 
yield and enantioselectivity. The next step was to protect the resulting homoallylic 
alcohol as a p-methoxybenzyl (PMB) ether 1.38. The choice of PMB was deliberate, as  
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the chelating ability of PMB with common Lewis acids should aid in the formation of the 
C3 and C7 stereocenters in a substrate-controlled manner. Removal of BPS group with 
TBAF, followed by Parikh-Doering oxidation, gave the aldehyde 1.25 cleanly in very 
good yields.114 Chelation-controlled Mukaiyama aldol addition with aldehyde 1.25, using 
Ti(OiPr)2Cl2 as a Lewis acid, allowed us to introduce the C3 stereocenter with the desired 
1,3-anti relationship as essentially a single diastereomer, yielding 1.41 (Figure 1.19). The 
anti relationship between C5 and C3 in 1.41 was established using Rychnovsky’s 
acetonide method.115 Compound 1.41 was subjected to TBS protection followed by 
reaction with DDQ to remove the PMB protecting group. Next the TBS protecting group 
was also removed to convert the diol into the acetonide 1.42 using 2,2-
dimethoxypropane. During the removal of the TBS protecting group, the thioester was  
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transesterified in the presence of methanol, which was not of any consequence for 
stereochemical studies. NMR analysis revealed that the 13C chemical shifts of the 
geminal dimethyl groups and the carbon bearing the germinal dimethyls were indeed 
consistent with the expected chemical shifts reported by Rychnovsky assuming a twist 
boat type conformation 1.42. Rationalization of the stereochemical outcome of this 
reaction came from an earlier work in our group, which proposed a transition state similar 
to 1.40. In this transition state, steric hindrance prevents the nucleophile from attacking 
the aldehyde on the same face as that bearing the allyl group.116 With the correct 
stereochemical relationship established, alcohol 1.41 was then protected with a BPS 
group, which is known to be nonchelating.117 The selection of BPS was important at this 
point as we were about to take advantage of the C5 stereocenter again to introduce the 
next stereocenter at C7 and we were concerned that another chelating group at C3 would 
create some problems arising from competitive chelation. The required aldehyde 1.23 
was obtained by the use of a catalytic amount of OsO4 and NMO as co-oxidant and 
subsequent cleavage of the vicinal diol by Pb(OAc)4 (Figure 1.20).118 At this point we 
were ready to do another chelation-controlled addition on the aldehyde 1.23 to set the C7 
stereocenter. 
 The synthesis of the stannane 1.22 for this addition began with the α-alkylation of  
 
 





















commercially available ethyl 3,3-dimethylacrylate 1.24 with 2-iodo-1-
(tbutyldimethylsilanoxy)ethane using LDA as a base (Figure 1.21). The next step was to 
isomerize the terminal olefin 32 to an internal olefin 1.26. Interestingly, that olefin does 
not isomerize in the presence of the basic medium of the reaction mixture. Thus, the 
olefin was isomerized in a separate step using tBuOK as base to give α,β-unsaturated 
ester 1.27. The solvent was degassed prior to use and utmost care was taken to prevent 
any introduction of oxygen into the reaction mixture, which can potentially oxidize the 
intermediate enolate.119 The α,β-unsaturated ester 1.27 was reduced to the primary 
alcohol 1.46 using DIBAL-H. The hydroxyl group was then converted to a leaving group 
(mesylate), which was then displaced by tributyltin lithiate in situ to form the stannane 
1.22. The stannane was stable enough to be purified by column chromatography. 
 With stannane 1.22 and the aldehyde 1.23 in hand, we were successfully able to 
couple the two components in the presence of the chelating Lewis Acid Me2AlCl to give 
the alcohol 1.48 as a single diastereomer in good yield (Figure 1.22). Not only did this  
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step allow us to set the desired C7 stereocenter, but it proved to be an efficient way to 
install the C8 geminal dimethyl group as well. The Lewis acid solution was prepared 
freshly as it was found to be detrimental to use old stock solution. The stereochemical 
outcome of this reaction can be explained by a similar transition state like 1.40. 
Additionally, Evans group had proposed a boat-like transition state 1.47 based on 
computational studies.120 The PMB group was now deprotected using DDQ under pH 7 
buffered reaction conditions in the presence of ample quantities of water.121 Next, 
ozonolysis of the olefin resulted in exclusive formation of the cyclized hemiketal 1.50 
without formation of any corresponding open chain isomer. Methanolysis of the 
hemiketal 1.50 in the presence of methanol and a catalytic amount of CSA gave the ketal 
1.51 in quantitative yield. The acidic condition of the reaction medium also removed the 
terminal TBS group at C11.122 Stereochemistry of the ketal was established by nOe 
studies by Dr. Dennie Welch in our group.111a The primary alcohol 1.51 was then 
oxidized under Parikh-Doering conditions to yield aldehyde 1.20 in good yield. 
 
Model studies for deletion of the C9 hydroxy group 
 Before embarking on the journey towards the synthesis of Merle 30, we decided 
to use a model substrate to study the deletion of the C9 hydroxy group of bryostatin 1. 
The conditions developed in this transformation would then be used in a more advanced 
intermediate. The alcohol 1.51 was protected as TBS ether 1.52. Acidic conditions with 
PPTS and Et3SiH did not reduce the C9 ketal functionality. However, using TMSOTf as 




Synthesis of the C-ring silane 1.19 
 The route for the synthesis of the β-hydroxyallyl silane 1.19 was initially 
developed by Dr. Anh Truong and then scaled up by Mr. Jeffrey C. Stephens in our 
group.123 Since this route was reported in reference no. 123, no detailed discussion will 
be given here until the synthesis of 1.29. Please refer to the aforementioned reference, 
and Chapter 2 for a full discussion on a modified route to a fully functionalized C-ring 
intermediate. Present discussion will focus on synthesis of 1.19 starting from the olefin 
intermediate 1.29. Ozonolysis of the olefin 1.29 followed by a reductive work-up 
produced the aldehyde 1.54, which was immediately converted to the trans-α,β-
unsaturated thioester 1.56 in very good yield using a Horner-Wadsworth-Emmons 
olefination with the phosphonate 1.55. Removal of the TBS protecting group followed by 
a dehydrative cyclization gave the glycal 1.57 in very good yield. A selective half-
reduction of the thioester 1.57 using DIBAL-H provided the aldehyde 1.27 (Figure 1.23). 
With the aldehyde 1.27 in hand, the next step (Figure 1.23) was to convert the aldehyde 
to the β-hydroxyallyl silane 1.19 using CAA. Dr. Yam Poudel from our group had 
previously attempted to reproduce the results of the CAA reaction performed by Dr. Anh 
Truong on the same substrate 1.27. However, those results were not reproducible and he 
then attempted to synthesize the compound 1.19 in a step-wise fashion. The stannane 
1.28 was added to the aldehyde in a nonstereoselective fashion by heating in toluene at 
reflux. Next, we oxidized the diastereomeric mixture 1.58 to form the ketone 1.59. At this 
stage, we found a CBS reduction was successfully able to produce the desired silane 1.19 
as a single diastereomer in very good yield. As the (S)-CBS reagent is not stable in THF 





Figure 1.23. Synthesis of the C-ring silane 1.19 
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a bench stable solid powder of (S)-CBSBH3 reagent 1.60. The absolute stereochemistry 
of C15 was established by a Mosher ester analysis performed by Dr. Yam Poudel and can 
be explained by a transitions state like 1.61.124 
 
Completion of the synthesis of Merle 30 
 With the aldehyde 1.20 and the β-hydroxyallylsilane 1.19 in hand, our flagship 
reaction pyran annulation was applied to provide us with the tricyclic core of Merle 30 
1.62 in moderate yield (Figure 1.24). We were able to recover some TMS protected C-
ring silane and unreacted A-ring aldehyde 1.20. The TMS protected C-ring silane was 
converted back to C-ring silane 1.19 using mild acidic conditions with PPTS/MeOH. This 
intermediate 1.62 was prepared on about 300 mg scale and used for further 
functionalization towards Merle 30 and later Merle 32 (described later). Several attempts 
to improve the yield of this reaction such as varying temperatures, solvents, and order of 
addition did not result in significant progress. Use of various Lewis acids such as 
lanthanide metal triflates and silyl triflates (TBSOTf, TESOTf) either decomposed the 
substrates or protected the C-ring hydroxyallylsilane as silyl ethers. The steric 
environment around the bond-forming atoms in the pyran annulation reaction with 
compounds 1.19 and 1.20 seems to be the reason behind the moderate yield. 
 With the tricyclic core in hand, Dr. Yam Poudel focused on the functionalization 
of the C-ring glycal (Figure 1.24). A chemoselective epoxidation of the glycal using 
MMPP and subsequent epoxide opening with methanol in situ provided the ketal at C19 
and a mixture of (1:1) diastereomers of alcohols at C20. This inconsequential mixture of 
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next step was to try the key reaction of deletion of C9 oxygenated functionality that we 
already successfully applied in a model substrate 1.52 (Figure 1.22). Although the ketone 
1.18 contains two methyl ketals, the reactivity of the two functional groups is very 
different.  The C-ring methyl ketal is located next to a ketone at C20 and the formation of 
an oxocarbenium intermediate using a Lewis acid would be energetically highly 
unfavorable. This unique situation provided an opportunity for a chemoselective 
reduction of C9 methyl ketal using triethylsilane and TMSOTf as the Lewis acid to 
provide 1.63. The stereochemistry was proved using nOe correlations between C5, C7, 
and C9 hydrogen atoms. After exploring various choices of the sequences of steps and 
various optimizations, Dr. Yam Poudel found out that C13-C30 olefin on the B-ring 
needed to be oxidized to a ketone first in order to hydrolyze the thioester at C1. 
Additionally, the conversion of the ketone in the B-ring to the enoate functionality was 
not selective towards the desired Z-olefin with the open chain intermediates. A more 
conformationally constrained macrolactone would provide a better selectivity in the 
olefination using Fuji’s BINOL. To achieve this, the olefin at C13 was regioselectively 
cleaved by drop-wise addition of saturated ozone solution to provide the diketone 1.64. 
Next removal of the PMB group at C25, followed by hydrolysis of the thioester at C1, 
provided the seco-acid 1.66. Yamaguchi macrolactonization on the seco-acid provided 
the macrolactone core 1.67. The regioselective Horner-Wadsworth-Emmons olefination 
on the C13-C30 ketone using Fuji’s chiral phosphonate 1.68 provided the B-ring enoate 
compound 1.69 in good yield and moderate diastereoselectivity (Z:E = 4:1) (Figure 
1.25).126 Stereochemical proof of the olefin geometry came from the nOe correlations 
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the E-isomer using preparative TLC. 
 The next step was to install the enoate on the C-ring (Figure 1.25). Dr. Yam 
Poudel after some optimizations was able to convert the ketone 1.69 to the alcohol 1.70 
using K2CO3/MeOH and the methyl acetal of methyl glyoxylate. Heating the crude aldol 
product 1.70 with acetic anhydride and DMAP in pyridine provided the aldol 
condensation product 1.71. A moderately selective Luche reduction followed by 
immediate esterification with octadieonic anhydride installed the bryostatin 1 side chain. 
The diastereomeric mixtures (dr = 4:1) were separated using another preparative TLC.  
Removal of BPS group followed by global deprotection using LiBF4 afforded C9 deoxy 
bryostatin 1 or Merle 30. 
 
Biological evaluation of C9 deoxy bryostatin 1 or Merle 30 
 Merle 30 was found to have an inhibitory dissociation constant (Ki = 0.38 nM) 
comparable to that of bryostatin 1 (Ki = 0.48 ± 0.03 nM) studied in mouse PKCα.127 This 
suggested that the absence of H-bonding between the C9-OH and Met 239 of PKC 
backbone does not affect its binding affinity. This was not surprising given that other 
bryostatin analogues lacking the C9-OH have shown high affinity for PKCs (Figure 1.9). 
Functional activity of Merle 30 in living cells was assessed using the U937 cells and is 
shown in Figure 1.26 along with Merle 28. PMA showed strong antiproliferative 
responses, whereas bryostatin 1 caused only a minor, biphasic decrease in cell 
proliferation. When used in combination, bryostatin 1 was observed to block the anti-
proliferative effect of PMA in a dose-dependent manner. Additionally, PMA induces 




Figure 1.26. Biological profile of Merle 30 
 
bryostatin–like biological responses. Interestingly, Merle 30 showed a little tilt towards 
PMA-like character with larger decrease in cell proliferation and greater attachment. Our 
studies with Merle 27, 28, and 30 revealed that deletion of C13 enoate, C9 hydroxy 
groups would provide more PMA-like character. 
 Merle 30 was also examined for proliferation and secretion of TNFα in LNCaP 
cells. PMA induces cell proliferation and induces apoptosis, whereas bryostatin 1 does 
not. Merle 30 did not inhibit proliferation but antagonized the inhibition by PMA. For 








PMA (0.1, 1, 10, 100, 1000 nM)
Bryostatin 1 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Bryostatin 1
Merle 30 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Merle 30





















PMA (0.1, 1, 10, 100, 1000 nM)
Bryostatin 1 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Bryostatin 1
Merle 30 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Merle 30












induction of TNFα secretion, the three agents behave differently. PMA induces a potent 
response while bryostatin has no response. Merle 30 induced a weak biphasic response. 
Additionally, those compounds which do not induce secretion themselves block the 
response to PMA. We also found a strong correlation between bryostatin-like patterns of 
gene expression and bryostatin-like patterns of biological response in U937 cells.108 In 
conclusion, the C9 hydroxy group plays a minor role in both binding affinity and 
functional responses.   
 
Synthesis of Merle 32 
 As mentioned earlier, the interactions between the lipid bilayer and the C1 
domain bound to bryostatin are a key area to look into. The bryostatin northern 
hemisphere overlays the top face of the C1 domain, which interacts with the lipid bilayer. 
The combination of polar and nonpolar functionalities on the northern hemisphere plays a 
balanced role in the unique biological responses of bryostatin 1. So far with the syntheses 
of Merle 27, 28, and 30, we had individually scanned the roles of the C30 carbomethoxy 
group, the C9 hydroxy, and the C7 acetate group. Next, we focused on the role of the C8 
geminal dimethyl group.  
 With the synthesis of Merle 30, we had already developed reactions to delete the 
C9 hydroxy group. We envisaged that the intermediate 1.63 could be utilized for further 
functionalization towards Merle 32 where all the polar functional groups would be 
deleted, leaving the C8 gem-dimethyl, and the two exocyclic olefins at C7 and C13. This 
would resemble Merle 23 except at the C8 position, which will also enable us to directly 
compare its biological properties with that of Merle 23. 
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 The synthesis of Merle 32 (Figure 1.27) was developed by Dr. Yam Poudel and it 
commenced from the common intermediate 1.63. The C25 PMB ether was deprotected 
using DDQ. Next, an oxidative hydrolysis using mCPBA enabled us to selectively 
hydrolyze C1 thioester in the presence of the C7 acetate. The reaction was stopped at 3.5 
hours in order to prevent epoxidation of the C13-C30 olefin. Yamaguchi 
macrolactonization of the seco-acid 1.74 then furnished the macrolactone 1.75 in very 
good yield. To prevent competing enolization of the C7 acetate in the ensuing aldol 
reaction, the C7 acetate was removed using K2CO3/MeOH without any macrolactone 
opening at C1. The resulting free alcohol was then protected as TES ether 1.77. The aldol 
reaction of the C-ring ketone 1.77 with freshly distilled methyl glyoxylate using LDA as 
base provided the aldol product, which was subjected to elimination using acetic 
anhydride to form α,β-unsaturated ester 1.78 as a single diastereomer. Luche reduction of 
the C20 ketone followed by an immediate esterification using 2,4-octadienoic anhydride 
provided the advanced intermediate 1.79 with a fully functionalized C-ring. Mild acidic 
conditions of PPTS/MeOH revealed the C7 alcohol by removing the TES group. 
Oxidation of the alcohol using Dess-Martin periodinane (DMP) provided the ketone 1.80 
(Figure 1.28). Dr. Yam Poudel, after several attempts using various procedures, was 
finally able to convert the ketone 1.80 to the exocyclic olefin using Wittig conditions. 
Removal of the BPS group at the C3 position of 1.81 followed by global deprotection 
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Figure 1.28. Completion of the synthesis of Merle 32 
 
Biological evaluation of Merle 32 
 The biological evaluation of Merle 32 began with the determination of its binding 
affinity (Ki) towards PKC in vitro. Its Ki (1.08 ± 0.16 nM) proved comparable to 
bryostatin 1 (Ki = 0.48 ± 0.03 nM) and to other bryopyran analogues in the Merle series. 
In the proliferation and attachment assays in U937 cells, Merle 32 resembled PMA and 
not bryostatin 1 (Figure 1.29 and 1.30). PMA induces attachment and inhibits 
proliferation, whereas bryostatin 1 has little effect. Bryostatin 1 blocks both responses to 
PMA in a dose-dependent manner when both the agents are applied together. Merle 32 
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leukemia cell lines.128 Even with the human prostate cancer cell line (LNCaP), Merle 32 
induced attachment and inhibited proliferation (Figure 1.31). From all these assays, it was 
clear that the C8 gem-dimethyl group in Merle 32 was not solely responsible for the 
unique biology of bryostatin 1. Comparison with Merle 23 corroborated this observation 
clearly (Figure 1.30). 
 Downregulation of PKC isoforms and other C1 domain-containing proteins after 
ligand binding was also studied with Merle 32.128 Dose-dependent patterns of 
downregulation were determined for PMA, bryostatin 1, and Merle 32 in K562 cells. 
Bryostatin 1 was more effective in downregulating PKCα and β and showed a biphasic 
downregulation with PKCδ. Additionally, it did not cause the prominent induction of 
PKCε and RasGRP3 observed in these cells with PMA. Merle 32 showed a pattern very 
similar to that of PMA but with less potency. Another assay monitored the response of 
LNCaP cells towards TNFα secretion on exposing the cells to the Merle compounds in 
the presence of Lactacystin. Lactacystin is a proteasome inhibitor, which prevents the 
downregulation of PKC. Merle 28, 30, and 32 switched to display PMA-like properties in 
the presence of Lactacystin. These results also suggested that the properties of the Merle 
compounds could be reverted to more PMA-like (Figure 1.32).  
 Comparison of Merle 30 and 32 showed that they behaved differentially in U937 
cells. Additionally, in MV-411 cells and K562 cells, Merle 30 and 32 showed similar 
contrasting responses. Merle 32 inhibited proliferation and induced attachment in MV-
411 cells, similar to PMA (Figure 1.33). Merle 30 seems to have an effect intermediate 
between bryostatin 1 and PMA in the proliferation assay in K562 cells (Figure 1.34). This 










Figure 1.32. Reversal of the biological responses of various analogues 
 
1 and could start resembling PMA.  
In addition to the cell attachment and proliferation assays, the analogues were also 
tested by examining the translocation of PKCδ. LNCaP cells were transfected with GFP-
PKCδ and then treated with the indicated molecules. The translocation of GFP-PKCδ was 
detected by confocal microscopy in real time with images taken every 30 s. The images 
shown (Figure 1.35) are representative of those from three independently performed 
experiments. The most lipophilic PKC ligands induce translocation of GFP-PKCδ mostly 
to the plasma membrane, whereas less-lipophilic PKC ligands, including bryostatin 1 and 
Merle 28, induce translocation to internal membranes. The more lipophilic compounds 
Merle 23, 32, and PMA showed clear similarity in translocating PKCδ to the plasma 











Figure 1.34. Proliferation responses of Merle 30 and 32 in K562 cells 
 
 




Total synthesis of bryostatin 1 and 7 
 The retrosynthetic plan for the syntheses of Merle 30 and 32 explored the 
possibility of a convergent route via the intermediates 1.19 and 1.20 (Figure 1.15). 
Although that route was used successfully in the syntheses of Merle 28, 30, and 32, 
several problems in the route posed serious challenges while scaling up. Some of the 
problems included simultaneous aldol reaction on the C7 acetate during the late stage 
functionalization of C-ring and low selectivity during Luche reduction of the C20 ketone 
in advanced intermediates. Additionally, the retrosynthetic analysis of the C-ring silane 
1.19 was essentially linear in nature and hence, the synthesis was not very efficient 
(Figure 1.17). At this stage Thomas Cummins in our group explored a more convergent 
retrosynthetic analysis of C-ring. In this retrosynthesis, we also explored the idea of a 
disconnection that would produce synthetic equivalents of A-ring β-hydroxyallyl silane 
1.84 and C-ring aldehyde 1.83 (Figure 1.36). These two moieties are equally complex 
and we envisioned that they could be coupled using pyran annulation. The other 
disconnection was at the macrolactone ester linkage, which could arise from Yamaguchi 
macrolactonization. The A-ring β-hydroxyallyl silane 1.84 could arise from the same 
aldehyde 1.20 prepared earlier for the syntheses of Merle 30 and 32.  
The C-ring enoate was thought to arise from the ketone 1.85 through an aldol 
condensation with methyl glyoxylate. The installation of the natural side chain of 
bryostatin 1 would happen after the selective reduction of the C20 ketone of aldol 
condensate. We imagined that the ketone 1.85 would arise from sequential oxidation 
reactions on the glycal 1.86. The dihydropyran ring of 1.86 was envisioned to arise from 




















































































































disconnection at the ester linkage of 1.87 would then give the synthetic equivalents of the 
carboxylic acid 1.88 and the known secondary alcohol 1.31.123a The carboxylic acid 1.88 
could be prepared from commercially available methyl isobutyrate in four steps and the 
alcohol 1.31 could be obtained from commercially available (R)-isobutyl lactate. 
 
Synthesis of the A-ring β-hydroxyallyl silane 1.84 
 Synthesis of the A-ring silane 1.84 began from the previously prepared aldehyde 
1.20. Previous efforts to prepare a similar silane were performed by Dr. Dennie Welch, 
but the synthetic route failed to provide the desired silane.111b Dr. Yam Poudel attempted 
to perform the CAA reaction with the silane 1.28, but no product was observed in this 
reaction, possibly due to the sterically hindered nature of the aldehyde 1.20. Another 
alternative approach was to add the stannane 1.28 to the aldehyde 1.20 with no 
diastereoselectivity. This inconsequential mixture of diastereomers was then oxidized to 
the ketone 1.90. After screening several reducing agents in presence of Lewis acids, Yam 
was able to prepare the β-hydroxyallyl silane 1.84 in moderate selectivity. The 
stereochemistry of the major diastereomer was proved via chemical transformations and 
comparing NMR spectra.124 The most likely explanation for the diastereoselectivity 
comes from a half chair chelate structure 1.91 where the hydride nucleophile attacks from 
the bottom face, which leads to a chair-like transition state rather than a high-energy twist 






Figure 1.38. Synthesis of the β-hydroxyallyl silane 1.84 
 
A convergent synthesis of the C-ring aldehyde 1.83  
Synthesis of the carboxylic acid 1.88 began with the alkylation of commercially 
available methyl isobutyrate 1.92 followed by a free radical bromination (Figure 1.39). 
The resulting 4-bromoester 1.93 was then treated with tbutyldimethylsilanol in the 
presence of silver triflate and a base to displace the bromide. Basic hydrolysis of the 
methyl ester furnished the carboxylic acid 1.88. 
Synthesis of the secondary alcohol 1.31 using a series of 1,2 and 1,3 chelation-
controlled allylations has been reported earlier from our group and will not be discussed 
here.123a The carboxylic acid 1.88 was coupled with the alcohol 1.31 to provide the ester 





































































Figure 1.39. Synthesis of the carboxylic acid 1.88 
 
to provide the terminal alcohol 1.95, which was then converted to an aldehyde using 
Parikh-Doering oxidation. A one-carbon homologation using a Wittig reaction produced 
the terminal olefin 1.87. With the olefinic ester 1.87 in hand, we then subjected it to the 
Rainier-modified Takai-Utimoto reaction also known as Rainier metathesis.129 To our 
delight, Thomas was able to convert 1.87 to the glycal 1.86 in a very good yield. PbCl2 is 
a necessary additive to facilitate this reaction, as reported earlier by Takai and 
coworkers.130 Use of ethyl bromide replacing methyl bromide was observed to produce 
exclusively the cyclic enol ether following Rainier’s procedure. Epoxidation of the glycal 
using MMPP followed by in situ opening with methanol furnished a ketal at C19 and an 
inconsequential mixture of diastereomers at C20, which was immediately oxidized to the 
ketone 1.85 using Ley oxidation. An aldol condensation between the ketone and freshly 
distilled methyl glyoxylate provided the α,β-unsaturated ester 1.96 as a single geometrical 
isomer in excellent yield. The ketoester was then reduced to the alcohol using Luche 
conditions and then immediately esterified using acetic anhydride. The TBS group was 
removed to form the primary allylic alcohol, which was then oxidized to the aldehyde 
1.83. The choice of acetate as the protecting group in 1.97 was preplanned. Yam Poudel 
had previously found that the hydrolysis of the C7 acetate using K2CO3/MeOH 
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en route to Merle 32. This observation encouraged us to pursue bryostatin 7 using the 
same synthetic route. Additionally, this would also allow us to install various ester 
functionalities at a late stage during the synthesis of bryostatin analogues. 
 
Completion of the synthesis of bryostatin 1 
 With both fragments in hand, A-ring hydroxyallylsilane 1.84 and C-ring aldehyde 
1.83 were subjected to the crucial pyran annulation reaction (Figure 1.41). The reaction 
provided the tricyclic core 1.98 in moderately good yield. The major by-product observed 
by Dr. Yam Poudel was a spirocyclization, which resulted from an intramolecular 
cyclization of the hydroxyallylsilane to the C9 position. Hydrolysis of the thioester at C1 
was not successful with the BPS group on C3, possibly due to steric hindrance. This 
prompted us to remove the C3 BPS group, which allowed us to hydrolyze the thioester 
followed by the protection of the C3 hydroxy group with TES. The presence of the free 
hydroxy group at C3 can form a hydrogen bonding interaction with the C1 carbonyl of 
the thioester, potentially facilitating the hydrolysis. Removal of the PMB protecting 
group provided us with the seco-acid, which was then subjected to Yamaguchi 
macrolactonization to provide 1.101. At this stage, Yam found that the olefin C13-C30 
could not be cleaved selectively using ozonolysis or OsO4 in the presence of the C9 
methoxy group and the enoate at C21 of the C-ring. Fortunately, sterically hindered 
reagents like AD mix-α or β were able to dihydroxylate the C13-C30 olefin of 1.101 
selectively. The cleavage of the bond C13-C30 between the vicinal dihydroxyl groups 
was accomplished by NaIO4 to provide 1.102. Fuji’s chiral BINOL-derived phosphonate 
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intermediate 1.103 was then used to prepare both bryostatins 1 and 7. 
 When the bisacetate 1.103 was treated with K2CO3/MeOH, we were delighted to 
see that the C20 acetate was selectively cleaved in presence of C7 acetate. The free 
hydroxy group was immediately esterified with octadienoic anhydride to form the 
protected bryostatin 1 derivative 1.104. A global deprotection then completed the first 
total synthesis of bryostatin 1. From the same intermediate 1.103, a global deprotection 
also produced bryostatin 7 in good yield (Figure 1.42).          
 
Biological evaluation of bryostatin 7 
 The biological evaluation of bryostatin 7 began with finding out the binding 
affinity toward purified PKCα. The less lipophilic bryostatin 7 was found to bind slightly 
better (Ki = 0.26 ± 0.06 nM) than bryostatin 1 (Ki = 0.48 ± 0.03 nM) in mouse PKCα. 
This result is in contrast to that of the other ligands such as phorbol esters and 
indolactams. To examine any possible PKC isoform selectivity in vitro, our collaborators, 
Dr. Blumberg and coworkers, determined the binding affinities of bryostatin 7 for human 
PKC isoforms α, βII, δ, and ε (Table 1.3). These isoforms were chosen as PKC βII, δ, and 
ε are the predominant phorbol ester-sensitive PKC isoforms in the U937 cells and PKC α, 
δ, and ε are the predominant phorbol ester-sensitive PKC isoforms in the LNCaP cells.108 
Bryostatin 7 showed little selectivity among these PKC isoforms and bound to PKC 
modestly more strongly than did bryostatin 1. Phorbol ester PDBu also showed little 
selectivity. Thus for phorbol ester, bryostatin 1, and 7, binding affinities for the different 
isoforms were very similar, and the binding affinities of them for any particular isozyme 
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bryostatin 7, PKCα Ki = 0.26 ± 0.06 nM
bryostatin 1, PKCα Ki = 0.48 ± 0.03 nM
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PDBu 0.3 ± 0.05 0.28 ± 0.02 0.20 ± 0.0003 0.33 ± 0.08 0.22 ± 0.05 
Bryostatin 1 0.48 ± 0.03 0.73 ± 0.05 0.42 ± 0.01 0.26 ± 0.02 0.24 ± 0.01 
Bryostatin 7 0.26 ± 0.06 0.44 ± 0.01 0.32 ± 0.01 0.21 ± 0.02 0.16 ± 0.01 
aValues represent the mean SEM of triplicate independent experiments    
 
 As previously described, we examined the biological profile of bryostatin 7 in 
U937 cells by growth inhibition and cellular attachment assays. Bryostatin 7 closely 
resembled bryostatin 1 in its effect in U937 cells. Like bryostatin 1, bryostatin 7 caused a 
very limited, biphasic inhibition of U937 cell proliferation (Figure 1.43). Again, like 
bryostatin 1, bryostatin 7 was able to suppress the growth inhibition induced by PMA. 
Bryostatin 7 also caused a reduced level of cell attachment compared to that induced by 
PMA and, when co-administered, was able to inhibit the attachment induced by PMA. A 
comparison of the dose-response curves indicated that bryostatin 7 inhibited proliferation 
slightly more than did bryostatin 1 and induced slightly more attachment than did 
bryostatin 1.  Bryostatin 1 and 7 induced similar levels of TNFα secretion while PMA 
induced a higher level of secretion. Additionally, bryostatin 7, like bryostatin 1, was able 
to synergize with Ara-C to induce loss of mitochondrial potential in U937 cells.127b 
Bryostatin 1 and 7 showed similar levels of downregulation of PKC βII, whereas PMA 
treatment induced less downregulation. Bryostatin 7 showed 3-fold weaker potency than 





Figure 1.43. Biological responses of U937 leukemia cells to PMA, bryostatin 1, and 
bryostatin 7 
 
proliferation assays. For PKCδ, bryostatin 1 and 7 showed a biphasic dose-response 
curve for downregulation, as observed with bryostatin 1 in other cells. Again, bryostatin 7 
showed 3-fold weaker potency (Figure 1.44). 
In LNCaP cells, bryostatin 7, like bryostatin 1, fails to inhibit proliferation and 
was able to block the inhibition of proliferation by PMA (Figure 1.45). Similar to 
bryostatin 1, bryostatin 7 induced minimal secretion of TNFα and inhibits the secretion of 
TNFα induced by PMA. 
Proliferation of U937 Attachment of U937 








Figure 1.44. Downregulation of PKC βII and PKCδ in U937 cells 
 
Cells were treated with the indicated concentrations of PMA, bryostatin 1, and bryostatin 
7 for 24 h. Levels of PKCβII and PKCδ were quantitated in total cell lysates by Simple 
Western (Simon) using anti-PKCδ antibodies. Loading was normalized to β-actin or α-
tubulin, which provided loading controls, and normalized values were expressed relative 
to that of the DMSO-treated cells. Values represent the mean SEM of three independent 
experiments. The lower panels show representative images of immunoblots performed on 
total cell lysates using the same antibodies and visualized by chemiluminescence. 
  
   




Figure 1.45. Biological response of LNCaP cells to PMA, bryostatin 1, and 7 
 
Previously, it has been mentioned that PMA differed from bryostatin 1 in 
membrane translocation of PKCδ. Comparison of various phorbol esters and related 
ligands showed that PKCδ translocation patterns correlated with the tumor-promoting 
abilities. The compounds that were tumor-promoting showed a similar translocation 
pattern to that of PMA, whereas the compounds that were nonpromoting showed patterns 
similar to bryostatin 1. As higher lipophilicity compared to bryostatin 1 was associated 
with the tumor-promoting ability of PMA, it was hypothesized that bryostatin 7 being 
less lipophilic than bryostatin 1 should induce even less membrane translocation. 
To test this hypothesis, the LNCaP cells were transiently transfected with mouse 





Figure 1.46. Translocation of mouse (A) and human (B) GFP-PKCδ in LNCaP cells after 
treatment with PMA, bryostatin 1, or bryostatin 7 
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Bryostatin 7, as expected, caused translocation of mouse GFP-PKCδ to the nuclear and 
internal membranes, whereas PMA translocated it to the plasma membrane. Interestingly, 
using human GFP-PKCδ bryostatin 1 initially translocated to plasma membranes 
although to a much lesser extent than PMA. Bryostatin 7, on the other hand, translocated 
only to internal membranes. This trend can also be observed in human PKCε for the 
translocation of YFP-PKCε (Figure 1.47). Clearly in human PKCδ and ε, bryostatin 1 
shows some resemblance to PMA while the less lipophilic bryostatin 7 has a distinct 
pattern. Bryostatin 7 caused no plasma membrane translocation with shift to an internal 
punctate distribution consistent with association with internal membranes. Additionally, 
from these studies, it is clear that various ester functionalities at the C20 position play an 
important role in the translocation behaviors of bryostatins. 
 
 
Figure 1.47. Translocation of human YFP-PKCε in LNCaP cells after treatment 






 The power of the pyran annulation has been demonstrated through these complex 
total syntheses of bryostatin 1, 7, Merle 30, Merle 32, and various other analogues. Our 
extensive studies on the structure and activity relationship of various functional groups on 
the northern hemisphere of bryostatin 1 indicated that the C7 acetate, C30 carbomethoxy, 
C9 hydroxy, C20 octadienoate, and C8 gem-dimethyl groups individually do not play 
critical roles in imparting bryostatin 1 biology. At this point, our understanding is that the 
subtle balance of the polar and nonpolar functional groups play an important role in the 
interaction of bryostatin 1 with the lipid bilayer and the various PKC isozymes. This 
ternary structure of bryostatin 1, PKC, and the lipid bilayer is the key chemical entity that 
we have to focus on for a better understanding of the unique biological profile of 
bryostatin 1. To further investigate on the interactions, we endeavored in the syntheses of 
various analogues, which will be discussed in the Chapter 2.    
 
Experimental section 
General experimental procedures, materials, and instrumentation  
Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals.131 Diisopropylamine, triethylamine, pyridine, Hünig’s base, 
EtOAc, and CH2Cl2 were distilled from CaH2 under an atmosphere of dry N2. THF, Et2O, 
and toluene were distilled from Na under an atmosphere of dry N2. Ti(OiPr)4 and TiCl4 
were distilled prior to use. A stock solution of Ti(OiPr)4 (1.0 M in CH2Cl2) was prepared 
and used for the BITIP catalyst preparations. The titer of n-butyllithium was determined 
by the method of Eastham and Watson.132 All other reagents were used without further 
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purification. Yields were calculated for material judged homogeneous by thin layer 
chromatography and nuclear magnetic resonance (NMR) spectroscopy. Thin layer 
chromatography was performed on Merck Kieselgel 60 F254 plates eluting with the 
solvent indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic 
solution of 12-molybdophosphoric acid. Glassware for reactions was oven dried at 125 
oC and cooled under a dry atmosphere prior to use. Liquid reagents and solvents were 
introduced by oven-dried syringes through septum-sealed flasks under a nitrogen 
atmosphere. Column flash chromatography was performed with Silicycle Grade 70 – 230 
mesh, 60 – 200 µm, 60 Å silica gel, slurry packed with 1% EtOAc/hexanes in glass 
columns. Preparative thin layer chromatography was performed on Analtech Inc. Silica 
Gel GF 20 cm × 20 cm × 2000 µm plates or on Merck Kieselgel 60 F254 20 cm × 20 cm × 
250 µm plates. Nuclear magnetic resonance spectra were acquired on Varian VXR-500, 
Varian Inova-500 spectrometer 500 MHz for 1H and 125 MHz for 13C. Prior to use, 
CDCl3 was filtered through a plug of Fischer Scientific 80 – 200 mesh Alumina 
Adsorption stored at 110 oC. Chemical shifts for proton nuclear magnetic resonance (1H 
NMR) spectra are reported in parts per million relative to the signal of trimethylsilane at 
0 ppm, relative to the signal of residual CHCl3 at 7.27 ppm, or relative to the signal of 
residual C6D5H at 7.16 ppm. Chemical shifts for carbon nuclear magnetic resonance (13C 
and DEPT) spectra are reported in parts per million relative to the signal of 
trimethylsilane at 0 ppm, relative to the center line of the CDCl3 triplet at 77.23 ppm, or 
relative to the center line of the C6D6 triplet at 128.62 ppm. Chemical shifts of the 
unprotonated carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C 
NMR spectrum. The abbreviations s, bs, d, dd, ddd, dddd, t, td, tt, q, dq, dqd, ddq, ABq, 
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quin, and m stand for the resonance multiplicity singlet, broad singlet, doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, triplet, 
triplet of doublets, triplet of triplets, quartet, doublet of quartets, doublet of quartet of 
doublets, doublet of doublet of quartets, AB quartet, quintet, and multiplet, respectively. 
IR spectra were obtained from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer. 
Melting points were obtained using a Mel-Temp electrochemical melting point apparatus 
and are uncorrected. Optical rotations were obtained on a Perkin Elmer model 343 
polarimeter (Na D line) using a microcell with 1 dm path length. Specific rotations 
([α]20D, Unit: ocm2/g) are based on the equation α = (100. α)/(l.c) and are reported as 
unitless numbers where the concentration c is in g/100 mL and the path length l is in 
decimeters. Mass spectrometry was performed at the mass spectrometry facility of the 
Department of Chemistry at the University of Utah on a Finnigan MAT 95 double 
focusing high-resolution mass spectrometer. Compounds were named using 
ChemBioDraw 13.0. 
 
Experimental procedures and analytical data 
  
Preparation of 3-((tert-butyldiphenylsilyl)oxy)propan-1-ol 1.34.111a To a 
stirring solution of BPSCl (59.0 mL, 227 mmol, 1.00 equiv) in CH2Cl2 (1335 mL, 0.17 
M) in a 2000 mL round-bottom flask at room temperature were added 1,3-propanediol 
(81.6 mL, 1.13 mol, 5.00 equiv), triethylamine (63.2 mL, 454 mmol, 2.00 equiv), and 
DMAP (1.4 g, 11.3 mmol, 0.05 equiv). After 36 h, the mixture was diluted with a 1:1 




(100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a 7.5 x 28 cm silica 
gel column eluting with solvent gradient of 10% (1000 mL) through 30% (1000 mL) and 
40% EtOAc/hexanes (1000 mL). The eluant was collected in 125 mL fractions and then 
in two 2000 mL round-bottom flasks. The fractions containing product (27 - 33) and the 
contents of the two 2000 mL round-bottom flasks were combined and concentrated under 
reduced pressure to give alcohol 1.34 (58.0 g, 81%) as a crystalline solid: Rf 0.36 (30% 
EtOAc/hexanes); 300 MHz 1H NMR (CDCl3) δ 7.72 – 7.66 (m, 4H), 7.49 – 7.36 (m, 6H), 
3.90 – 3.82 (m, 4H), 2.41 (t, J = 5.5, 1H), 1.82 (quin, J = 5.5 Hz, 2H), 1.07 (S, 9H); 75 
MHz 13C NMR (CDCl3) δ 135.8, 133.4, 130.0, 128.0, 63.6, 62.3, 34.4, 27.0, 19.3. 
 
Preparation of 3-((tert-butyldiphenylsilyl)oxy)propanal 1.35.111a To a stirring 
solution of oxalyl chloride (26.3 mL, 276 mmol, 1.50 equiv) in CH2Cl2 (1842 mL, 0.15 
M) in a 3000 mL three-neck round-bottom flask equipped with a mechanical stirrer at -78 
oC was slowly added a solution of dimethyl sulfoxide (39.2 mL, 552 mmol, 3.00 equiv) 
in CH2Cl2 (51.3 mL). After 1 h, a solution of alcohol 1.34 (57.8 g, 184 mmol, 1.00 equiv) 
in CH2Cl2 (92.0 mL) was added via cannula. Triethylamine (128 mL, 920 mmol, 5.00 
equiv) was added dropwise via syringe after 1 h. After an additional 1 h, the reaction was 
determined complete by TLC analysis. The cold bath was removed, the reaction mixture 
warmed to room temperature, and subsequently quenched with water. The solvent was 
removed under reduced pressure and then the resulting slurry was diluted with 20% 
EtOAc/hexanes. The phases were separated and the organic phase was washed with water 





concentrated under reduced pressure to give pale yellow oil. Purification was 
accomplished by flash column chromatography on a 7.5 x 12 cm silica gel column 
eluting with 20% EtOAc/hexanes (6000 mL) and the eluant was collected in 2000 mL 
fractions. The fractions containing product (2 - 6) were combined and concentrated under 
reduced pressure to give the aldehyde 1.35 (55.1 g, 96%) as colorless crystalline solid: Rf 
0.51 (30% EtOAc/ hexanes); 300 MHz 1H NMR (CDCl3) δ 9.85 (t, J = 2.2 Hz, 1H), 7.72 
– 7.69 (m, 4H), 7.49 – 7.40 (m, 6H), 4.06 (t, J = 6.1 Hz, 2H), 2.64 (td, J = 5.9, 2.0 Hz, 
2H), 1.09 (s, 9H); 75 MHz 13C NMR (CDCl3) d 202.0, 135.7, 133.4, 130.0, 128.0, 58.4, 
46.5, 26.9, 19.3. 
 
Preparation of (S)-1-((tert-butyldiphenylsilyl)oxy)hex-5-en-3-ol 1.37.111a To a 
50 mL three-neck round-bottom flask charged with a magnetic stir bar and equipped with 
a reflux condenser were added oven-dried 4 Å molecular sieves (1.28 g, 400 g/mol of 
aldehyde), (S)-BINOL (183 mg, 0.640 mmol, 0.20 equiv), CH2Cl2 (10 mL, 0.06 M), 
Ti(OiPr)4 (1.00 M in CH2Cl2, 320 µL, 0.320 mmol, 0.10 equiv), and TFA (freshly 
prepared 0.10 M solution in CH2Cl2, 22.4 µL, 0.022 mmol, 7.0 x 10-3 equiv). The 
resulting red-brown solution was heated to 40 oC for 1 h. The mixture was cooled to 
room temperature and the reflux condenser exchanged for a rubber septum. A solution of 
aldehyde 1.35 (1.00 g, 3.20 mmol, 1.00 equiv) in CH2Cl2 (1.28 mL) was added via 
cannula, the mixture stirred for 30 min, and then cooled to -78 oC. Allyltributyl tin 1.36 
(1.29 mL, 4.16 mmol, 1.30 equiv) was added, the mixture stirred for 30 min, and the 
flask placed in a -20 oC freezer. After 5 days, the mixture was removed from the freezer 




removed and the mixture stirred for 30 min, allowed to settle, and then filtered through a 
plug of Celite®. The aqueous phase was extracted with CH2Cl2 (2 × 100 mL) and the 
combined organic phase was washed with water (2 × 100 mL) and brine (100 mL). The 
organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a 2.5 × 24 cm silica 
gel column eluting with a solvent gradient of hexanes (500 mL) and 5% acetone/ hexanes 
(750 mL) collecting 25 mL fractions. The fractions containing product (18 - 24) were 
combined and the solvent was removed under reduced pressure to give the homoallylic 
alcohol 1.37 (1.12 g, 99%) as colorless oil. The ratio of the enantiomers was determined 
to be 99:1 (using the other enantiomer made by the same procedure, er = 98:2) by HPLC 
analysis using a Daicel Chiralcel OD-H silica column (length: 25 cm), eluting with a 
mobile phase of 2.5% 2-propanol/ hexanes and a flow rate of 0.5 mL/ min, respectively, 
detecting with a Rainin Dynamax Refractive Index Detector Model RI-1: tr (major) = 
8.15 min, tr (minor) = 9.21 min; Rf 0.58 (30% EtOAc/ hexanes); 400 MHz 1H NMR 
(CDCl3) δ 7.69 – 7.62 (m, 4H), 7.45 – 7.34 (m, 6H), 5.83 (dddd, J = 17.2, 10.2, 7.1, 7.1 
Hz, 1H), 5.12 – 5.07 (m, 1H), 5.07 – 5.05 (m, 1H), 3.98 – 3.90 (m, 1H), 3.90 – 3.78 (m, 
2H), 3.15 (d, J = 2.6, 1H), 2.31 – 2.18 (m, 2H), 1.77 – 1.62 (m, 2H), 1.03 (s, 9H); 125 
MHz 13C NMR (CDCl3) δ 135.8, 135.8, 135.2, 133.3, 133.2, 133.0, 130.0, 128.0, 117.6, 
71.0, 63.5, 42.2, 38.1, 27.0, 19.2; 125 MHz DEPT (CDCl3) δ CH3: 27.0, CH2: 117.6, 
63.5, 42.2, 38.1, CH: 135.8, 135.8, 130.0, 130.0, 128.0, 71.0. 
 
Preparation of (S)-tert-butyl((3-((4-methoxybenzyl)oxy)hex-5-en-1-




1.00 equiv) and freshly prepared 4-methoxybenzyl trichloroacetimidate (10.8 g, 38.1 
mmol, 2.50 equiv) in CH2Cl2 (31 mL, 0.50 M) in a 100 mL round-bottom flask, under an 
atmosphere of N2, was added (±)-camphor-10-sulfonic acid (1.10g, 4.57 mmol, 0.30 
equiv) in one portion. The reaction was allowed to proceed for 24 h at rt, after which time 
TLC analysis indicated essentially complete consumption of the starting material. The 
reaction mixture was concentrated under reduced pressure, diluted with 20% EtOAc/ 
hexanes (50 mL), filtered over a pad of Celite®, and concentrated under reduced pressure 
to give a red slurry. Purification was accomplished by flash column chromatography on a 
(4.5 x 30) cm silica gel column eluting with 5% EtOAc/ hexanes, collecting 25 mL 
fractions. The fractions containing product (15 - 27) were combined and concentrated 
under reduced pressure to give PMB ether 1.38 (5.65 g, 78%) as colorless oil: Rf 0.49 
(30% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 7.70 – 7.66 (m, 4H), 7.46 – 7.36 
(m, 6H), 7.23 – 7.19 (m, 2H), 6.86 – 6.83 (m, 2H), 5.85 (dddd, J = 17.3, 10.3, 7.0, 7.0 
Hz, 1H), 5.12 – 5.05 (m, 2H), 4.45 (ABq, J = 11.1 Hz, Δν = 44.9 Hz, 2H), 3.86 – 3.83 
(m, 1H), 3.80 (s, 3H), 3.78 – 3.69 (m, 2H), 2.33 (t, J = 7.0 Hz, 2H), 1.87 – 1.77 (m, 2H), 
1.10 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 159.3, 135.8, 135.1, 134.2, 134.1, 131.2, 
129.8, 129.5, 127.8, 127.8, 117.1, 113.9, 75.3, 71.0, 60.7, 55.5, 38.7, 37.2, 27.1, 19.4; 
125 MHz DEPT (CDCl3) δ CH3: 55.5, 27.1, CH2: 117.1, 71.0, 60.7, 38.7, 37.2, CH: 
135.8, 135.1, 129.8, 129.5, 127.8, 127.8, 113.9, 75.3. 
 
Preparation of (S)-3-((4-methoxybenzyl)oxy)hex-5-en-1-ol 1.39.111a To a 
stirring solution of BPS ether 1.38 (32.0 mg, 0.07 mmol, 1.00 equiv) in THF (540 µL, 




M solution of tetrabutylammonium fluoride (135 µL, 0.13 mmol, 2.00 equiv) in THF, 
dropwise via syringe. The reaction was allowed to proceed for 15 h at rt, after which time 
TLC analysis indicated complete consumption of the starting material. The reaction 
mixture was then quenched with a saturated aqueous NH4Cl solution (10 mL), extracted 
with 80% EtOAc/hexanes (3 × 10 mL). The combined organic layer was washed once 
with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a (15 × 2) cm 
silica gel column, eluting with 30% EtOAc/ hexanes (200 mL), collecting 6 mL fractions. 
The fractions containing product (29 – 47) were concentrated under reduced pressure to 
give the primary alcohol 1.39 (15.8 mg, >99%) as colorless oil: Rf 0.10 (30% EtOAc/ 
hexanes); 400 MHz 1H NMR (CDCl3) δ 7.29 – 7.26 (m, 2H), 6.90 – 6.87 (m, 2H), 5.83 
(dddd, J = 17.3, 10.2, 7.2, 7.2 Hz, 1H), 5.15 – 5.09 (m, 2H), 4.51 (ABq, J = 11.1 Hz, Δν 
= 68.9 Hz, 2H), 3.80 (s, 3H), 3.78 – 3.67 (m, 3H), 2.47 – 2.40 (m, 1H), 2.35 (ddd, J = 
14.2, 7.0, 7.0 Hz, 1H), 1.81 – 1.71 (m, 2H); 125 MHz 13C NMR (CDCl3) δ 159.5, 134.5, 
130.5, 129.7, 117.7, 114.1, 77.5, 70.9, 61.0, 55.5, 38.2, 36.1; 125 MHz DEPT (CDCl3) δ 
CH3: 55.5, CH2: 117.7, 70.9, 61.0, 38.2, 36.1, CH: 134.5, 129.7, 114.1, 77.5. 
 
Preparation of (S)-3-((4-methoxybenzyl)oxy)hex-5-enal 1.25.111a To a stirring 
solution of alcohol 1.39 (1.75 g, 7.40 mmol, 1.00 equiv) in CH2Cl2 (80 mL, 0.10 M) in a 
250 mL round-bottom flask under an atmosphere of N2, at -10 oC, was added N,N-
diisopropylethylamine (9.75 g, 52.0 mmol, 7.00 equiv). After 10 min at -10 oC, dimethyl 
sulfoxide (5.7 mL, 74.0 mmol, 10.0 equiv) was added to the reaction mixture via syringe 





complex (5.10 g, 29.6 mmol, 4.00 equiv) was then added in one portion. The reaction 
was allowed to proceed for 1 h at -10 oC, after which time TLC analysis indicated 
complete consumption of the starting material. The reaction was quenched by adding 
saturated aqueous solution of NaHCO3 (100 mL) and the phases were separated. The 
aqueous phase was extracted with 20% EtOAc/ hexanes (3 × 50 mL). The combined 
organic phase was washed twice with brine (50 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was by flash column chromatography 
on a (15 × 4) cm silica gel column eluting with 10% EtOAc/ hexanes (750 mL), 
collecting 10 mL fractions. The fractions containing product (29 – 45) were concentrated 
under reduced pressure to give the aldehyde 1.25 (1.60 g, 92%) as colorless oil: Rf 0.60 
(50% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 9.77 (dd, J = 2.3, 1.8 Hz, 1H), 
7.26 – 7.23 (m, 2H), 6.90 – 6.86 (m, 2H), 5.81 (dddd, J = 14.3, 9.7, 7.1, 7.1 Hz, 1H), 5.16 
– 5.14 (m, 1H), 5.12 (m, 1H), 4.51 (ABq, J = 11.1 Hz, Δν = 40.5 Hz, 2H), 4.05 – 4.01 (m, 
1H), 3.81 (s, 3H), 2.67 (ddd, J = 14.3, 7.1, 2.3 Hz, 1H), 2.56 (ddd, J = 16.7, 4.4, 1.8 HZ, 
1H), 2.47 – 2.42 (m, 1H), 2.40 – 2.35 (m, 1H); 125 MHz 13C NMR (CDCl3) δ 201.6, 
159.5, 133.8, 130.3, 129.6, 118.4, 114.0, 73.5, 71.1, 55.5, 48.2, 38.5; 125 MHz DEPT 
(CDCl3) δ CH3: 55.5, CH2: 118.4, 71.1, 48.2, 38.5, CH: 201.6, 133.8, 129.6, 114.0, 73.5. 
  
Preparation of S-(tert-butyl) (3R,5S)-3-hydroxy-5-((4-methoxybenzyl)oxy)oct-
7-enethioate 1.41.111a To a stirring solution of aldehyde 1.25 (103 mg, 0.44 mmol, 1.00 
equiv) in toluene (3.0 mL, 0.15 M) in a 10 mL round-bottom flask, under an atmosphere 
of N2, at -78 oC, was added a freshly prepared 1.0 M solution of TiCl2(OiPr)2 in toluene 





The resulting bright yellow solution was allowed to stir for 15 min, followed by dropwise 
addition of thioketene acetal 1.26 (233 mg, 1.14 mmol, 2.60 equiv), in toluene (300 µL), 
down the inside of the reaction flask over a 5-min period. An additional 200 µL of 
toluene rinse was used to transfer the remaining thioketene acetal residue from the 
syringe into the reaction flask. TLC analysis after 4 h, at -78 oC, indicated complete 
consumption of the aldehyde starting material. The reaction was quenched by transferring 
directly into a 250 mL Erlenmeyer flask that contained a vigorously stirring mixture of 
CH2Cl2 (100 mL) and aqueous pH 7.0 phosphate buffer (50 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic phases were washed with a saturated NH4Cl solution (2 × 50 mL), then with 
brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to 
give pale yellow oil. Purification was accomplished by flash column chromatography on 
a (3.5 × 20) cm silica gel column eluting with a solvent gradient of hexanes (50 mL) 
through 10% EtOAc/ hexanes (250 mL) and 20% EtOAc/ hexanes (200 mL), collecting 
10 mL fractions. The fractions containing product (50 – 62) were combined and 
concentrated under reduced pressure to give β-hydroxy thioester 1.41 (154.7 mg, 96%) as 
colorless oil: Rf 0.67 (50% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 7.29 – 7.26 
(m, 2H), 6.90 – 6.87 (m, 2H), 5.81 (dddd, J = 17.2, 10.2, 7.1, 7.1 Hz, 1H), 5.14 – 
5.07 (m, 2H), 4.51 (ABq, J = 11.0 Hz, Δν = 57.0 Hz, 2H), 4.33 – 4.26 (m, 1H), 3.81 (s, 3 
H), 3.79 – 3.76 (m, 1H), 3.17 (d, J = 3.8 Hz, 1H), 2.64 – 2.57 (m, 2H), 2.45 – 2.40 (m, 
1H), 2.34 (ddd, J = 14.0, 7.0, 7.0 Hz, 1H), 1.68 – 1.57 (m, 2H), 1.47 (s, 9H); 125 MHz 
13C NMR (CDCl3) δ 200.1, 159.5, 134.5, 130.6, 129.8, 117.7, 114.2, 114.1, 75.5, 71.3, 
66.0, 55.5, 51.6, 48.6, 40.2, 38.4, 30.0; 125 MHz DEPT (CDCl3) δ CH3: 55.5, 30.0, CH2: 
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117.7, 71.3, 51.6, 40.2, 38.4, CH: 134.5, 129.8, 114.2, 114.1, 75.5, 66.0. 
 
Preparation of methyl 2-((4R,6S)-6-allyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
1.42. To a stirring solution of a thioester 1.41 (200 mg, 0.545 mmol, 1.00 equiv) in 
CH2Cl2 (2.7 mL, 0.20 M) in a 15 mL round-bottom flask under an atmosphere of N2, was 
added TBSCl (205 mg, 1.36 mmol, 2.50 equiv) and imidazole (92.6 mg, 1.36 mmol, 2.50 
equiv) and the mixture was allowed to stir for 24 h. The reaction was judged complete by 
TLC analysis. The phases were separated and the aqueous phase was extracted with 20% 
EtOAc/ hexanes (3 × 20 mL). The combined organic phases were washed once with brine 
(20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure and used 
for the next step without further purification.   
To a stirring crude solution of a thioester 1.41 (assumed to be 0.545 mmol, 1.00 
equiv), CH2Cl2 (9.1 mL, 0.06 M), and water (1.6 mL) in a 15 mL round-bottom flask 
under an atmosphere of N2, at rt, was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(185.6 mg, 0.817 mmol, 1.50 equiv) in one portion. The reaction was allowed to proceed 
for 1 h, during which time solution color changed from dark green to orange. TLC 
analysis at 1 h indicated complete consumption of PMB ether starting material. The 
reaction mixture was diluted with 30% EtOAc/ hexanes (50 mL) and filtered, over a plug 
of Celite®, Florisil®, and MgSO4. The filtrate was concentrated under reduced pressure to 
give a mixture of anisaldehyde and mono deprotected product, which was taken directly 






 To a stirring solution of crude silyl ether (assumed to be 0.545 mmol, 1.00 equiv) 
and MeOH (4 mL) in a 15 mL round-bottom flask under N2, at rt, was added p-
toluenesulfonic acid monohydrate (10.3 mg, 0.05 mmol, 0.10 equiv) in one portion. TLC 
analysis after 30 min shows complete consumption of TBS ether starting material. The 
reaction mixture was diluted with 2,2-dimethoxypropane (4 mL) and stirred for an 
additional 10 min. The magnetic stir bar was extracted and the solvent was removed 
under reduced pressure. The concentrate was diluted with 2,2-dimethoxypropane (2 mL) 
and the mixture was again concentrated under reduced pressure. 2,2-dimethoxypropane 
(4 mL) was added to the concentrated mixture and the reaction was allowed to proceed 
for 15 min, after which time TLC analysis indicated complete consumption of diol. The 
reaction mixture was diluted with CH2Cl2 (50 mL), washed with a saturated aqueous 
NaHCO3 solution (10 mL), brine (10 mL), dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give the crude product as red oil. Purification was done by 
flash column chromatography on a (2.5 x 10) cm column, eluting with 5% EtOAc/ 
hexanes, collecting 10 mL fractions. The fractions containing product (14 - 17) were 
combined and concentrated under reduced pressure to give acetonide 1.42 (74 mg, 25%) 
as colorless oil: Rf 0.50 (30% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) 
δ 5.80 (dddd, J = 17.2, 10.2, 6.8 Hz, 1H), 5.13 – 5.04 (m, 2H), 4.27 (dddd, J = 11.4, 9.5, 
8.2, 5.5 Hz, 1H), 3.87 (dddd, J = 15.3, 12.9, 9.0, 6.2 Hz, 1H), 3.69 (s, 1H), 2.55 (dd, J = 
15.6, 8.1 Hz, 1H), 2.44 (dd, J = 15.6, 5.4 Hz, 1H), 2.32 (ddd, J = 14.2, 6.0, 6.0 Hz, 1H), 
2.21 (ddd, J = 14.4, 7.2, 6.0, 1H), 1.72 (ddd, J = 12.8, 9.1, 6.0, 1H), 1.63 (ddd, J = 12.9, 
10.0, 6.0, 1H), 1.37 (s, 3H), 1.34 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 171.6, 134.5, 




Preparation of S-(tert-butyl) (3R,5S)-3-((tert-butyldiphenylsilyl)oxy)-5-((4-
methoxybenzyl)oxy)oct-7-enethioate 1.43.111a To a stirring solution of a β-hydroxy 
thioester 1.41 (1.38 g, 3.78 mmol, 1.00 equiv) and imidazole (773 mg, 11.4 mmol, 3.00 
equiv) in DMF (13.0 mL, 0.30 M) in a 25 mL round-bottom flask under an atmosphere of 
N2, at rt, was added tert-butyl(chloro)diphenylsilane (1.18 mL, 4.54 mmol, 1.20 equiv) 
via syringe. The mixture was allowed to stir for 24 h, after which the reaction was 
quenched with addition of saturated aqueous solution of NaHCO3. The phases were 
separated and the aqueous phase was extracted with 20% EtOAc/ hexanes (3 × 50 mL). 
The combined organic phase was washed once with brine (50 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography on a silica gel column (2.5 × 30 cm) eluting with 5% EtOAc/ 
hexanes, collecting 10 mL fractions. The fractions containing product (25 - 35) were 
combined and concentrated under reduced pressure to give silyl ether 1.43 (2.10 g, 92%) 
as pale yellow oil: Rf 0.47 (30%EtOAc/hexanes); 400 MHz 1H NMR (CDCl3) δ 7.74 – 
7.70 (m, 4H), 7.45 – 7.36 (m, 6H), 7.14 – 7.11 (m, 2H), 6.86 – 6.83 (m, 2H), 5.61 (dddd, 
J = 17.4, 10.2, 7.1, 7.1 Hz, 1 H), 4.99 – 4.95 (m, 2H), 4.41 (tt, J = 6.6, 5.6 Hz, 1H), 4.31 
(d, J = 11.1 Hz, 1H), 4.06 (d, J = 11.1 Hz, 1H), 3.81 (s, 3 H), 3.38 – 3.34 (m, 1H), 2.72 
(dd, J = 14.6, 6.2 Hz, 1H), 2.66 (dd, J = 14.6, 5.8 Hz, 1H), 2.14 – 2.05 (m, 2H), 1.76 
(ddd, J = 14.2, 8.2, 5.9 Hz, 1H), 1.66 (ddd, J = 14.2, 6.2, 3.9 Hz, 1H), 1.44 (s, 9H), 1.04 






129.9, 129.8, 129.3, 127.8, 127.8, 117.3, 113.8, 75.7, 70.3, 69.2, 55.4, 53.1, 48.1, 42.4, 
38.6, 30.0, 27.2, 19.5.  
 
Preparation of S-(tert-butyl) (3R,5R)-3-((tert-butyldiphenylsilyl)oxy)-5-((4-
methoxybenzyl)oxy)-7-oxoheptanethioate 1.23.111a To a stirring solution of olefin 1.43 
(1.91 g, 3.16 mmol, 1.00 equiv) in THF (14 mL, 0.22 M), t-butanol (14 mL), and water (3 
mL) in a 50 mL round-bottom flask under N2, at rt, was added 4-methylmorpholine N-
oxide (462 mg, 3.94 mmol, 1.25 equiv) in one portion. A 0.10 M solution of OsO4 (1.6 
mL, 0.157 mmol, 0.05 equiv) in THF was added dropwise, via syringe. The reaction was 
allowed to proceed for 14 h, after which time TLC analysis indicated complete 
consumption of olefin starting material. The reaction was quenched by addition of 
saturated aqueous Na2S2O3 solution in one portion. The mixture was stirred for 1 h, 
during which time a color change from yellow to dark brown was observed. The 
quenched reaction mixture was diluted with water (20 mL), EtOAc (100 mL), and the 
phases were separated. The aqueous phase was extracted with EtOAc (3 × 100 mL). The 
combined organic phases were washed with brine (2 × 50 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give the crude diol as thick yellow 
liquid, which was then taken directly to the next reaction without any further purification. 
 To a stirring solution of crude diol (assumed to be 3.16 mmol, 1.00 equiv) in 
benzene (32 mL, 0.10 M) under an atmosphere of N2, at rt, was added Pb(OAc)4 (1.54 g, 







complete consumption of the starting material. The reaction mixture was diluted with 
hexanes (100 mL) then filtered over a pad of Celite® and Na2SO4. The filtrate was 
concentrated under reduced pressure then high vacuum to yield aldehyde 1.23 (2.00 g, 
quant. over 2 steps) as viscous colorless oil: Rf = 0.72 (50% EtOAc/ hexanes); 400 MHz 
1H NMR (CDCl3) δ 9.54 (t, J = 2.3 Hz, 1H), 7.73 – 7.69 (m, 4H), 7.46 – 7.37 (m, 6H), 
7.11 – 7.08 (m, 2H), 6.85 – 6.82 (m, 2H), 4.43 (tt, J = 6.4, 5.9 Hz, 1H), 4.19 (ABq, J = 
11.0 Hz, Δν = 40.0 Hz, 2H), 3.85 – 3.80 (m, 2H), 3.80 (s, 3H), 2.72 (dd, J = 14.6, 5.9 Hz, 
1H), 2.63 (dd, J = 14.6, 6.4 Hz, 1H), 2.34 (ddd, J = 16.5, 6.6, 2.3 Hz, 1H), 2.26 (ddd, J = 
16.5, 4.9, 2.3 Hz, 1H), 1.96 (ddd, J = 14.3, 6.8, 5.9 Hz, 1H), 1.64 (ddd, J = 14.3, 5.9, 5.5 
Hz, 1H), 1.43 (s, 9H), 1.05 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 201.2, 197.7, 159.4, 
136.1, 136.1, 133.9, 133.7, 130.3, 130.0, 130.0, 129.5, 127.9, 127.9, 113.9, 71.4, 70.7, 
68.5, 55.5, 52.6, 48.6, 48.3, 42.8, 29.9, 27.1, 19.6. 
  
Preparation of ethyl 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methylbut-3-
enoate 1.44.111a To a cooled (0 oC) stirring solution of diisopropylamine (19.7 mL, 140 
mmol, 1.2 equiv) in THF (702 mL, 0.20 M) in a flame-dried 2000 mL round-bottom flask 
under an atmosphere of N2 was added a 2.47 M solution of nBuLi (52.1 mL, 130 mmol, 
1.10 equiv) in hexanes, dropwise via syringe. The resulting yellow solution was stirred 
for 30 min at 0 oC and then cooled to -78 oC. Ethyl 3,3-dimethylacrylate 1.24 (16.3 mL, 
117 mmol, 1.00 equiv) was added dropwise via syringe to the reaction mixture. After 30 
min, a solution of 2-iodo-1-(tert-butyldimethylsilanoxy)-ethane (33.5 g, 117 mmol, 1.00 






additional THF rinse (5 mL) was used to transfer the remaining iodide residue into the 
reaction flask via cannula. The reaction was allowed to proceed for 15 h, allowing the -78 
oC bath to expire overnight, after which the TLC analysis indicated complete 
consumption of the ester starting material. The reaction was quenched by the addition of 
saturated aqueous NH4Cl solution (250 mL). The resulting mixture was diluted with 
water (250 mL) and Et2O (500 mL) and the phases were separated. The aqueous phase 
was extracted with Et2O (2 × 250 mL). The combined organic phases were washed with 
brine (250 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to 
give the crude product as red oil. Purification was accomplished by flash column 
chromatography on a (5 x 30) cm silica gel column eluting with a solvent gradient of 
hexanes (2000 mL) through 1% EtOAc/ hexanes (2000 mL), collecting 25 mL fractions. 
The fractions containing product (8 - 100) were combined and concentrated under 
reduced pressure to give alkylated ester 1.44 (26.8 g, 80%) as colorless oil: Rf 0.58 (15% 
EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 4.88 (quin, J = 1.5 Hz, 1H), 4.87 – 4.86 
(m, 1H), 4.12 (app dq, J = 7.0, 1.1 Hz, 2H), 3.58 (app t, J = 6.5 Hz, 2H), 3.23 (t, J = 7.7 
Hz, 1H), 2.06 (dddd, J = 13.9, 8.1, 6.2, 6.2 Hz, 2H), 1.78 – 1.71 (m, 1H), 1.73 (s, 3H), 
1.23 (t, J = 7.0 Hz, 3H), 0.88 (s, 9H), 0.02 (s, 3H), 0.02 (s, 3H). 
 
Preparation of ethyl 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methylbut-2-
enoate 1.45.111a An oven-dried 1000 mL round-bottom flask was charged with ester 1.44 
(11.2 g, 39.1 mmol, 1.00 equiv) and a magnetic stir bar. The flask was purged by a steady 







flask that was purged with N2 for 1 h, was added to the reaction flask via a Gastight® 
syringe. After cooling the mixture to 0 oC, KOtBu (4.39 g, 39.1 mmol, 1.00 equiv) was 
added to the reaction flask in one portion, under a steady steam of N2. The reaction was 
allowed to proceed for 3 h at 0 oC and then quenched by transfer into a 1000 mL 
Erlenmeyer flask that contained a stirring mixture of a saturated aqueous NH4Cl solution 
(100 mL) and Et2O (100 mL). The phases were separated. The organic phase was washed 
twice with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure to give pale yellow oil. Purification was accomplished by flash column 
chromatography on a (5 x 25) cm silica gel column eluting with 5% EtOAc/ hexanes 
(1000 mL), collecting 25 mL fractions. The fractions containing product (22 - 56) were 
combined and concentrated under reduced pressure to give the ester 1.45 (9.90 g, 95%) as 
colorless oil: Rf  0.34 (10% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 4.19 (q, J = 
7.1 Hz, 2H), 3.64 (t, J = 7.2 Hz, 2H), 2.56 (t, J = 7.2 Hz, 2H), 2.00 (s, 3H), 1.86 (s, 3H), 
1.30 (t, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 169.6, 
145.3, 124.4, 62.5, 60.2, 33.7, 26.2, 23.3, 22.6, 18.6, 14.5, -5.1. 
 
Preparation of 2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methylbut-2-en-1-ol 
1.46.111a To a stirring solution of ester 1.45 (6.59 g, 23.0 mmol, 1.00 equiv) and CH2Cl2 
(230 mL, 0.10 M) in a 500 mL round-bottom flask under an atmosphere of N2, at -20 oC, 
was added a 1.0 M solution of diisobutylaluminum hydride (57.5 mL, 57.5 mmol, 2.5 
equiv) in CH2Cl2, dropwise, via syringe. The reaction was allowed to proceed for 2 h at -







was quenched by dropwise addition of methanol. The mixture was transferred into a 1000 
mL Erlenmeyer flask containing a vigorously stirring mixture of a saturated aqueous 
solution of potassium sodium tartrate (200 mL) and CH2Cl2 (200 mL). The resulting 
mixture stirred for overnight, after which the phases were separated and the aqueous 
phase extracted with CH2Cl2 (3 × 100 mL). The organic phases were combined and 
washed twice with brine (100 mL), dried over Na2SO4, filtered, and then concentrated 
under reduced pressure to give pale yellow oil. Purification was accomplished by flash 
column chromatography on a 3 × 25 cm silica gel column eluting with 2.5% EtOAc/ 
hexanes (2000 mL), collecting in 25 mL fractions. The fractions containing product (25 - 
65) were combined and concentrated under reduced pressure to give the alcohol 1.46 (4.6 
g, 88%) as clear colorless oil: Rf 0.09 (15% EtOAc/ hexanes); 400 MHz 1H NMR 
(CDCl3) δ 4.10 (s, 2 H), 3.70 (t, J = 6.0 Hz, 2H), 3.25 (s, 1H), 2.42 (t, J = 5.7 Hz, 2H), 
1.76 (s, 3H), 1.70 (s, 3H), 0.91 (s, 9H), 0.08 (s, 3H). 
 
Preparation of tert-butyldimethyl((4-methyl-3-((tributylstannyl)methyl)pent-
3-en-1-yl)oxy)silane 1.22.111a To a stirring solution of allylic alcohol 1.46 (4.59 g, 18.8 
mmol, 1.00 equiv) in THF (19 mL, 1.00 M) in a flame-dried 250 mL round-bottom flask 
under an atmosphere of N2, at -78 °C, was added a 2.53 M solution of nBuLi (8.17 mL, 
20.7 mmol, 1.10 equiv) in hexanes dropwise via syringe. The resulting yellow solution 
was stirred for 30 min at -78 °C. Simultaneously, to a stirring solution of 
diisopropylamine (2.76 mL, 19.7 mmol, 1.05 equiv) in THF (20 mL, 1 M) in a 100 mL 







nBuLi (7.72 mL, 19.5 mmol, 1.04 equiv) in hexanes dropwise via syringe. After 45 min, 
freshly prepared tributyltin hydride (5.2 mL, 19.3 mmol, 1.03 equiv) was added via 
syringe to the freshly prepared LDA solution. At the same time, methanesulfonyl chloride 
(1.45 mL, 18.8 mmol, 1.00 equiv) was added to the lithium alkoxide solution at -78 °C. 
After 1.5 h, the Bu3SnLi solution was added dropwise to the reaction flask via cannula. 
An additional THF (2 mL) rinse was used to transfer Bu3SnLi residue from the flask into 
the reaction mixture via cannula. The reaction was allowed to proceed for 2 h at -78 °C, 
then for an additional 18 h during which time the -78 °C bath was allowed to expire. The 
mixture was quenched by addition of water (25 mL), and then diluted with 10% EtOAc/ 
hexanes (200 mL) and the phases were separated. The organic phases were washed twice 
with water (50 mL), once with brine (50 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure to give yellow oil. Purification was accomplished by 
flash column chromatography on a 3 x 30 cm silica gel column eluting with hexanes 
(2000 mL), collecting in 8 mL fractions. The fractions containing product (20 – 133) 
were combined and concentrated under reduced pressure to give allylstannane 1.22 (3.30 
g, 78%) as colorless oil: Rf 0.17 (hexanes); 400 MHz 1H NMR (CDCl3) δ 3.63 (t, J = 7.7 
Hz, 2H), 2.20 (t, J = 7.7 Hz, 2H), 1.72 (app s, flanked by Sn satellites, 1H), 1.67 (app s, 
flanked by Sn satellites, 3H), 1.59 (app s, flanked by Sn satellites, 3H), 1.56 – 1.40 (m, 
6H), 1.31 (sextet, J = 7.3 Hz, 6 H), 0.92 (s, 9H), 0.90 (t, J = 7.3 Hz, 9H), 0.85 – 0.82 (m, 
6H), 0.08 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 128.3 (flanked by Sn satellites, JC-Sn = 
23 Hz), 120.6 (flanked by Sn satellites, JC-Sn = 22 Hz), 62.6 (flanked by Sn satellites, JC-Sn 
= 7 Hz), 38.7, 29.4 (flanked by Sn satellites, JC-Sn = 10 Hz), 27.7 (flanked by Sn satellites, 
JC-Sn = 27 Hz), 26.3, 21.1 (flanked by Sn satellites, JC-Sn = 6 Hz), 20.4 (flanked by Sn 
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satellites, JC-Sn = 6 Hz), 18.7, 17.2 (flanked by Sn satellite doublets, JC-Sn = 124 Hz), 13.9, 
10.1 (flanked by Sn satellite doublets, JC-Sn = 153 Hz), - 5.0 (flanked by Sn satellite 
doublets, JC-Sn = 28 Hz). 
 
Preparation of S-(tert-butyl) (3R,5S,7S)-11-((tert-butyldimethylsilyl)oxy)-3-
((tert-butyldiphenylsilyl)oxy)-7-hydroxy-5-((4-methoxybenzyl)oxy)-8,8-dimethyl-9-
methyleneundecanethioate 1.48.111a To a stirring solution of aldehyde 1.23 (2.00 g, 3.29 
mmol, 1.00 equiv) in toluene (33 mL, 0.10 M) in a 100 mL round-bottom flask under an 
atmosphere of N2, at -78 °C, was added a freshly prepared 3.0 M solution of Me2AlCl 
(5.5 mL, 16.5 mmol, 5.00 equiv) in toluene dropwise, via syringe, down the inside of the 
flask. The solution was stirred for 10 min at -78 °C, then stannane 1.22 (2.20 g, 4.28 
mmol, 1.30 equiv) in toluene (3.5 mL) was added dropwise, via syringe, down the inside 
of the reaction flask. The reaction was allowed to proceed for 2 h at -78 °C, and then 
quenched by direct transfer into a 500 mL Erlenmeyer flask that contained a vigorously 
stirring mixture of a saturated aqueous potassium sodium tartrate solution (100 mL) and 
20% EtOAc/hexanes (100 mL). The resulting mixture was allowed to stir for overnight 
and then the phases were separated. The aqueous phase was extracted with 30% 
EtOAc/hexanes (3 × 100 mL). The combined organic phases were washed once with 
brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to 
give the crude product as pale yellow oil. Purification was accomplished by flash column 









5% EtOAc/hexanes (500 mL) through 10% EtOAc/hexanes (750 mL), collecting 10 mL 
fractions. The fractions containing product (59 – 103) were combined and concentrated 
under reduced pressure to give the alcohol 1.48 (2.1 g, 72%) as a single diastereomer by 
1H and 13C NMR, and as colorless oil: Rf 0.64 (30% EtOAc/hexanes); 400 MHz 1H NMR 
(CDCl3) δ 7.76 – 7.72 (m, 4H), 7.46 – 7.38 (m, 6H), 7.16 – 7.14 (m, 2H), 6.86 – 6.83 (m, 
2H), 4.99 (s, 1H), 4.93 (s, 1H), 4.34 (app quin, J = 5.6 Hz, 1H), 4.24 (ABq, J = 11.0 Hz, 
Δν = 49.0 Hz, 2H), 3.81 – 3.77 (m, 2H), 3.81 (s, 3H), 3.68 (d, J = 9.3 Hz, 1H), 3.64 – 
3.59 (m, 1H), 2.72 (dd, J =14.3, 5.6 Hz, 1H), 2.66 (dd, J = 14.3, 5.6 Hz, 1H), 2.43 (d, J = 
2.6 Hz, 1H), 2.28 (ddd, J = 15.0, 7.3, 7.3 Hz, 1H), 2.23 (ddd, J = 15.0, 6.2, 6.2 Hz, 1H), 
1.98 (td, J = 13.9, 6.6 Hz, 1H), 1.60 (td, J = 13.9, 5.6 Hz, 1H), 1.46 (s, 9H), 1.26 – 1.16 
(m, 2H), 1.06 (s, 9H), 0.97 (s, 3H), 0.93 (s, 9H), 0.90 (s, 3H), 0.09 (s, 6H); 125 MHz 13C 
NMR (CDCl3) δ 197.8, 159.2, 151.8, 136.2, 136.1, 134.1, 133.9, 130.9, 129.9, 129.8, 
129.5, 127.8, 113.8, 111.2, 74.4, 71.6, 71.0, 68.9, 63.5, 55.4, 52.4, 48.1, 43.9, 42.6, 35.5, 




4,14-dioxa-3,15-disilaheptadecan-9-yl acetate 1.21.111a To a stirring solution of alcohol 
1.48 (2.00 g, 2.39 mmol, 1.00 equiv), triethylamine (1 mL, 7.18 mmol, 3.00 equiv), 
DMAP (29.2 mg, 0.239 mmol, 0.10 equiv) in CH2Cl2 (24 mL, 0.10 M) in a 50 mL round-









mmol, 2.00 equiv) dropwise via syringe. TLC analysis after 18 h indicated complete 
consumption of alcohol starting material. The reaction mixture was diluted with 30% 
EtOAc/hexanes (100 mL), washed twice with a saturated aqueous NaHCO3 solution (50 
mL), once with brine (50 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure to give the crude product as pale yellow oil. Purification was 
accomplished by flash column chromatography on a (2.5 x 25) cm column, eluting with 
5% EtOAc/ hexanes (1000 mL), collecting 10 mL fractions. The fractions containing 
product (31-69) were combined and concentrated under reduced pressure to give 
acetylated product 1.21 (1.90 g, 95%) as colorless oil: Rf 0.59 (30% EtOAc/hexanes); 400 
MHz 1H NMR (CDCl3) δ 7.73 – 7.68 (m, 4H), 7.45 – 7.36 (m, 6H), 7.22 – 7.20 (m, 2H), 
6.85 – 6.83 (m, 2H), 5.28 (d, J = 9.2 Hz, 1H), 4.90 (s, 1H), 4.83 (s, 1H), 4.28 – 4.23 (m, 
1H), 4.21 (ABq, J = 10.3 Hz, Δν = 29.0 Hz, 2H), 3.80 (s, 3H), 3.67 (app t, J = 7.3 Hz, 
2H), 3.25 – 3.19 (m, 1H), 2.65 (dd, J =14.6, 6.2 Hz, 1H), 2.55 (dd, J = 14.6, 6.2 Hz, 1H), 
2.27 (ddd, J = 15.0, 7.3, 7.3 Hz, 1H), 2.22 (ddd, J = 15.0, 7.3, 7.3 Hz, 1H), 1.99 (s, 3H), 
1.97 – 1.90 (m, 1H), 1.52 – 1.46 (m, 1H), 1.45 (s, 9H), 1.32 – 1.17 (m, 2H), 1.05 (s, 9H), 
0.96 (s, 3H), 0.94 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 
197.8, 170.9, 159.2, 150.9, 136.2, 136.1, 133.9, 131.1, 130.0, 129.9, 129.7, 127.9, 127.8, 
113.8, 111.2, 74.6, 73.5, 71.3, 68.7, 63.4, 55.4, 52.4, 48.2, 43.5, 42.9, 35.8, 34.7, 30.0, 












disilaheptadecan-9-yl acetate 1.49.111a To a stirring mixture of PMB ether 1.21 (1.59 g, 
1.81 mmol, 1.00 equiv) in CH2Cl2 (12 mL, 0.15 M), and pH 7.0 phosphate buffer (6.0 
mL) in a 50 mL round-bottom flask under an atmosphere of N2, at rt, was added 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (823 mg, 3.62 mmol, 2.00 equiv) in one portion. 
TLC analysis after 2 h indicated complete consumption of alcohol starting material. The 
reaction mixture was transferred to a 100 mL Erlenmeyer flask, containing 30% 
EtOAc/hexanes (50 mL), and filtered over a plug of Celite®, Florisil®, and Na2SO4. The 
plug was flushed with additional 30% EtOAc/hexanes (3 × 30 mL) portions. The filtrate 
was concentrated under reduced pressure to give the crude product as colorless oil. 
Purification was accomplished by flash column chromatography on a silica gel column 
(2.5 x 25) cm, eluting with 5% EtOAc/hexanes, collecting 10 mL fractions. The fractions 
containing product (64 – 77) were combined and concentrated under reduced pressure to 
give alcohol 1.49 (1.30 g, 95%) as colorless oil: Rf 0.15 (10% EtOAc/ hexanes); 400 
MHz 1H NMR (CDCl3) δ 7.72 – 7.68 (m, 4H), 7.46 – 7.38 (m, 6H), 5.08 (dd, J = 11.4, 
1.5 Hz, 1H), 4.94 (s, 1H), 4.87 (s, 1H), 4.43 – 4.38 (m, 1H), 3.72 (app dddd, J = 17.9, 9.9, 
7.0, 7.0 Hz, 2H), 3.49 (app t, J = 8.8 Hz, 2H), 2.68 – 2.60 (m, 3H), 2.26 (app t, J = 7.3 
Hz, 2H), 1.93 (s, 3H), 1.60 (ddd, J = 14.3, 9.2, 4.0 Hz, 1H), 1.55 (ddd, J = 14.3, 8.1, 2.6 
Hz, 1H), 1.45 – 1.23 (m, 2H), 1.41 (s, 9H), 1.04 (s, 9H), 1.02 (s, 3H), 1.02 (s, 3H), 0.91 
(s, 9H), 0.07 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 197.7, 172.2, 150.6, 136.1, 136.0, 
133.8, 133.8, 130.0, 129.9, 127.9, 111.3, 75.2, 68.4, 63.8, 63.3, 52.5, 48.1, 44.4, 42.9, 






dimethyltetrahydro-2H-pyran-4-yl acetate 1.50.111a To a stirring solution of alkene 
1.49 (1.27 g, 1.67 mmol, 1.00 equiv) in CH2Cl2 (33.5 mL, 0.05 M) in a 100 mL round-
bottom flask, at -78 °C, was bubbled a steady stream of ozone. After 10 min, during 
which time the solution color changed from colorless to dark blue, ozone bubbling was 
ceased, completion of the reaction was judged by TLC analysis and then replaced with a 
steady stream of N2 for 5 min to purge the solution. Methyl sulfide (33.5 mL) was added 
to the reaction mixture and the resulting solution was stirred for 14 h. The stir bar was 
removed and the reaction mixture was concentrated under reduced pressure to give the 
crude product as yellow oil. Purification was accomplished by flash column 
chromatography on a silica gel column (2.5 x 25) cm, eluting with 5% EtOAc/hexanes 
(500 mL), collecting 10 mL fractions. The fractions containing product (11 – 33) were 
combined and concentrated under reduced pressure to give cyclic hemiketal 1.50 (1.13 g, 
90%) as colorless oil: Rf 0.20 (10% EtOAc/hexanes); 400 MHz 1H NMR (CDCl3) δ 7.74 
– 7.69 (m, 4H), 7.45 – 7.36 (m, 6H), 5.23 (s, 1H), 5.07 (dd, J = 11.7, 4.8 Hz, 1H) 4.31 
(dddd, J = 8.4, 5.9, 5.9, 5.9 Hz, 1H), 4.17 (ddd, J = 12.1, 10.3, 1.8 Hz, 1H), 3.81 (dddd, J 
= 10.6, 7.7, 5.1, 3.3 Hz, 1H), 3.73 (ddd, J = 10.3, 4.0, 2.9 Hz, 1H), 2.70 (app d, J = 6.2 
Hz, 2H), 2.01 (s, 3H), 1.92 – 1.86 (m, 1H), 1.73 (td, J = 14.3, 8.1 Hz, 1H), 1.58 – 1.41 










0.90 (s, 9H), 0.83 (s, 3H), 0.10 (s, 3H), 0.10 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 
198.0, 170.6, 136.1, 136.1, 129.9, 129.7, 127.8, 127.7, 102.3, 73.4, 69.3, 64.7, 60.3, 52.5, 




pyran-4-yl acetate 1.51.111a To a stirring solution of hemiketal 1.50 (1.13 g, 1.48 mmol, 
1.00 equiv) in MeOH (37.0 mL, 0.04 M) in a 100 mL round-bottom flask, at rt, was 
added (±)-camphor-10-sulfonic acid (86 mg, 0.37 mmol, 0.25 equiv) in one portion, 
under a steady stream of N2. The reaction was allowed to proceed for 2 h, after which 
time TLC analysis indicated complete consumption of starting material. The reaction 
mixture was diluted with 50% EtOAc/hexanes (100 mL), quenched by the addition of a 
saturated aqueous NaHCO3 solution (50 mL), and then the resulting phases were 
separated. The organic phase was washed twice with brine (50 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography on a silica gel column (2.5 x 20) cm, eluting with 30% 
EtOAc/hexanes, collecting 10 mL fractions. The fractions containing product (22 - 34) 
were combined and concentrated under reduced pressure to give cyclic ketal 1.51 (1.13 g, 
quant.) as colorless oil: Rf 0.18 (30% EtOAc/hexanes); 400 MHz 1H NMR (CDCl3) δ 
7.70 – 7.64 (m, 4H), 7.47 – 7.37 (m, 6H), 5.06 (dd, J = 11.7, 4.8 Hz, 1H), 4.28 (quin, J = 










2.72 (dd, J = 14.6, 6.2 Hz, 1H), 2.62 (dd, J = 14.6, 6.2 Hz, 1H), 2.30 (t, J = 6.2 Hz, 1H), 
2.05 – 1.96 (m, 1H), 2.03 (s, 3H), 1.84 – 1.73 (m, 2H), 1.53 – 1.41 (m, 2H), 1.44 (s, 9H), 
1.13 – 1.10 (m, 1H), 1.04 (s, 9H), 0.91 (s, 3H), 0.83 (s, 3H); 125 MHz 13C NMR (CDCl3) 
δ 198.0, 170.7, 136.1, 136.0, 134.0, 133.8, 130.0, 130.0, 127.9, 104.9, 73.4, 68.8, 66.0, 




4-yl acetate 1.20.111a To a stirring solution of alcohol 1.51 (99.7 mg, 0.151 mmol, 1.00 
equiv) in CH2Cl2 (3.0 mL, 0.05 M) in a 15 mL round-bottom flask under an atmosphere 
of N2, at -10 oC, was added N,N-diisopropylethylamine (136.5 mg, 1.06 mmol, 7.00 
equiv). After 10 min at -10 oC, dimethyl sulfoxide (107.0 µL, 1.51 mmol, 10.0 equiv) was 
added to the reaction mixture via syringe and the solution was allowed to stir for 
additional 10 min. Sulfur trioxide pyridine complex (96.2 mg, 0.605 mmol, 4.00 equiv) 
was then added in one portion The reaction was allowed to proceed for 1 h at -10 oC, 
after which time TLC analysis indicated complete consumption of the starting material. 
The reaction was quenched by adding saturated aqueous solution of NaHCO3 (10 mL) 
and the phases were separated. The aqueous phase was extracted with 20% EtOAc/ 
hexanes (3 × 30 mL). The combined organic phase was washed twice with brine (10 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure Purification was by 











EtOAc/ hexanes (300 mL), collecting 5 mL fractions. The fractions containing product 
(25 – 35) were concentrated under reduced pressure to give the aldehyde 1.20 (87.5 mg, 
88%) as colorless oil: Rf 0.55 (30% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 9.66 
(t, J = 3.1 Hz, 1H), 7.73 – 7.66 (m, 4H), 7.50 – 7.37 (m, 6H), 5.02 (dd, J = 11.5, 4.6 Hz, 
1H), 4.28 (quin, J = 6.6 Hz, 1H), 3.42 (dddd, J = 11.5, 7.6, 4.0, 4.0 Hz, 1H), 3.00 (s, 3H), 
2.73 (dd, J = 14.6, 6.6 Hz, 1H), 2.64 (dd, J = 14.6, 5.5 Hz, 1H), 2.53 (app t, J = 3.1 Hz, 
2H), 2.03 (s, 3H), 1.78 (quin, J = 7.1 Hz, 1H), 1.51 (td, J = 14.1, 4.4 Hz, 1H), 1.46 – 1.41 
(m, 1H), 1.44 (s, 9H), 1.13 – 1.00 (m, 1H), 1.04 (s, 9H), 0.88 (s, 3H), 0.83 (s, 3H); 125 
MHz 13C NMR (CDCl3) δ 201.5, 197.9, 170.6, 136.1, 136.0, 134.1, 133.7, 130.1, 130.0, 
127.9, 104.1, 72.8, 69.1, 66.4, 53.0, 48.8, 48.3, 45.8, 43.5, 42.0, 32.9, 30.0, 27.2, 21.4, 




dimethyltetrahydro-2H-pyran-4-yl acetate 1.52. To a stirring solution of the alcohol 
1.51 (127.6 mg, 0.193 mmol, 1.00 equiv), imidazole (33.0 mg, 0.484 mmol, 2.50 equiv), 
DMAP (2.40 mg, 0.019 mmol, 0.10 equiv) in DMF (968 µL, 0.20 M) in a 5 mL round-
bottom flask in the atmosphere of N2, at rt, was added TBSCl (73 mg, 0.484 mmol, 2.50 
equiv) in one portion. After 12 h, the reaction was judged complete by TLC analysis. The 
reaction was quenched by addition of saturated aqueous solution of NaHCO3 (5 mL). The 










washed once with brine (50 mL), dried over Na2SO4, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography on a (1.5 × 15) 
cm silica gel column, eluting with 5% EtOAc/hexanes (250 mL), collecting 5 mL 
fractions. The fractions containing product (11-15) were combined and concentrated 
under reduced pressure to give the TBS ether 1.52 (173 mg, quant.) as colorless oil: Rf 
0.76 (30% EtOAc/ hexanes); [α]D20 = + 15.9 (c = 1.06, CHCl3); 400 MHz 1H NMR 
(CDCl3) δ 7.70 – 7.65 (m, 4H), 7.46 – 7.36 (m, 6H), 4.96 (dd, J = 11.8, 4.9 Hz, 1H), 4.26 
(m, 1H), 3.70 – 3.63 (m, 1H), 3.57 (dddd, J = 15.7, 10.3, 5.7, 5.7 Hz, 1H), 3.20 (m, 1H), 
2.96 (s, 3H), 2.73 – 2.71 (m, 1H), 2.00 (s, 3H), 1.93 – 1.78 (m, 2H), 1.68 (ddd, J = 16.1, 
8.0 Hz, 1H), 1.45 (s, 9H), 1.33 – 1.28 (m, 1H), 1.03 (s, 9H), 0.89 (s, 12H), 0.82 (s, 3H), 
0.04 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 198.0, 170.7, 136.2, 136.0, 134.5, 133.8, 
130.0, 129.8, 127.9, 127.8, 104.1, 73.8, 69.8, 66.0, 59.6, 53.3, 48.6, 48.2, 43.8, 41.7, 36.1, 
33.0, 30.0, 27.1, 26.2, 21.4, 20.5, 19.6, 18.5, 17.4, -5.00, -5.01; 125 MHz DEPT (CDCl3) 
δ CH3: 48.2, 30.0, 27.1, 26.2, 21.4, 20.5, 17.4, -5.00, -5.01, CH2: 59.6, 53.3, 43.8, 36.1, 
33.0, CH: 136.2, 136.0, 130.0, 129.8, 127.9, 127.8, 73.8, 69.8, 66.0; IR (thin film) 3458, 
3002, 2963, 1745, 1682, 1473, 1425, 1384, 1365, 1111, 650 cm–1. HRMS (ESI/TOF) 














1.00 equiv), Et3SiH (117 mL, 0.734 mmol, 20.0 equiv) in CH2Cl2 (734 µL, 0.05 M) in a 5 
mL reaction vial in an atmosphere of N2, at -78 oC, was added TMSOTf (124 µL, 0.11 
mmol, 3.00 equiv) slowly down the inside of the vial. The reaction was quenched with 
the addition of Hünig’s base (2 mL) at -78 oC. The cold bath was removed and the 
reaction mixture was stirred at rt for 15 min. The reaction mixture was then diluted with 
30% EtOAc/hexanes (10 mL) and then washed twice with water (10 mL), once with 
brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a (1 x 10) cm silica 
gel column, eluting with 5% EtOAc/ hexanes (100 mL), collecting 5 mL fractions. The 
fractions containing product (13-16) were combined, and concentrated under reduced 
pressure to give the C9 deoxygenated A ring compound 1.53 (18 mg, 66%) as colorless 
oil: Rf  = 0.48 (15% EtOAc/ hexanes); [α]D20 = + 22.9 (c = 1.01, CHCl3); 400 MHz 1H 
NMR (CDCl3) δ 7.73 – 7.65 (m, 4H), 7.45 – 7.36 (m, 6H), 4.45 (dd, J = 11.6, 4.8, 1H), 
4.34 – 4.26 (m, 1H), 3.69 – 3.63 (m, 1H), 3.52 (m, 1H), 3.09 (m, 1H), 2.97 – 2.89 (m, 
1H), 2.68 – 2.67 (m, 2H), 2.03 (s, 3H), 1.74 – 1.56 (m, 2H), 1.44 (s, 9H), 1.03 (s, 9H), 
0.89 (s, 9H), 0.79 (s, 3H), 0.74 (s, 3H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 
198.9, 170.7, 136.1, 136.0, 136.0, 134.6, 134.5, 133.9, 130.0, 129.9, 129.8, 127.8, 127.7, 
80.2, 77.5, 72.8, 69.4, 60.8, 52.8, 48.1, 43.9, 37.4, 34.0, 32.7, 30.0, 27.2, 27.2, 27.1, 26.2, 
22.4, 21.3, 19.6, 18.5, 13.7, 7.00, 4.61, -4.98; 125 MHz DEPT (CDCl3) d CH3: 30.0, 27.2, 
27.1, 26.2, 22.4, 21.3, 13.7, 7.00, -4.98, CH2: 60.8, 52.8, 43.9, 34.0, 32.7, 4.61, CH: 
136.1, 136.0, 129.9, 129.8, 127.8, 127.7, 80.2, 77.5, 72.8, 69.4; IR (thin film) 3450, 3000, 
2961, 2859, 1741, 1682, 1473, 1425, 1386, 1363, 1236, 1111, 698 cm–1. HRMS 




 Preparation of S-ethyl (9S,11R,12R,E)-12-((benzyloxy)methoxy)-9-((tert-
butyldimethylsilyl)oxy)-11-((4-methoxybenzyl)oxy)-4,4-dimethyl-5-oxotridec-2-
enethioate 1.56.102c To a solution of alkene 1.29 (1.76 g, 2.87 mmol, 1.0 equiv) in a 20:1 
EtOAc/MeOH mixture (57.4 mL, 0.05M) in a 100 mL round-bottom flask, at -78 °C, was 
added NaHCO3 (2.40 g, 28.7 mmol, 10.0 equiv). A steady stream of O3 was bubbled 
through the reaction mixture until a light blue color developed. The excess O3 was 
removed by bubbling O2 through the mixture for 15 min until the light blue color faded. 
A solution of PPh3 (1.13 g, 4.30 mmol, 1.5 equiv) in CH2Cl2 (5 mL) was added to the 
reaction mixture, and the mixture was slowly warmed to rt with stirring. After 12 h, the 
mixture was filtered, and concentrated under reduced pressure. The resulting yellow oil 
was taken-up in 10% Et2O/pentane (100 mL) in a 500 mL round-bottom flask, and placed 
in a -20 °C freezer for 6 h. The triphenylphosphine oxide precipitate was removed via 
filtration, and rinsed with ice cold 1% Et2O/pentane (50 mL). The solvent was removed 
under reduced pressure to provide crude aldehyde 1.54 as a light yellow oil, which was 
taken into the next step without further purification; Rf = 0.51 (30% EtOAc/hexanes). 
 To a stirring solution of S-ethyl 2-(diethoxyphosphoryl)ethanethioate (1.55) (1.52 g, 
6.31 mmol, 2.2 equiv) in THF (16 mL, 0.18M) in a 50 mL round-bottom flask at 0 °C, 
was added NaH (151.5 mg, 6.31 mmol, 2.2 equiv) slowly over 10 min. The reaction 
mixture was stirred at 0 °C for an addition of 30 min, and then a solution of the 









was added slowly via cannula. The transfer was completed by rinsing with THF (2 × 2 
mL). Stirring was continued at 0 °C for an addition 2 h, and the reaction mixture was then 
quenched by the addition of saturated aqueous NH4Cl solution (20 mL). The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined 
organic phase was washed with brine (30 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography, eluting with 20% EtOAc/hexanes. The fractions containing product 
were combined and concentrated under reduced pressure to provide thioester 1.56 (1.71 
g, 85%) as clear colorless oil: Rf = 0.63 (30% EtOAc/hexanes); 500 MHz 1H NMR 
(CDCl3) δ 7.40-7.35 (m, 4H), 7.35-7.25 (m, 1H), 7.25-7.23 (m, 2H), 6.98 (d, J = 15.9 Hz, 
1H), 6.88-6.83 (m, 2H), 6.15 (d, J = 15.9 Hz, 1H), 4.81 (d, J = 7.3 Hz, 1H), 4.79 (d, J = 
7.3 Hz, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 10.6 Hz, 
1H), 4.44 (d, J = 10.6 Hz, 1H), 4.01 (qd, J = 6.4, 4.7 Hz, 1H), 3.89 (m, 1H), 3.80 (s, 3H), 
3.63 (ddd, J = 9.4, 4.5, 2.3 Hz, 1H), 2.97 (q, J = 7.4 Hz, 2H), 2.41(m, 2H), 1.68 (ddd, J = 
15.1, 8.5, 2.6 Hz, 1H), 1.61-1.53 (m, 3H), 1.46-1.40 (m, 2H), 1.30(t, J = 7.5 Hz, 3H), 
1.27 (s, 6H), 1.18 (d, J = 6.4 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H); 125 MHz 
13C NMR (CDCl3) δ 210.7, 190.1, 160.0, 147.4, 138.2, 131.2, 129.8, 129.3, 128.6, 128.0, 
127.9, 127.7, 114.0, 93.4, 78.2, 73.0, 72.1, 69.6, 69.5, 55.5, 50.7, 38.6, 37.8, 37.4, 26.2, 
23.7, 23.5, 19.2, 18.3, 15.3, 14.9, -3.6, -4.2. 
 










1.57.102c To a stirring solution of thioester 1.56 (91.4 mg, 0.130 mmol, 1.0 equiv) in 20:1 
CH3CN/water (2.6 mL, 0.05 M), in a 50 mL high density polyethylene bottle at 0 °C, 
were added pyridine (434 µL), and aqueous HF soln. (48%, 200 µL). (Caution: laboratory 
coats, proper gloves should be worn) The solution was stirred at 0 °C for 30 min and was 
then warmed to rt. After 30 min of stirring at rt, additional aqueous HF solution (48%, 
200 µL) was added every hour until TLC analysis indicated complete consumption of the 
starting material. The reaction mixture was quenched by carefully transferring the 
reaction mixture into a stirring mixture of saturated aqueous NaHCO3 solution (50 mL) 
and EtOAc (50 mL) via plastic pipette. Solid NaHCO3 was then added until 
effervescence was complete. The phases were separated and the aqueous phase was 
extracted with EtOAc (3 × 10 mL). The combined organic phase was washed with water 
(3 × 20 mL), saturated aqueous CuSO4 solution (2 × 20 mL), and brine (3 × 20 mL). The 
solution was dried over Na2SO4, filtered, and concentrated to provide the intermediate 
alcohol as clear light yellow oil. This material was carried into the next step without 
further purification. 
 To a stirring solution of the previously described intermediate alcohol (assumed to 
be 0.130 mmol) in benzene (5.0 mL, 0.03 M), in a 25 mL round-bottom flask equipped 
with a condenser and Dean-Stark trap, was added CSA (1 mg, 0.002 mmol, 0.05 equiv). 
The solution was heated at reflux for 1 h, and was then allowed to cool to rt. The reaction 
mixture was quenched by the addition of pyridine (0.1 mL), and the mixture was then 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography on a (1 × 10) cm silica gel column, eluting with 5-8% EtOAc/hexanes, 
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collecting 9 mL fractions. The fractions containing product (15-60) were combined and 
concentrated under reduced pressure to yield dihydropyran 1.57 (67 mg, 90%) as clear 
colorless oil: Rf = 0.56 (30% EtOAc/ hexanes); 500 MHz 1H NMR (CDCl3) δ 7.38-7.34 
(m, 4H), 7.33-7.28 (m, 1H), 7.25 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 15.9 Hz, 1H), 6.86 (d, J 
= 8.6 Hz, 1H), 6.09 (d, J = 15.9 Hz, 1H), 4.85 (d, J = 6.9 Hz, 1H), 4.82 (d, J = 6.9 Hz, 
1H), 4.68-4.59 (m, 4H), 4.49 (d, J = 11.1 Hz, 1H), 4.04-3.94 (m, 2H), 3.84-3.78 (m, 4H), 
2.89 (q, J = 7.4 Hz, 2H), 2.14-2.04 (m, 1H), 2.03-1.96 (m, 1H), 1.84-1.73 (m, 2H), 1.65-
1.58 (m, 1H), 1.55-1.46 (m, 1H), 1.24-1.19 (m, 12H); 125 MHz 13C NMR (CDCl3) δ 
190.6, 159.3, 157.1, 151.9, 138.2, 131.1, 129.7, 128.6, 128.0, 127.8, 125.7, 113.9, 94.6, 
93.6, 77.7, 73.9, 73.6, 72.0, 69.6, 55.5, 41.4, 36.2, 28.2, 25.3, 25.2, 23.3, 20.5, 15.6, 14.9; 
125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.5, 25.3, 25.2, 15.6, 14.9; CH2 δ 93.6, 73.6, 
69.6, 36.2, 28.2, 23.3, 20.5; CH δ 151.9, 129.7, 128.6, 128.0, 127.8, 125.7, 113.9, 94.6, 
77.7, 73.9, 72.0. 
 
 Preparation of (E)-4-((S)-2-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-enal 1.27.102c 
To a stirring solution of thioester 1.57 (1.28 g, 2.25 mmol, 1 equiv) in CH2Cl2 (22.5 mL, 
0.1 M) at - 78 oC was added a solution of DIBAL-H in toluene (4.5 mL of 1.5 M, 1.1 
mmol, 3 equiv) dropwise over a period of 30 min. This mixture was stirred at -78 oC for 
1.5 h, then EtOAc (2 mL) was added dropwise over 10 min. The solution was stirred for 









dropwise. The cold bath was removed, and the mixture was stirred vigorously for 12 h at 
ambient temperature. The layers were separated and the aqueous layer was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with brine (2 × 10 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified via flash column chromatography, eluting with 10% EtOAc/hexanes (300 mL 
and 15% EtOAc/hexanes (250 mL) collecting 9 mL fractions. The fractions containing 
product (35-65) were collected and concentrated under reduced pressure to provide α,β- 
unsaturated aldehyde 1.27 (893 mg, 78%) as colorless oil: Rf = 0.54 (30% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 9.47 (d, J = 7.8 Hz, 1H), 7.37 – 7.23 (m, 
8H), 6.87 – 6.83 (m, 4H), 6.10 (dd, J = 16.1, 7.81 Hz, 1H), 4.81 (ABq,  = 10.7 Hz, 2H), 
4.62 – 4.60 (m, 4H), 4.46 (d, J = 10.7 Hz, 1H), 4.05 – 3.94 (m, 2H), 3.80 – 3.75 (m, 1H), 
3.79 (s, 3H), 2.13 - 2.06 (m, 1H), 2.03 – 1.97 (m, 1H), 1.83 – 1.76 (m, 2H), 1.64 – 1.58 
(m, 1H), 1.55 – 1.47 (m, 1H), 1.25 (d, J = 3.4 Hz, 6H), 1.20 (d, J = 6.3 Hz, 3H); 125 
MHz 13C NMR (CDCl3) δ  194.5, 165.5, 159.3, 156.6, 138.0, 130.8, 129.7, 129.4, 128.5, 
127.9, 127.7 113.9, 94.7, 93.5, 77.5, 73.5, 73.2, 72.0, 69.5, 55.3, 42.0, 35.1, 28.0, 25.2, 
25.0, 20.4, 15.4. 
 











((trimethylsilyl)methyl)octa-1,5-dien-4-ol 1.58.124 To a solution of aldehyde 1.27 (55.2 
mg, 0.108 mmol, 1 equiv) in toluene (362 µL, 0.30 M) in a 5 mL round-bottom flask was 
added a trimethyl(2-((tributylstannyl)methyl)allyl)silane 1.28 via syringe. The mixture 
was heated to reflux at 120 oC for 24 h in which TLC showed the completion of reaction. 
The reaction mixture was allowed to cool to rt and the solvent was removed under 
reduced pressure. Purification was accomplished using flash column chromatography 
with a 1 x 10 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 5 mL 
fractions. The fractions containing product (11-26) were combined and concentrated 
under reduced pressure to provide alcohol 1.58 (62 mg, 90%) as 1:1 mixture of 
diastereomers as colorless oil. Rf = 0.57 (30% EtOAc/hexanes); 500 MHz 1H NMR 
(C6D6) δ 7.38-7.08 (m, 7H), 6.82-6.80 (m, 2H), 6.04 (dd, J = 15.6, 6.3 Hz, 1H), 5.67 (dd, 
J = 15.6, 5.8 Hz, 1H), 4.83-4.70 (m, 4H), 4.67-4.6 (m, 4H), 4.29-4.4.05 (m, 4H), 3.30 (s, 
3H), 2.59-2.50 (m, 2H), 2.29-2.15 (m, 2H), 2.02- 1.83 (m, 5H), 1.76-1.71 (m, 1H), 1.64-
1.38 (m, 5H), 1.33 (dd, J = 8.7, 2.4 Hz, 6H), 1.23 (dd, J = 6.3 Hz, 4H), 0.00 (s, 9H). 
 
 Preparation of (E)-7-((S)-2-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-7-methyl-2-
((trimethylsilyl)methyl)octa-1,5-dien-4-one 1.59.124 To a stirring solution of alcohol 
1.58 (35.6 mg, 0.056 mmol, 1.0 equiv) in CH2Cl2 (558 µL, 0.1 M) in a 10 mL round-










0.391 mmol, 7.0 equiv) dropwise via syringe. After 10 min at -15 °C, dimethyl sulfoxide 
(39.5 µL, 0.558 mmol, 10.0 equiv) was added to the reaction mixture via syringe and the 
solution was stirred for an additional 10 min. Sulfur trioxide pyridine complex (35.5 mg, 
0.223 mmol, 4.0 equiv) was then added in one portion. The reaction mixture was allowed 
to proceed for 1 h at -15 °C, after which time TLC analysis indicated complete 
consumption of starting material. The reaction mixture was diluted with EtOAc (10 mL), 
quenched by addition of saturated aqueous NaHCO3 solution (2 mL). The layers were 
separated and the aqueous layer was extracted with EtOAc (2 × 10 mL). The combined 
organic layers were washed with brine (2 × 10 mL), dried over MgSO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography on a 1 × 10 cm column, eluting with 10% EtOAc/hexanes, collecting 5 
mL fractions. The fractions containing product (20-55) were combined and concentrated 
under reduced pressure to give the ketone 1.59 (31 mg, 88% yield) as colorless oil: Rf = 
0.53 (20% EtOAc/hexanes); 500 MHz 1H NMR (C6D6) δ 7.39-7.09 (m, 7H), 6.83-6.81 
(m, 2H), 6.34 (d, J = 15.6 Hz, 1H), 4.81-4.75 (m, 4H), 4.69 (d, J = 10.7 Hz, 2H), 4.63 (d, 
J = 2.9 Hz, 1H), 4.59 (d, J = 11.2 Hz, 2H), 4.53 (t, J = 3.9 Hz, 1H), 4.14-4.00 (m, 3H), 
3.30 (s, 3H), 3.11 (s, 2H), 1.98-1.89 (m, 1H), 1.86 (ddd, J = 9.2, 6.8, 2.4 Hz, 1H), 1.81-
1.75 (m, 1H), 1.61-1.56 (m, 3H), 1.51-1.47 (m, 1H), 1.41-1.32 (m, 1H), 1.23 (s, 3H), 1.22 
(d, J = 4.3 Hz, 3H), 1.19 (s, 3H), -0.00 (s, 9H); 125 MHz 13C NMR (C6D6) δ 197.0, 
160.4, 157.9, 154.1, 142.3, 139.2, 132.0, 129.8, 128.9, 128.3, 128.0, 126.4, 114.4, 112.4, 





 Preparation of (R,E)-7-((S)-2-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-7-methyl-2-
((trimethylsilyl)methyl)octa-1,5-dien-4-ol 1.19.124 A stirring solution of CBSBH3 (8.97 
mg, 0.031 mmol, 1.1 equiv) in CH2Cl2 (280 µL, 0.1 M) was cooled to -40 oC. To this 
solution was added a solution of ketone 1.59 (17.8 mg, 0.028 mmol, 1 equiv) in 60 µL of 
toluene dropwise via syringe pump down the side of the flask over 15 min. The mixture 
was stirred at -40 oC for 1 h, after which it was quenched by slow addition of MeOH. The 
reaction was allowed to come to rt over 10-15 min and the solvent was evaporated under 
reduced pressure. Purification was accomplished using flash column chromatography 
with a 0.5 x 10 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 5 ml 
fractions. The fractions containing product (45-60) were combined and concentrated 
under reduced pressure to provide the alcohol 1.19 (15 mg, 85%) as a clear colorless oil: 
Rf = 0.31 (20% EtOAc/hexanes);  500 MHz 1H NMR (C6D6) δ 7.39-7.10 (m, 7H), 6.82-
6.80 (m, 2H), 6.05 (d, J = 16.4 Hz, 1H), 5.67 (dd, J = 15.6, 6.3 Hz, 1H), 4.82 (d, J = 6.8 
Hz, 2H), 4.77 (d, J = 6.8 Hz, 1H), 4.74 (s, 1H), 4.73 (d, J = 11.2 Hz, 1H), 4.68-4.67 (m, 
3H), 4.62 (d, J = 12.2 Hz, 1H), 4.29 (dd, J = 12.6, 6.5 Hz, 1H), 4.22-4.18 (m, 1H), 4.12 
(td, J = 4.9, 1.9 Hz, 1H), 4.10-4.05 (m, 1H), 3.29 (s, 3H), 2.29-2.21 (m, 2H), 1.99 (ddd, J 
= 13.6, 10.2, 1.4 Hz, 1H), 1.94 (ddd, J = 9.7, 6.8, 2.4 Hz, 1H), 1.89-1.83 (m, 1H), 1.77 (s, 










1.47-1.37 (m, 2H), 1.34 (s, 3H), 1.33 (s, 3H), 1.23 (d, J = 6.3 Hz, 3H), -0.00 (s, 9H). 
 




dimethyltetrahydro-2H-pyran-4-yl acetate 1.62.124 To a stirring solution of aldehyde 
1.20 (85.7 mg, 0.130 mmol, 1.1 equiv) and hydroxyallylsilane 1.19 (75.5 mg, 0.118 
mmol, 1.0 equiv) in Et2O (2.4 mL, 0.05 M) in a flame dried 15 mL round-bottom flask at 
-78 oC was added a solution of TMSOTf in Et2O (142 µL, 1.0 M, 0.142 mmol, 1.2 equiv). 
After 1.5 h at - 78 oC, the reaction was quenched by addition of diisopropylethylamine 
(0.2 mL), followed by addition of saturated aqueous NaHCO3 solution (2 mL). The 
mixture was warmed to rt, the phases were separated, and the aqueous phase was 
extracted with Et2O (2 × 15 mL). The organic phases were combined, dried over Na2SO4, 
and concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography on a 1 × 10 cm silica gel column, eluting with hexanes/EtOAc (9:1), 
collecting 5 mL fractions. The fractions containing product (17-62) were combined and 
concentrated under reduced pressure to provide the pyran 1.62 (78.5 mg, 55%) as white 
foam: Rf = 0.56 (30% EtOAc/hexanes); 500 MHz 1H NMR (C6D6) δ 7.83-7.80 (m, 4H), 















16.1, 5.3 Hz, 1H), 5.35 (dd, J = 11.7 Hz, 4.8, 1H), 4.88 (s, 1H), 4.82 (d, J = 6.8 Hz, 1H), 
4.77 (d, J = 4.3 Hz, 1H), 4.71-4.66 (m, 3H), 4.64-4.63 (m, 4H), 4.57-4.54 (m, 1H), 4.20-
4.16 (m, 1H), 4.08- 4.06 (m, 2H), 3.88-3.85 (m, 1H), 3.65-3.63 (m, 1H), 3.30 (s, 3H), 
2.93 (s, 3H), 2.91-2.89 (m, 2H), 2.33-2.24 (m, 2H), 2.19-2.15 (m, 1H), 2.11 (t, J = 12.4 
Hz, 1H), 2.01-1.94 (m, 2H), 1.91-1.76 (m, 4H), 1.72 (d, J = 3.9 Hz, 1H), 1.69-1.66 (m, 
1H), 1.64 (s, 3H), 1.60- 1.52 (m, 4H), 1.43 (s, 9H), 1.34 (s, 3H), 1.33 (s, 3H), 1.23 (d, J = 
6.3Hz, 3H), 1.19 (s, 9H), 1.07(s, 3H), 1.03 (s, 3H). 
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  CHAPTER 2 
 
STUDIES ON THE EFFECT OF POLAR FUNCTIONAL GROUPS ON THE 
NORTHERN HEMISPHERE OF BRYOSTATIN 1 ANALOGUES 
 
Introduction 
 Bryostatin 1, a marine natural product isolated from the bryozoans Bugula 
neritina, has been in the forefront of research studies on promising drugs against various 
ailments like cancer, Alzheimer’s disease, HIV, etc.1 The unique biological profile of 
bryostatin 1 has been traced back to its capability to bind with the cysteine-rich C1 
domains of PKC isozymes with high affinity.2 However, various other ligands such as the 
tumor promoting phorbol esters also bind to PKC isozymes at the same C1 domain but 
shows opposing character in many biological end points to that of bryostatin 1. In the 
backdrop of this interesting biological observation, we became interested in investigating 
further the specific structural features of bryostatin 1 that might explain its unique 
biology. Our group started a project almost a decade earlier, specifically designed to 
address this issue, and devised synthetic strategies to prepare bryostatin analogues. With 
the syntheses of Merle 23, 27, 28, 30, and 32, it became clear that the functional groups at 
C7, C9, C13, and C30 on the northern hemisphere of bryostatin 1 are not individually 
critical to the unique biology. However, combinations of these groups are critical to keep 
the right balance in favor of bryostatin-like properties over PMA-like properties.3
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Lessons learned from our studies led to a new hypothesis that addresses the need to study 
the roles of the functional groups in greater detail. 
 
Lessons learned from Keck’s analogue program 
The first highly potent analogue that came out of our group was Merle 23, which 
was tested in our collaborator Dr. Peter Blumberg’s laboratory at the National Cancer 
Institute for various biological end points. The experiments conducted by Blumberg and 
coworkers showed that although Merle 23 bound to PKC with high affinity, it was PMA-
alike in attachment and proliferation assays in U937 cells. These two assays were chosen 
because PMA and bryostatin are known to have different effects for these biological end 
points in this cell line.3b, 3e This was the first demonstrated example of a bryostatin 
analogue that resembles PMA rather than bryostatin despite its structural similarity with 
bryostatin 1. This led to further investigations with analogues that differed from 
bryostatin 1 only in certain positions in the northern hemisphere.  
The first attempts with designing analogues focused on utilizing the flagship 
reaction Keck Yu annulation, commonly known as pyran annulation.4 The analogue that 
was first synthesized, i.e., Merle 23, lacked all the polar functional groups in addition to 
the C8 gem-dimethyl group in the northern hemisphere of bryostatin 1 (Figure 2.1). Later, 
Merle 28 was synthesized that reintroduced all of these functional groups in the A- and 
B-rings, except for the C30 carbomethoxy group.3h The next-generation analogues 
included Merle 27, Merle 30, and 32. Merle 27 reintroduced the C7 acetate on Merle 23.3f 
Merle 30 excluded the C9 hydroxy group from bryostatin 1 while Merle 32 was 




















Merle 21, Ki = 0.70 ± 0.01 nM
Merle 22, Ki = 1.05 ± 0.04 nM
Merle 23, Ki = 0.70 ± 0.06 nM
Merle 27, Ki = 3.00 ± 0.6   nM
Merle 28, Ki = 0.52 ± 0.06 nM
Merle 30, Ki = 0.38 nM
Merle 32, Ki = 1.08 ± 0.16 nM
Merle 33, Ki = 0.68 nM













2.1 R = Ph, Merle 21
2.2 R = C7H15, Merle 22




































































assayed for function in the U937 human leukemia cell line, where PMA inhibits 
proliferation and induces cellular attachment while bryostatin 1 fails to do so and blocks 
the PMA response.5 Merle 21-23 were found to show striking resemblance with PMA 
rather than bryostatin although Merle 23 differs from bryostatin 1 only in the northern 
hemisphere at C7, C8, C9, and C30 (Figure 2.2), a region previously regarded as just a 
“spacer domain”. The biological profile of Merle 27 (not shown in the Figure 2.2) and 28 
showed that the C7 acetate and the C30 carbomethoxy group are not solely responsible 
for bryostatin biology. Studies with Merle 30 showed that C9 hydroxy group was also not 
responsible for the unique biology of bryostatin. Merle 32, on the other hand, showed that 
the C8 gem-dimethyl group did not switch the biological profile of Merle 23 from PMA-
like to bryostatin-like. Merle 33, a recent analogue synthesized by Dr. Wei Li, lacked the 








           
 
Figure 2.2. Proliferation and attachment assays in U937 cells with various analogues and 
Bryostatin 1, 2, and 7 under various concentrations3a, 3d-h 
Bryo 1 Bryo 2 Merle 28 Merle 30 Merle 32 
Merle 

















































resembled bryostatin 1. 
Various bryostatin analogues were also tested in the Blumberg laboratory in the 
LNCaP human prostate cancer cells for their induction of 6 of the phorbol ester regulated 
genes. We found that the degree of response of the LNCaP cells at 8 h to the various 
derivatives ranged between that of PMA and that of bryostatin 1 or a little below. Similar 
observations were made in the U937 cells that were treated for 24 h (Figure 2.3). We 
observed a strong correlation between the bryostatin-like patterns of gene expression and 
the bryostatin-like patterns of biological response in the U937 cells.3d 
 Among the genes examined in this study, TNFα is worth discussing further as the 
TNFα protein is an important contributor to the inhibition of LNCaP cell growth in 
response to phorbol esters. The analogues were intermediate between PMA and 
bryostatins in their induction of TNFα mRNA expression at 8 h.3d  
 Additionally, time dependence of the modulation of mRNA levels of 8 specific 
genes was observed and bryostatin 1 showed a markedly transient duration of action 
(Figure 2.3). The close similarity in the levels of gene induction by PMA and bryostatin 1 
at 2 h in the LNCaP cells showed that the induction of different gene sets is not the 
predominant feature. However, after 2 h, the relative action of bryostatin rapidly 
diminished. The fact that Merle 23 resembled PMA more closely than bryostatin 1 after 2 
h emphasizes the idea that the substituents on the A and B-rings can modulate the 












Figure 2.3. Transcriptional activity of different bryostatin analogues 
(A) qPCR analysis was performed for the genes on RNA prepared from LNCaP cells 
treated for 8 h with 1000 nM of the analogues (B) qPCR analysis was performed for the 
indicated genes on RNA prepared from U937 cells treated for 24 h with 1000 nM of the 
indicated compounds (100 nM for bryostatin 2) (C) The averaged effect of bryostatin 
analogues on gene expression in LNCaP and U937 cells and their biological effects in 
U937 cells. 






Polarity hypothesis in relation to the biological properties of bryostatins  
 With the studies of the analogues synthesized in our group, it became clear that 
the analogues falls somewhere in between PMA and bryostatin 1 in terms of biology 
depending on the combination of the hydrophilic and hydrophobic groups. We turned our 
focus on figuring out the crucial combination that would be essential for bryostatin 
biology. Bryostatin binds to PKC at the exact same position where phorbol esters bind. 
Most likely, bryostatin binds to the hydrophobic cleft formed by the pulled apart strands 
of a β-sheet at the top of C1 domain and this hydrophobic surface is covered by the 
northern hemisphere of bryostatin 1 upon binding.6 Additionally, the actual binding of 
bryostatin 1 with the C1 domain is measured in the presence of phospholipid, which 
forms the ternary complex of ligand – C1 domain – lipid. Therefore, the complete 
understanding of bryostatin biology is not possible without considering the critical 
interactions of the hydrophobic and polar groups of the northern hemisphere of 
bryostatins with the top surface of the hydrophobic cleft of the C1 domain and the 
phospholipid. Interestingly, Blumberg group observed that tumor inhibitors or non-
promoters such as less lipophilic bryostatin 1 bound to both C1A and C1B domains 
whereas tumor promoter and more lipophilic PMA bound to C1B domain selectively.7 
Consequently, a further investigation on the polarity of the analogues became crucial at 
this stage. 
 Our collaborator Dr. Megan Peach at the Chemical Biology laboratory of the 
National Cancer Institute performed modeling studies and concluded that the A and B-
ring regions of the analogues with PMA-like character were less hydrophilic than the 
same regions of analogues having bryostatin-like character. Merle 23 and Merle 32 (not 
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shown in Figure 2.4) has less hydrophilic A and B-ring regions and behaves like PMA. 
Merle 28 has relatively more hydrophilic groups such as the C9 hydroxy and C7 acetate 
groups and behaves more like bryostatin than PMA. Merle 30, lacking only the C9 
hydroxy group, clearly behaved more like bryostatin than PMA. These correlations 
prompted us to hypothesize that an appropriate amount of hydrophilicity in the A and B-
ring regions along with the bryostatin core structure is needed for the unique bryostatin-
like activity and the specific surface formed at the top of C1 domain may define the 
localization and the protein-protein interactions of the activated PKCs, rendering them 
with different biological functions. 
 To examine this hypothesis, we simply calculated clogP values for various “top 
half” structures (Figure 2.5), with the idea that the southern hemisphere is largely buried 
in the cleft of the C1 domain and unavailable for interaction with other structures. We 
envisioned that various combinations of ester and enoate functionalities would match the   
 
Red: hydrophobic = lipophilic; Blue: hydrophilic = lipophilic 
 
Figure 2.4. Modeling studies by Dr. Megan Peach for Merle 23, 27, 28, 30, bryostatin 2, 
and 1 (Red indicates less hydrophilic regions and the blue indicates more hydrophilic 
regions)8 
 



















































calculated clogP values. Intriguingly, we found a trend between polarity and 
corresponding biological responses of the analogues. Although the analogues which fall 
under the intermediate category do not quite follow the trend, we hoped to get more data 
points by synthesizing more analogues to validate this hypothesis. In line with this 
hypothesis, we proposed two possible analogues (Merle 34 and 38 in Figure 2.5). Merle 
34 (2.9) very closely resembles of the top half of bryostatin 1 in clogP value while Merle 
38 (2.10) has a very hydrophilic top half. The propionate group at C13 of Merle 34 was 
chosen to closely match clogP value for the “top half” of the structure to that of 
bryostatin 1. A shorter chain (acetate) or a longer chain (butanoate) would force the value 
of clogP for the analogue to deviate further away from the corresponding number for 
bryostatin 1. 
 
Retrosynthetic analysis of Merle 34 and 38 
 The retrosynthetic analysis of the analogues Merle 34 and 38 is outlined in Figure 
2.6. Using our experience from the syntheses of bryostatin 1 and 7, we envisaged that a 
similar disconnection at the C1 ester bond and at the B-ring pyran across C15 would 
provide us with the two equally complex synthetic equivalents of a β-hydroxyallyl silane 
2.12 and the fully functionalized C-ring aldehyde 2.11. Our flagship reaction of pyran 
annulation would couple the two complex intermediates to form the tricyclic core of 
Merle 34 and 37. After some protecting group manipulation and several oxidation 
reactions, we should be able to macrolactonize the tricyclic core at C1.  
 The A-ring β-hydroxyallyl silane 2.12 could be prepared from an ester 2.13 using 




Figure 2.6. Retrosynthetic analysis of Merle 34 and 38 
 
stereocenter at C7 could rise from a diastereoselective reduction of the corresponding 
ketone of the olefin 2.14. The A-ring substituted pyran 2.14 could arise from another 
pyran annulation between the aldehyde 2.15 and β-hydroxyallyl silane 2.17. The 
stereocenter at C11 could be installed by a Noyori asymmetric reduction of the β-keto 
ester 2.16. The β-hydroxyallyl silane 2.17 was disconnected to form the known synthetic 
equivalents of stannane 2.18 and the aldehyde 2.19. A chelation-controlled 
diastereoselective allylation would produce the β-hydroxyallyl silane 2.17. The C3 
stereocenter on the aldehyde 2.19 could be installed using a catalytic asymmetric 
allylation (CAA) using (R)-BITIP catalyst on the corresponding aldehyde at C3. 
 The fully functionalized C-ring aldehyde 2.11 (Figure 2.8) was disconnected first 












































R = -COCH2CH3, Merle 34, 2.9





Figure 2.7. Retrosynthetic analysis of A-ring intermediate 2.12 
 
 











































































































from the glycal 2.21. The synthetic precursor of the C15 TBS-protected alcohol could be 
an α,β-unsaturated methyl ester. The C-ring glycal 2.21 was envisioned to arise from the 
dehydrative cyclization of the keto-alcohol 2.22. The keto-alcohol 2.22 could arise from 
the known intermediate 2.23. Ozonolysis on the terminal olefin on 2.23 followed by a 
Horner-Wadsworth-Emmons olefination would provide us with the compound 2.22.  
 
Synthesis of Merle 34 and 38 
Synthesis of the A-ring β-hydroxyallyl silane 2.12 
 The synthesis of the A-ring β-hydroxyallyl silane 2.12 began with the 
monoprotection of the 1,3-propanediol with a robust BPS group (Figure 2.9). Swern 
oxidation of the free alcohol provided the aldehyde 2.26 in high yield.9 With the aldehyde  
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2.26 in hand, we applied Keck asymmetric allylation using (R)-BITIP as catalyst to 
install the C3 stereocenter in high enantioselectivity.10 Having the first stereocenter 
installed, we then utilized this stereocenter to install the next stereocenter at C5. The free 
alcohol was protected as PMB ether 2.29 to utilize the chelating ability of the PMB 
group. Ozonolysis on the terminal alkene provided the aldehyde 2.19. Using MgBr2OEt2 
as Lewis acid to form the desired chelated transition state 2.30, allyl silane 2.18 was 
added to the aldehyde 2.19 to form the β-hydroxyallyl silane 2.17 as a single 
diastereomer.11 
 Synthesis of the A-ring pyran compound 2.14 was previously achieved by Dr. 
Wei Li and scaled up by Kevin McGowan from our group. The synthesis of the aldehyde 
2.15 began by reacting benzyl alcohol with acrylonitrile under basic conditions to prepare 
the benzyl ether 2.32 (Figure 2.10). Using Blaise reaction on the ethyl bromoacetate and 
2.32 as the electrophile, we were able to prepare β-keto ester 2.16 in multigram scales.12 
With the β-keto ester 2.16 in hand, we utilized Noyori asymmetric hydrogenation to 
reduce the ketone with excellent enantioselectivity to install the stereocenter at C11.13 
The alcohol was then protected as TBS ether, which was then followed by removal of the 
benzyl group. Swern oxidation of the free alcohol provided the aldehyde 2.15. With the 
two partners 2.17 and 2.15 in hand, we were then able to couple them using the flagship 
pyran annulation to form the A-ring pyran 2.14. The next step was to switch the 
protecting group from TBS to TMS keeping the lability of the TMS group in mind for a 
later stage manipulation. Tosic acid monohydrate was used at ambient temperature to 
remove the TBS group in the presence of the BPS group at C1. However, the diol 2.36 
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group. The diol was converted to 2.35 without any issue. The alkene 2.37 was then 
subjected to ozonolysis followed by NaBH4 reduction to provide the alcohol 2.40 as a 
single diastereomer. The axial attack of small hydride sources like NaBH4 on 
cyclohexanone-derived ketone is a well-documented phenomenon and generally 
explained by the torsional repulsion between the electrons of the forming bond and the 
vicinal axial C-H bonds in case of equatorial attack and a stabilizing effect (Cieplak 
effect) by the vicinal C-H bonds on the forming σ* orbital in case of axial attack.14 The 
free alcohol was then protected temporarily as a TMS ether to form 2.13. With the ester 
2.13 in hand, we applied the Bunelle reaction followed by an acidic work-up to provide 
the β-hydroxyallyl silane 2.12.15 Anhydrous CeCl3 was very essential for this reaction 
and any trace of moisture could potentially ruin the active reagent. 
 
Synthesis of the aldehyde 2.11    
 Synthesis of the ketone 2.23 used a series of 1,2 and 1,3 chelation-controlled 
allylations; hydroformylation followed by prenylation has been reported earlier from our 
group and scaled up by Dr. Matthew Kraft.16 The terminal olefin on 2.23 was cleaved to 
form the aldehyde, which was then subjected to Horner-Wadsworth-Emmons olefination 
to provide the α,β-unsaturated methyl ester 2.42. In old routes we used to install a 
thioester in presence of the methyl ester. The goal was to reduce the thioester selectively 
to an aldehyde subsequently. Additionally, we functionalized the C-ring later in the 
synthesis. In contrast, the newer strategy was to functionalize the C-ring ahead of pyran 
annulation to make the synthesis more convergent. For this strategy, reduction of the 
methyl ester fully to an alcohol seemed a prudent choice, as protected alcohols are easier 
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to manipulate under various reaction conditions. Next, removal of TBS group was 
followed by dehydrative cyclization providing the C-ring glycal 2.21. The ester was then 
reduced to a primary alcohol 2.43, which was then protected as the TBS ether to give 
2.44. The C-ring glycal was then further functionalized across the C19-C20 unsaturation 
to form the ketal at C19 and ketone at C20. Thus, epoxidation of the olefin with MMPP 
followed by methanolysis formed the methyl ketal with an alcohol at C20 as a mixture of 
diastereomers. This mixture was then immediately oxidized under Ley conditions to the 
ketone 2.20 as essentially a single diastereomer. With the ketone in hand, we attempted 
the aldol condensation, which went smoothly without any incident. The exclusive 
formation of the E-enoate is not a very well understood reaction outcome. The initial 
attack on the aldehyde by the enolate of the ketone 2.20 can proceed via a chair like 
transition state to form the axially substituted aldol adduct or via a twist boat-like 
transition state to form the more stable equatorially substituted adduct. The 
stereochemistry at C21 of the intermediate aldol product could not be determined as the 
dehydration occurred readily under the reaction condition. The elimination of the C34 
hydroxyl group could be an SN2 type (for axially substituted adduct) or E1CB type (for 
equatorially substituted adduct) elimination. For all the possibilities, the reaction outcome 
suggests that a 1,3 allylic strain between the ketone carbonyl and the methyl ester forces 
the ester away from the ketone carbonyl in the developing transition state, leading to the 
condensation product 2.45. The keto ester 2.45 was later observed to be unstable and was 
therefore immediately converted to the octanoate 2.48 via Luche reduction and 
esterification. The Luche reduction was found to form the α-alcohol exclusively, possibly 
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this stage, switching the C25 PMB group became necessary as we anticipated potential 
problems resulting from the lack of chemoselectivity between the C3 PMB ether and the 
C25 PMB ether in the pyran annulation product. 
 We decided to switch the C25 PMB with a TBS group. After the removal of the 
PMB with DDQ, protection of C25 with TBS group and removal of the primary allylic 
TBS group chemoselectively provided the alcohol 2.51 (Figure 2.12). Dess Martin 
periodinane oxidation of the allylic alcohol 2.51 provided the required aldehyde 2.11. 
tBuOH proved to be beneficial in both the steps using DDQ and DMP and resulted in  
 
 




































































Completion of the syntheses of Merle 34 and 38 
 With the aldehyde 2.11 and the β-hydroxyallyl silane 2.12 in hand, we then 
attempted the pyran annulation reaction in the presence of the free alcohol at C7 (Figure 
2.13).4, 16a This reaction proved to be sensitive to moisture and temperature. The reaction 
barely went at -78 oC and went to completion only after raising the temperature to -50 oC. 
The side products included elimination of the C20 proton along with the methoxy group 
at C19. The reaction also proved that the free hydroxyl group at C7 can be tolerated 
under the pyran annulation conditions. The C7 free hydroxyl group was then converted to 
the acetate. The C1 BPS group was then targeted for removal using TBAF under acidic 
conditions to provide the alcohol 2.54. Notably, we were able to remove the BPS group 
in the presence of the C25 secondary TBS group. The alcohol 2.54 was then subjected to 
sequential Parikh-Doering and Lindgren oxidations to provide the carboxylic acid 2.56.17 
The C25 TBS ether was then removed to form the seco-acid, which was then subjected to 
Yamaguchi macrolactonization to form 2.57 (Figure 2.14). Careful olefin cleavage at 
C13-C30 using saturated ozone solution provided the ketone 2.58 in good yield. With the 
ketone in hand, we then attempted the reduction using small hydride source as NaBH4. 
We were delighted to observe that the reaction went smoothly to produce the alcohol 2.59 
with high diastereoselectivity (7:1). The minor isomer was mixed with other impurities 
and could not be purified after repeated column chromatography. The major isomer 2.59 
was then esterified with propionic anhydride. The stereochemistry of the C13 hydroxy 



































































































































































































































    pH 7 buffer, CH2Cl2
2. LiBF4, CH3CN/H2O
    [65% (2 steps)]
2. 2,4,6-TCBC, Et3N, 
    THF/tol; DMAP, 











we then removed the PMB group using DDQ. Global deprotection under Lipshutz 
conditions provided the analogue Merle 34.18 Interestingly, after 1-2 h, TLC analysis 
showed the starting material was consumed with the formation of a nonpolar spot above 
the spot corresponding to the substrate in accord with the previous observations made by 
Dr. Yam Poudel during the total synthesis of bryostatin 1. This indicates the formation of 
the intramolecular hydrogen-bonding network observed in the crystal structure between 
the two pyran oxygen atoms, the C3 hydroxy group, and C19 hemiketal group. After 6 h, 
the spot moved downwards with much lower Rf value, indicating the removal of the 
BOM group. The common intermediate 2.59 was then treated with DDQ followed by 
global deprotection to provide the other analogue Merle 38 (Figure 2.15). 
 
Biological evaluation of Merle 34 and 38 
Binding affinity studies 
 The biological evaluation of Merle 34 and 38 began with finding out the binding 
affinity of the ligands to mouse PKCα. Interestingly, both ligands were found to bind 
PKCα with much diminished affinity compared to bryostatin 1. Merle 34 was found to 
 
 































    pH 7 buffer, CH2Cl2
2. LiBF4, CH3CN/H2O
    [70% (2 steps)]
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have Ki = 16.3 nM while Merle 38 had Ki of 13.21 nM. The decreased potency clearly 
indicated a potential role of the B-ring alkene functional group at C13-C30 and the C7 
acetate in combination with other groups on the northern hemisphere of bryostatin 1. The 
binding affinity data also suggested that additional interactions with the carbomethoxy 
enoate at C13-C30 on the northern hemisphere could be responsible for binding of the 
ligand to PKC, which was also evident from the comparison of the binding affinity data 
of Merle 27 (Ki = 3.00 ± 0.06 nM) and Merle 33 (0.68 nM). The nature of the 
interactions is not known at this point and requires further investigation. 
 
Proliferation and attachment assays on U937 
Although Merle 34 “top half” had a comparable clogP value with that of 
bryostatin 1, the proliferation and attachment assays with U937 cells showed that Merle 
34 behaved very similarly to Merle 33. PMA inhibited proliferation while bryostatin 1 
had little effect on it and Merle 34 had a biphasic response in this cell line. When used in 
combination with PMA, Merle 34 was able to reverse the response of PMA in a dose-
dependent manner. Similarly in attachment assay, PMA induced attachment while 
bryostatin 1 had very little effect. Merle 34 again showed a biphasic response in a dose-
dependent manner. When applied in combination with PMA, Merle 34 reversed the 
response of PMA at higher concentrations. Evidently, Merle 34 is intermediate between 
PMA and bryostatin 1 in these two assays and resembled Merle 33 with a bit more PMA-
like character (Figure 2.16). 
Merle 38 was calculated to have a highly hydrophilic “top half” with a very low 





Figure 2.16. Proliferation and attachment assays on U937 cells with Merle 34 
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modestly inhibited proliferation, but only at high doses. However, the lower potency and 
thus higher concentrations required with Merle 38 make these comparisons more 
difficult. When applied in combination with PMA, Merle 38 did not reverse the response 
to PMA. In the attachment assay, Merle 38 was found to induce attachment albeit to a 
lesser extent than PMA. When combined with PMA, Merle 38 failed to reverse the 
responses of PMA (Figure 2.17).  
 
Studies on TNFα secretion in U937 cells 
 Our collaborator, Dr. Blumberg, also studied the effects of the analogues on 
TNFα secretion in U937 cells. Interestingly, in this assay, Merle 38 shows a biphasic 
nature in a dose-dependent manner and approaches bryostatin 1 like properties only at 
much higher concentrations (Figure 2.18). When used in combination with PMA, Merle 
38 reversed the responses of PMA to a considerable extent at higher concentrations. 
Again, lower potency of Merle 38 makes it harder for direct comparison with PMA and 
bryostatin 1.  
 
Studies on Toledo cells 
 Bryostatin 1 and PMA behave very similar in human non-Hodgkin lymphoma cell 
line known as Toledo cells. Bryostatin 1 (IC50 = 0.076 ± 0.00 nM) and PMA (IC50 = 
0.076 ± 0.17 nM) have almost identical IC50 and Merle 38 (IC50 = 104.83 ± 2.45 nM) was 
found to have much less potency than bryostatin 1 (Figure 2.19). In this assay, Merle 38 
inhibited proliferation only at higher concentrations and resembled another recent 
analogue Merle 37 synthesized by graduate student Mr. Mark Peterson from our group. 
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Figure 2.17. Proliferation and attachment assays on U937 cells with Merle 38 and 







































 Keck-Yu annulation, the flagship reaction for our analogue program proved to be 
a general reaction even in the presence of a free hydroxy group. Elevated temperature to -
50 °C proved to be tolerated without any loss of diastereoselectivity. Our extensive 
structure and activity studies with Merle 34 and 37 showed that the underlying principles 
behind the polarity hypothesis are more complex than previously assumed. A simple 
correlation with clogP values with the analogue biological profile cannot be drawn 
without a better understanding of the role of the C13-C30 carbomethoxy enoate moiety 
and its role in bryostatin biology in the context of the roles of other functional groups in 
the northern hemisphere. This study further emphasized the argument that the northern 
hemisphere of bryostatin 1 is not a mere spacer domain and a subtle balance of the polar 
and nonpolar functional groups play an important role in the interaction of bryostatin 1 
with the phospholipid and the various PKC isozymes. With the biological profile of 
Merle 34 and 38 in hand, we can safely rectify the diagram shown in Figure 2.5 and put 
them in the “intermediate” group with a tendency towards the phorbol ester like 
compounds (Figure 2.20). However, the greatly decreased potency of these compounds 
suggests that a change from sp2 to sp3 at C13 is not well tolerated. It would be of interest 
to see if this depends at all on stereochemistry at C13 in sp3 hybridized analogues.     
 
Experimental section 
General experimental procedures, materials, and instrumentation  
Solvents were purified according to the guidelines in Purification of Common 































































EtOAc, and CH2Cl2 were distilled from CaH2 under an atmosphere of dry N2. THF, Et2O, 
and toluene were distilled from Na under an atmosphere of dry N2. Ti(OiPr)4 and TiCl4 
were distilled prior to use. A stock solution of Ti(OiPr)4 (1.0 M in CH2Cl2) was prepared 
and used for the BITIP catalyst preparations. The titer of n-butyllithium was determined 
by the method of Eastham and Watson.20 All other reagents were used without further 
purification. Yields were calculated for material judged homogeneous by thin layer 
chromatography and nuclear magnetic resonance (NMR) spectroscopy. Thin layer 
chromatography was performed on Merck Kieselgel 60 F254 plates eluting with the 
solvent indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic 
solution of 12-molybdophosphoric acid. Glassware for reactions was oven dried at 125 
oC and cooled under a dry atmosphere prior to use. Liquid reagents and solvents were 
introduced by oven-dried syringes through septum-sealed flasks under a nitrogen 
atmosphere. Column flash chromatography was performed with Silicycle Grade 70 – 230 
mesh, 60 – 200 µm, 60 Å silica gel, slurry packed with 1% EtOAc/hexanes in glass 
columns. Preparative thin layer chromatography was performed on Analtech Inc. Silica 
Gel GF 20 cm × 20 cm × 2000 µm plates or on Merck Kieselgel 60 F254 20 cm × 20 cm × 
250 µm plates. Nuclear magnetic resonance spectra were acquired on Varian VXR-500, 
Varian Inova-500 spectrometer 500 MHz for 1H and 125 MHz for 13C. Prior to use, 
CDCl3 was filtered through a plug of Fischer Scientific 80 – 200 mesh Alumina 
Adsorption stored at 110 oC. Chemical shifts for proton nuclear magnetic resonance (1H 
NMR) spectra are reported in parts per million relative to the signal of trimethylsilane at 
0 ppm, relative to the signal of residual CHCl3 at 7.27 ppm, or relative to the signal of 
residual C6D5H at 7.16 ppm. Chemical shifts for carbon nuclear magnetic resonance (13C 
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and DEPT) spectra are reported in parts per million relative to the signal of 
trimethylsilane at 0 ppm, relative to the center line of the CDCl3 triplet at 77.23 ppm, or 
relative to the center line of the C6D6 triplet at 128.62 ppm. Chemical shifts of the 
unprotonated carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C 
NMR spectrum. The abbreviations s, bs, d, dd, ddd, dddd, t, td, tt, q, dq, dqd, ddq, ABq, 
quin, and m stand for the resonance multiplicity singlet, broad singlet, doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, triplet, 
triplet of doublets, triplet of triplets, quartet, doublet of quartets, doublet of quartet of 
doublets, doublet of doublet of quartets, AB quartet, quintet, and multiplet, respectively. 
IR spectra were obtained from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer. 
Melting points were obtained using a Mel-Temp electrochemical melting point apparatus 
and are uncorrected. Optical rotations were obtained on a Perkin Elmer model 343 
polarimeter (Na D line) using a microcell with 1 dm path length. Specific rotations 
([α]20D, Unit: ocm2/g) are based on the equation α = (100. α)/(l.c) and are reported as 
unitless numbers where the concentration c is in g/100 mL and the path length l is in 
decimeters. Mass spectrometry was performed at the mass spectrometry facility of the 
Department of Chemistry at the University of Utah on a Finnigan MAT 95 double 
focusing high-resolution mass spectrometer. Compounds were named using 
ChemBioDraw 13.0. 
 




Preparation of (S)-1-((tert-butyldiphenylsilyl)oxy)hex-5-en-3-ol 2.28.21 To a 
500 mL three-neck round-bottom flask charged with a magnetic stir bar and equipped 
with a reflux condenser were added oven-dried 4 Å molecular sieves (34 g, 400 g/mol of 
aldehyde), (R)-BINOL (4.91g, 17.2 mmol, 0.20 equiv), CH2Cl2 (272 mL, 0.06 M), 
Ti(OiPr)4 (1.00 M in CH2Cl2, 8.6 mL, 8.58 mmol, 0.10 equiv), and TFA (freshly prepared 
1.0 M solution in CH2Cl2, 600 µL, 0.600 mmol, 7.0 x 10-3 equiv). The resulting red-
brown solution was heated to 40 oC for 1 h. The mixture was cooled to room temperature 
and the reflux condenser exchanged for a rubber septum. A solution of aldehyde 2.26 
(26.8 g, 85.8 mmol, 1.00 equiv) in CH2Cl2 (34 mL) was added via cannula, the mixture 
stirred for 30 min, and then cooled to -78 oC. Allyltributyl tin 2.27 (34.6 mL, 111.5 
mmol, 1.30 equiv) was added, the mixture stirred for 30 min, and the flask placed in a -20 
oC freezer. After 5 days, the mixture was removed from the freezer and a saturated 
aqueous NaHCO3 solution (200 mL) was added at 0 oC. The cold bath was removed and 
the mixture stirred for 30 min, allowed to settle, and then filtered through a plug of 
Celite®. The aqueous phase was extracted with CH2Cl2 (2 × 250 mL) and the combined 
organic phase was washed with water twice (100 mL) and brine (100 mL). The organic 
phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a 5 × 24 cm silica gel 
column eluting with a solvent gradient of hexanes (1000 mL) and 5% acetone/ hexanes 
(1000 mL) collecting 25 mL fractions. The fractions containing product (25 - 44) were 
combined and the solvent was removed under reduced pressure to give the homoallylic 
alcohol 2.28 (29.5 g, 95%) as colorless oil. The ratio of the enantiomers was determined 
to be 98:2 (using the other enantiomer made by the same procedure, er = 98:2) by HPLC 
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analysis using a Daicel Chiralcel OD-H silica column (length: 25 cm), eluting with a 
mobile phase of 2.5% 2-propanol/ hexanes and a flow rate of 0.5 mL/ min, respectively, 
detecting with a Rainin Dynamax Refractive Index Detector Model RI-1: tr (minor) = 
8.15 min, tr (major) = 9.21 min; Rf 0.58 (30% EtOAc/ hexanes); 400 MHz 1H NMR 
(CDCl3) δ 7.69 – 7.62 (m, 4H), 7.45 – 7.34 (m, 6H), 5.83 (dddd, J = 17.2, 10.2, 7.1, 7.1 
Hz, 1H), 5.12 – 5.07 (m, 1H), 5.07 – 5.05 (m, 1H), 3.98 – 3.90 (m, 1H), 3.90 – 3.78 (m, 
2H), 3.15 (d, J = 2.6, 1H), 2.31 – 2.18 (m, 2H), 1.77 – 1.62 (m, 2H), 1.03 (s, 9H); 125 
MHz 13C NMR (CDCl3) δ 135.8, 135.8, 135.2, 133.3, 133.2, 133.0, 130.0, 128.0, 117.6, 
71.0, 63.5, 42.2, 38.1, 27.0, 19.2; 125 MHz DEPT (CDCl3) δ CH3: 27.0, CH2: 117.6, 
63.5, 42.2, 38.1, CH: 135.8, 135.8, 130.0, 130.0, 128.0, 71.0. 
 
Preparation of (S)-tert-butyl((3-((4-methoxybenzyl)oxy)hex-5-en-1-
yl)oxy)diphenylsilane 2.29.21 To a stirring solution of alcohol 2.28 (5.40 g, 15.2 mmol, 
1.00 equiv) and freshly prepared 4-methoxybenzyl trichloroacetimidate (10.8 g, 38.1 
mmol, 2.50 equiv) in CH2Cl2 (31 mL, 0.50 M) in a 100 mL round-bottom flask, under an 
atmosphere of N2, was added (±)-camphor-10-sulfonic acid (1.10g, 4.57 mmol, 0.30 
equiv) in one portion. The reaction was allowed to proceed for 24 h at rt, after which time 
TLC analysis indicated essentially complete consumption of the starting material. The 
reaction mixture was concentrated under reduced pressure, diluted with 20% EtOAc/ 
hexanes (50 mL), filtered over a pad of Celite®, and concentrated under reduced pressure 
to give a red slurry. Purification was accomplished by flash column chromatography on a 
(4.5 × 30) cm silica gel column eluting with 5% EtOAc/ hexanes, collecting 25 mL 




under reduced pressure to give PMB ether 2.29 (5.65 g, 78%) as colorless oil: Rf 0.49 
(30% EtOAc/ hexanes); 400 MHz 1H NMR (CDCl3) δ 7.70 – 7.66 (m, 4H), 7.46 – 7.36 
(m, 6H), 7.23 – 7.19 (m, 2H), 6.86 – 6.83 (m, 2H), 5.85 (dddd, J = 17.3, 10.3, 7.0, 7.0 
Hz, 1H), 5.12 – 5.05 (m, 2H), 4.45 (ABq, J = 11.1 Hz, Δν = 44.9 Hz, 2H), 3.86 – 3.83 
(m, 1H), 3.80 (s, 3H), 3.78 – 3.69 (m, 2H), 2.33 (t, J = 7.0 Hz, 2H), 1.87 – 1.77 (m, 2H), 
1.10 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 159.3, 135.8, 135.1, 134.2, 134.1, 131.2, 
129.8, 129.5, 127.8, 127.8, 117.1, 113.9, 75.3, 71.0, 60.7, 55.5, 38.7, 37.2, 27.1, 19.4; 
125 MHz DEPT (CDCl3) δ CH3: 55.5, 27.1, CH2: 117.1, 71.0, 60.7, 38.7, 37.2, CH: 
135.8, 135.1, 129.8, 129.5, 127.8, 127.8, 113.9, 75.3. 
 
Preparation of (S)-5-(tert-butyldiphenylsilyloxy)-3-(4-methoxybenzyloxy) 
pentanal 2.19.22 To a stirring solution of alkene 2.29 (447 mg, 0.941 mmol, 1.0 equiv) in 
a mixture of 20% MeOH/CH2Cl2 (100 mL) in a 50 mL round-bottom flask was added 
sodium bicarbonate (790 mg) in one portion. The reaction mixture was cooled to -78 ºC, 
and then a steady stream of ozone was bubbled into the solution for 1 min, during which 
time the color changed to light grey. The mixture was then purged with a steady stream 
of oxygen. Dimethyl sulfide (2.8 mL, 37.6 mmol, 40.0 equiv) was added in one portion to 
the solution, which was then allowed to warm to rt over a period of 1 h. Solid NaHCO3 
was removed by filtration and the solution was concentrated under reduced pressure to 
give a yellow oil. Purification was accomplished by flash chromatography on a 2.5 × 10 
cm silica gel column, eluting with 20% EtOAc/hexanes (600 mL), collecting 9 mL 






under reduced pressure to give the product 2.46 (404 mg, 90%) as colorless oil: 500 MHz 
1H NMR (CDCl3) δ 9.75 (t, J = 2.0 Hz, 1H), 7.69-7.62 (m, 4H), 7.48-7.34 (m, 6H), 7.18 
(d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz,, 2H), 4.45 (s, 2H),  4.19 (dddd, J = 6.6, 6.6, 6.4, 
5.7 Hz, 1H), 3.91-3.86 (m, 1H), 3.84 (s, 3H), 3.82-3.76 (m, 1H), 2.69 (ddd, J = 16.1, 7.1, 
2.4 Hz, 1H), 2.63 (ddd, J = 16.4, 6.7, 1.7 Hz, 1H), 2.00-1.91 (m, 1H), 1.87-1.80 (m, 1H), 
1.08 (s, 9H). 125 MHZ 13C NMR (CDCl3) δ 201.6, 159.5, 135.7, 133.8, 133.7, 130.4, 
129.9, 129.8, 129.6, 127.9, 113.9, 71.4, 71.3, 60.3, 55.4, 48.7, 37.3, 27.1, 19.3. 
 
Preparation of (4S, 6S)-8-(tert-butyldiphenylsilyloxy)-6-(4-
methoxybenzyloxy) -2-((trimethylsilyl)methyl)oct-1-en-4-ol 2.17.22 To a solution of 
aldehyde 2.19 (5.0 g, 10.5 mmol, 1.0 equiv) in CH2Cl2 (105 mL, 0.1 M) in a 250 mL 
round-bottom flask was added MgBr2·OEt2 (5.4 g, 21.0 mmol, 2.0 equiv) in one portion 
at rt. After 5 min at rt, the reaction mixture was cooled to -78 ºC and stirred for 30 min. 
Stannane 2.18 (8.76 g, 21.0 mmol. 2.0 equiv) was added dropwise via syringe. After 5 h 
at -78 ºC, the reaction was quenched by the addition of saturated aqueous NaHCO3 
solution (25 ml). The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were washed with brine (50 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 25 cm silica gel column, eluting with 8% 
acetone/hexanes (800 mL), collecting 9 mL fractions. The fractions containing product 






(4.7 g, 74%) as colorless oil: 500 MHz 1H NMR (CDCl3) δ 7.70-7.64 (m, 4H), 7.46-7.34 
(m, 6H), 7.20 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.65 (dd, J = 1.1, 0.8 Hz, 1H), 
4.66 (s, 1H), 4.48 (s, 2H), 4.04-3.93 (m, 2H), 3.85-3.79 (m, 1H), 3.81 (s, 3H), 3.76 (dt, J 
= 10.0, 5.8 Hz, 1H), 2.67 (d, J = 2.2 Hz, 1H), 2.12 (dd, J = 14.1, 8.2 Hz, 1H), 2.06 (dd, J 
= 13.8, 5.0 Hz, 1H), 1.94 (dq, J = 12.8, 6.0 Hz, 1H), 1.79 (dq, J = 13.8, 6.7 Hz, 1H), 1.72-
1.60 (m, 2H), 1.55 (ABq, J = 13.4 Hz, Δν = 18.1 Hz, 2H), 1.08 (s, 9H), 0.04 (s, 9H); 125 
MHZ 13C NMR (CDCl3) δ 159.6, 144.9, 135.8, 134.0, 139.9, 130.8, 129.8, 129.8,  127.9, 
127.8, 127.7, 114.0, 110.2, 74.0, 71.6, 66.5, 60.7, 55.6, 47.0, 40.8, 37.3, 27.1, 26.9, 19.4, 
-1.1. 
 
Preparation of ethyl (R)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoate 
2.15.22 To a stirring solution of the corresponding alcohol of 2.34 (167 mg, assumed to be 
0.604 mmol, 1 equiv, supplied by Dr. Wei Li) in CH2Cl2 (6 mL, 0.1 M) in a 25 mL 
round-bottom flask was added diisopropylethylamine (734 µL, 4.22 mmol, 7.0 equiv). 
The reaction mixture was cooled to -10 ºC, and then dimethyl sulfoxide (430 µL, 6.04 
mmol, 10.0 equiv) was added via syringe.  After 5 min at -10 ºC, SO3·Py (384 mg, 2.42 
mmol, 4.0 equiv) was added in one portion. After 1 h at -10 ºC, the reaction mixture was 
poured into a 250 mL Erlenmeyer flask containing 25 mL of saturated aqueous NaHCO3 
solution. The reaction mixture was stirred at rt for 1 h, then the phases were separated, 
and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The organic phases were 
combined and washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated 








21 cm silica gel column, eluting with 5% EtOAc/hexanes (600 mL), collecting 9 mL 
fractions. The fractions containing product (9-27) were combined and concentrated under 
reduced pressure to provide the aldehyde 2.15 (135 mg, 96% over 2 steps) as colorless 
oil: Rf = 0.52 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 9.81 (t, J = 2.0 Hz, 
1H), 4.63 (dddd, J = 6.2, 6.2, 5.9, 5.9 Hz, 1H), 4.13 (m, 2H), 2.67 (ddd, J  = 16.6, 5.3, 1.7 
Hz, 1H), 2.61 (ddd, J = 16.6, 6.4, 2.4 Hz, 1H), 2.55 (dd, J = 15.1, 6.4 Hz, 1H), 2.55-2.50 
(dd, J = 15.1, 6.4 Hz, 1H), 1.25 (t, J = 6.8 Hz, 3H), 0.84 (s, 9H), 0.07 (s,  3H), 0.07 (s, 
3H); 125 MHz 13C NMR (CDCl3) δ 201.1, 170.8, 65.2, 60.9, 51.1, 42.8, 25.8, 18.1, 14.4, 
-4.6, -4.6; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 25.8, 14.3, -4.6, -4.6; CH2 δ 60.8, 
51.1, 42.8; CH δ 201.1, 65.2; 
 
Preparation of (R)-ethyl-4-((2R,6S)-6-((S)-4-(hydroxy)-2-(4-methoxy benzyl 
oxy) butyl)-4-methylenetetra hydro-2H-pyran-2-yl)-3-hydroxy butanoate and (R)-
ethyl 4-((2R,6S)-6-((S)-4-(tert-butyldiphenyl silyloxy)-2-(4-methoxybenzyloxy)butyl)-
4-methylene tetrahydro-2H-pyran-2-yl)-3-hydroxy butanoate 2.36 and 2.35.22 To a 
stirring solution of silyl ether 2.14 (938 mg, 1.18 mmol, 1.0 equiv) in a mixture of 3:2 
benzene/MeOH (13.0 mL, 0.1 M) in a 50 mL round-bottom flask was added p-
toluenesulfonic acid (451 mg, 2.37 mmol, 2.0 equiv) in one portion. After 3 h at rt, the 
reaction mixture was quenched by the addition of triethylamine (2 mL), and then with 
saturated aqueous NaHCO3 solution. The phases were separated and the aqueous layer 
was extracted with CH2Cl2 (2 x 10 mL). The combined organic layer was washed with 
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brine (25 mL) and concentrated under reduced pressure. Purification was accomplished 
by flash chromatography on a 3 × 20 cm silica gel column, eluting with 20% 
EtOAc/hexanes (900 mL) and 45% EtOAc/hexanes (500 mL), collecting 20 mL 
fractions. The fractions containing product (23-43) were combined and concentrated 
under reduced pressure to give the mono-deprotected product 2.35 (545 mg, 68%) as 
colorless oil: Rf = 0.48 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.71-7.62 
(m, 4H), 7.47-7.35 (m, 6H), 7.20 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.3 Hz, 2H), 4.73 (d, J 
= 1.7 Hz, 1H), 4.40 (ABq, J = 11.1 Hz, Δν = 40.4 Hz, 2H), 4.30-4.24 (m, 1H), 4.18-4.12 
(m, 2H), 3.83-3.75 (m, 7H), 3.57-3.51 (m, 2H), 2.55 (dd, J = 15.6, 7.7 Hz, 1H), 2.45 (dd, 
J =15.6, 5.4 Hz, 1H), 2.25 (d, J = 13.1 Hz, 1H), 2.17 (d, J = 13.1 Hz, 1H), 2.00 (t, J = 
12.1 Hz, 1H), 1.94 (t, J = 11.4 Hz, 1H), 1.86-1.64 (m, 6H), 1.25 (t, J = 7.4 Hz, 3H), 1.08 
(s, 9H); 125 MHz 13C NMR (CDCl3) δ 172.1, 159.3, 143.9, 135.8, 134.0, 131.0, 129.8, 
129.7, 127.8, 114.0, 109.2, 78.3, 75.4, 72.7, 71.5, 67.8, 60.7, 60.5, 55.4, 42.5, 42.1, 41.9, 
41.0, 37.5, 27.1, 19.3, 14.4;  125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.4, 27.1, 14.4; 
CH2 δ 109.2, 71.6, 60.7, 60.5, 42.5, 42.1, 41.9, 41.0, 41.0, 37.5; CH δ 135.8, 129.8, 129.7, 
127.9, 114.0, 78.4, 75.5, 72.8, 67.8. 
  The fractions containing product (55-75) were combined and concentrated under 
reduced pressure to provide the di-deprotected product 2.36 (150 mg, 29%) as colorless 
oil: Rf = 0.38 (EtOAc); 500 MHz 1H NMR (CDCl3) δ 7.26 (d, J = 8.8 Hz, 2H), 6.87 (d, J 
= 8.8 Hz, 2H), 4.75 (s, 2H), 4.48 (ABq, J = 11.2, Δν = 36.4 Hz, 2H), 4.27-4.21 (m, 1H), 
4.16 (q, J = 7.3 Hz, 2H), 3.83-3.75 (m, 2H), 3.79 (s, 3H), 3.74-3.67 (m, 1H), 3.55-3.49 
(m, 2H), 2.46 (dd, J = 15.6, 7.8 Hz, 1H), 2.44 (dd, J = 15.6, 5.4 Hz, 1H), 2.27 (bs, 1H), 
2.25-2.16 (m, 2H), 2.00 (d, J = 12.2 Hz, 1H),1.95 (q, J = 11.7 Hz, 1H), 1.92-1.85 (m, 
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1H), 1.79-1.64 (m, 5H), 1.24 (t, J = 7.3 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 172.1, 
159.6, 143.7, 130.7, 129.9, 114.2, 109.4, 78.4, 75.6, 74.5, 71.5, 67.8, 60.8, 60.1, 55.6, 
42.5, 42.1, 41.4, 41.1, 41.0, 36.6, 14.3; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.5 
14.4; CH2 δ 109.5, 71.6, 60.8, 60.1, 42.5, 42.1, 41.4, 41.1, 41.0, 36.6; CH δ 129.9, 114.1, 
78.5, 75.8, 74.5, 67.8. 
To a stirring solution of diol 2.36 (110 mg, 0.253 mmol, 1.0 equiv) in CH2Cl2 (2.5 
mL, 0.1 M) in a 15 mL round-bottom flask were added DMAP (8 mg, 0.063 mmol, 0.25 
equiv), BPSCl (98.6 µL, 0.380 mmol, 1.5 equiv), and Et3N (53 µL, 0.380 mmol, 1.5 
equiv) via syringe.  After 12 h at rt, the reaction mixture was quenched by the addition of 
water (5.0 mL). The phases were separated and the aqueous phase was extracted with 
Et2O (3 × 10 mL). The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 1 × 10 cm silica gel column, eluting with 20% EtOAc/hexanes (500 
mL), collecting 9 mL fractions. The fractions containing product (10-14) were combined 
and concentrated under reduced pressure to provide the alcohol 2.35 (162 mg, 95%) as 
colorless oil. 
 
Preparation of (R)-ethyl 4-((2R,6S)-6-((S)-4-(tert-butyldiphenyl silyloxy)-2-(4-
methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-(trimethyl silylo 
xy) butanoate 2.37.22 To a stirring solution of alcohol 2.35 (297 mg, 0.440 mmol, 1.0 
equiv) in CH2Cl2 (5 mL, 0.1 M) in a 15 mL round-bottom flask were added TMSCl 
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(167.5 µL, 1.32 mmol, 3.0 equiv) and triethylamine (367 µL, 2.64 mmol, 6.0 equiv) 
dropwise via syringe. After 12 h at rt, the reaction mixture was quenched by the addition 
of saturated aqueous NaHCO3 solution (2 mL). The phases were separated and the 
aqueous phase was extracted with Et2O (3 × 10 mL). The organic phases were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 17 cm silica gel column, eluting with 
10% EtOAc/hexanes (400 mL), collecting 9 mL fractions. The fractions containing 
product (15-21) were combined and concentrated under reduced pressure to provide the 
silyl ether 2.37 (322 mg, 98%) as a colorless oil: Rf  = 0.60 (20% EtOAc/hexanes); 500 
MHz 1H NMR (CDCl3) δ 7.76-7.72 (m, 4H), 7.49-7.41 (m, 6H), 7.21 (d, J = 8.3 Hz, 2H), 
6.86 (d, J = 8.3 Hz, 2H), 4.76 (d, J = 1.0 Hz, 1H), 4.74 (s, 1H), 4.47 (ABq, J = 11.7 Hz, 
Δν = 28.4 Hz, 2H), 4.43-4.39 (m, 1H), 4.18-4.06 (m, 2H), 3.93 (m, 1H), 3.86-3.78 (m, 
5H), 3.60-3.52 (m, 1H), 3.48-3.40 (m, 1H), 2.53 (d, J = 1.0 Hz, 1H), 2.53 (s, 1H), 2.30 (d, 
J = 12.7 Hz, 1H), 2.22 (d, J = 12.8 Hz, 1H), 2.01 (d, J = 13.0 Hz, 1H), 1.95 (d, J = 12.4 
Hz, 1H), 1.94-1.84 (m, 3H), 1.72-1.66 (m, 3H), 1.22 (t, J = 7.3 Hz, 3H), 1.10 (s, 9H), 
0.16 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 171.7, 159.2, 144.7, 135.8, 134.1, 134.0, 
131.2, 129.7, 129.5, 127.8, 113.9, 108.7, 75.1, 72.8, 71.7, 66.8, 60.7, 60.4, 55.4, 44.2, 
43.0, 42.4, 41.3, 41.1, 37.8, 27.1, 19.3, 14.4, 0.5.  
 
Preparation of (R)-ethyl 4-((2S,6R)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-









anoate 2.38.22 To a stirring solution of alkene 2.37 (265 mg, 0.356 mmol, 1.0 equiv) in 
CH2Cl2 (35 mL, 0.01 M) in a 50 ml round-bottom flask was added NaHCO3 (200 mg). 
The mixture was cooled to -78 ºC, and then a steady stream of ozone was bubbled 
through the solution for 1 min, during which time the solution developed a light grey 
color. The solution was then purged with a steady stream of oxygen until the grey color 
disappeared. PPh3 (280 mg, 1.06 mmol, 3.0 equiv) was added in one portion, and the 
reaction mixture was allowed to warm to rt and stirred overnight. The solid NaHCO3 was 
removed by filtration and the filtrate was concentrated under reduced pressure to give 
yellow oil. Purification was accomplished by flash chromatography on a 3 × 21 cm silica 
gel column, eluting with 15% EtOAc/hexanes (500 mL), collecting 9 mL fractions. The 
fractions containing product (15-19) were combined and concentrated under reduced 
pressure to give the product 2.38 (242 mg, 91% yield) as a colorless oil: Rf = 0.37 (30% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) 7.75-7.65 (m, 4H), 7.49-7.35 (m, 6H), 7.17 
(d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 4.47 (d, J = 11.1 Hz, 1H), 4.38-4.32 (m, 
1H), 4.36 (d, J = 10.7 Hz, 1H), 4.11 (dddd, J = 10.6, 7.1, 7.1, 7.1 Hz, 1H), 4.05 (dddd, J 
= 10.6, 7.1, 7.1, 7.1 Hz, 1H), 3.93 (dddd, J = 9.1, 5.6, 5.6, 3.0 Hz, 1H), 3.83 (dddd, J = 
9.1, 9.1, 2.7, 2.7 Hz, 1H), 3.84-3.78 (m, 5H), 3.76-3.70 (m, 2H), 2.53 (dd, J = 14.8, 7.7 
Hz, 1H), 2.48 (dd, J = 14.8, 7.7 Hz, 1H), 2.40 (ddd, J = 14.4, 2.0, 2.0 Hz, 1H), 2.33 (ddd, 
J = 14.4, 2.0, 2.0 Hz, 1H), 2.25 (dd, J = 14.1, 11.8 Hz, 1H), 2.20 (dd, J = 14.1, 11.8 Hz, 
1H), 1.96-1.86 (m, 2H), 1.84-1.73 (m, 2H), 1.72-1.62 (m, 2H), 1.20 (t, J = 7.4 Hz, 3H), 
1.06 (s, 9H), 0.10 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 207.0, 171.5, 159.3, 135.8, 
135.8, 134.0, 134.0, 131.0, 129.8, 129.4, 127.9, 127.9, 113.9, 73.8, 73.6, 72.7, 71.6, 66.4, 
60.6, 60.5, 55.5, 48.3, 48.1, 43.9, 42.8, 42.6, 37.4, 27.1, 19.4, 14.4, 0.4; 125 MHz DEPT 
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13C NMR (CDCl3)  CH3 δ 55.5, 27.1, 14.4, 0.4; CH2 δ 71.6, 60.6, 60.6, 48.3, 48.1, 44.0, 
42.8, 42.6, 37.4; CH δ 135.8, 129.8, 129.5, 129.5, 127.9, 73.8, 73.6, 72.7, 66.4. 
 
Preparation of (R)-ethyl 4-((2R,4S,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-
(4-methoxy benzyloxy)butyl)-4-hydroxytetrahydro-2H-pyran-2-yl)-3-(trimethylsilyl 
oxy) butanoate 2.40.22 To a solution of ketone 2.38 (32.0 mg, 0.043 mmol, 1.0 equiv) in 
MeOH (3.0 mL, 0.015M) in a 15 mL round-bottom flask at -15 ºC was added NaBH4 (3.2 
mg, 0.086 mmol, 2.0 equiv) in one portion. After 30 min at -15 ºC, the mixture was 
quenched by the addition of acetone (0.1 mL), and then concentrated under reduced 
pressure.  Purification was accomplished by flash chromatography column on a 1 × 10 
cm silica gel column, eluting with 40% EtOAc/hexanes (500 mL), collecting 9 mL 
fractions. The fractions containing product (15-20) were combined and concentrated 
under reduced pressure to give the alcohol product 2.40 (30.0 mg, 94%) as a colorless oil: 
Rf = 0.15 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.74-7.63 (m, 4H), 7.46-
7.34 (m, 6H), 7.18 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.45 (d, J = 10.8 Hz, 
1H), 4.38 (d, J = 11.1 Hz, 1H), 4.40-4.32 (m, 1H), 4.10 (dddd, J = 10.6, 7.1, 7.1, 7.1 Hz, 
1H), 4.05 (dddd, J = 10.6, 7.1, 7.1, 7.1 Hz, 1H), 3.91-3.86 (m, 1H), 3.82-3.74 (m, 7H), 
3.56-3.50 (m, 1H), 3.46-3.39 (m, 1H), 2.50 (d, J = 5.5 Hz, 1H), 2.49 (d, J = 3.0 Hz, 1H),  
1.97 (ddd, J = 12.4, 4.4, 2.4 Hz, 1H), 1.90-1.76 (m, 4H), 1.68-1.45 (m, 5H), 1.20 (t, J = 
7.1 Hz, 3H), 1.06 (s, 9H), 0.12 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 171.8, 159.3, 









72.1, 71.7, 68.3, 66.8, 60.7, 60.5, 55.6, 43.9, 42.9, 42.3, 41.8, 41.5, 37.8, 27.1, 19.4, 14.4, 
0.5; 125 MHz DEPT 13C NMR (CDCl3)  CH3 δ 55.6, 27.1, 14.4, 0.5; CH2 δ 71.7, 60.7, 
60.5, 43.9, 42.9, 42.3, 41.8, 41.5, 37.8; CH δ 135.8, 135.8, 129.8, 129.5, 127.9, 127.9, 
114.0, 72.9, 72.1, 68.4, 66.8. 
 
Preparation of (R)-ethyl 4-((2R,4S,6R)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-
(4-methoxy benzyloxy)butyl)-4-(trimethylsilyloxy) tetrahydro-2H-pyran-2-yl)-3-
(trimethylsilyloxy) butanoate 2.13.22 To a solution of alcohol 2.40 (36.4 mg, 0.048 
mmol, 1.0 equiv) in CH2Cl2 (500 µL, 0.1 M) in a 10 mL round-bottom flask were added 
TMSCl (31 µL, 0.243 mmol, 5.0 equiv) and Et3N (67.5 µL, 0.480 mmol, 10.0 equiv) 
dropwise via syringe. After 12 h at rt, the reaction mixture was quenched by the addition 
of water (5 mL). The phases were separated and the aqueous phase was extracted with 
Et2O (3 × 10 mL). The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 1 × 10 cm silica gel column, eluting with 10% EtOAc/hexanes (200 
mL), collecting 9 mL fractions. The fractions containing product (8-12) were combined 
and concentrated under reduced pressure to give the product 2.13 (39.2 mg, 98% yield) as 
a colorless oil: Rf = 0.62 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.70 (ddd, 
J = 4.4, 1.4, 1.4 Hz, 2H), 7.67 (dd, J = 4.0, 1.7 Hz, 2H), 7.45-7.35 (m, 6H), 7.18 (d, J = 
8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 4.41 (ABq, J = 11.1 Hz, Δν = 41.0 Hz, 1H), 4.37-
4.30 (m, 1H), 4.10 (dddd, J = 10.7, 7.1, 7.1, 7.1 Hz, 1H), 4.05 (dddd, J = 10.7, 7.1, 7.1, 
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7.1 Hz, 1H), 3.90-3.84 (m, 1H), 3.80 (s, 3H), 3.80-3.71 (m, 3H), 3.56-3.50 (m, 1H), 3.45-
3.38 (m, 1H), 2.50 (d, J = 4.7 Hz, 1H), 2.48 (d, J = 2.7 Hz, 1H), 1.86-1.72 (m, 5H), 1.66-
1.54 (m, 3H), 1.20 (t, J = 7.1 Hz, 3H), 1.05 (s, 9H), 0.13 (s, 9H), 0.11 (s, 9H); 125 MHz 
13C NMR (CDCl3) δ 171.8, 159.3, 135.8, 135.8, 134.1, 134.1, 129.8, 129.6, 127.9, 114.0, 
72.9, 72.2, 72.1, 71.8, 68.8, 66.8, 60.7, 60.5, 55.5, 44.0, 43.1, 42.3, 42.3, 41.9, 37.7, 27.1, 
19.4, 14.4, 0.5, 0.5; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.5, 27.1, 14.4, 0.5, 0.5; 
CH2 δ  71.8, 60.7, 60.5, 44.0, 43.1, 42.3, 42.3, 41.9, 37.7; CH δ  135.8, 129.8, 129.6, 
127.9, 114.0, 72.9, 72.2, 72.1, 68.8, 66.8. 
	  
Preparation of (2S,4R,6S)-2-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxy 
benzyloxy) butyl)-6-((S)-2-hydroxy-4-((trimethylsilyl) methyl)pent-4-enyl)tetrahydr 
o-2H-pyran-4-ol 2.12.22 A 15 mL round-bottom flask was charged with CeCl37H2O 
(453.0 mg, 1.21 mmol, 10.0 equiv) and a stir bar. The reaction flask was heated to 170 ºC 
under 0.1 mm Hg vacuum. After 16 h at 170 ºC, the dried CeCl3 was cooled to rt, and the 
flask was purged with N2. THF (1.2 mL) was added via syringe, and the mixture was 
stirred at rt for 2 h.  
Preparation of the Grignard reagent: Another 15 mL three-necked round-bottom 
flask equipped with a condenser and a magnetic stir bar was charged with shiny 
magnesium turnings (122.0 mg, 5 mmol, 1.0 equiv), and a crystal of iodine. The flask 
was heated with a heat gun for 5 min while stirring. THF (5.0 mL, 1 M) was added via 
syringe, and the reaction mixture was heated with a heat gun at reflux. TMSCH2Cl (768 
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µL, 5.5 mmol, 1.1 equiv) was then added dropwise via syringe. The mixture was then 
stirred at rt for 1.5 h to give an assumed 1.0 M of 5 mL solution of TMSCH2MgCl.  
The CeCl3/THF mixture was cooled to -78 ºC, then a solution of TMSCH2MgCl 
(1.1 mL, 1.0 M in THF, 1.2 mmol, 10.0 equiv) was added dropwise via syringe. After 1 h 
at -78 ºC, a solution of ester 2.13 (100 mg, 0.121 mmol, 1.0 equiv) in THF (243 µL, 0.5 
M) was then added via cannula. An additional THF (500 µL) rinse was used to transfer 
the remaining ester residue into the reaction mixture. The solution was allowed to warm 
to rt and stirred overnight. The mixture was again cooled to -78 ºC, and then chilled 1N 
HCl solution (4.0 mL) was added dropwise via syringe. The reaction mixture was then 
warmed to rt and the phases were separated. The aqueous phase was extracted with Et2O 
(3 × 10 mL). The organic phases were combined, washed with saturated aqueous 
NaHCO3 solution (10 mL), then dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash chromatography on a 1 × 10 cm 
silica gel column, eluting with 50% EtOAc/hexanes (400 mL), collecting 9 mL fractions. 
The fractions containing product (9-25) were combined and concentrated under reduced 
pressure to give the product 2.12 (61.2 mg, 70%) as a colorless oil: Rf = 0.31 (50% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.74-7.63 (m, 4H), 7.45-7.37 (m, 6H), 
7.20 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.3 Hz, 2H), 4.67 (s, 1H), 4.64 (s, 1H), 4.48-4.43 
(ABq, J = 11.1 Hz, Δν = 42.5, 1H), 4.00-3.94 (m, 1H), 3.81-3.74 (m, 6H), 3.60-3.50 (m, 
2H), 3.44 (s, 1H), 2.22 (dd, J = 13.8, 7.1 Hz, 1H), 2.07 (dd, J  = 13.8, 6.0 Hz, 1H), 1.96 
(ddd, J  = 12.1, 2.4, 2.0 Hz, 1H), 1.87 (ddd, J  = 12.4, 2.4, 2.4 Hz, 1H), 1.84-1.78 (m, 
3H), 1.72-1.60 (m, 5H), 1.57 (s, 2H), 1.07 (s, 9H), 0.05 (s, 9H); 125 MHZ 13C NMR 
(CDCl3) δ 159.3, 144.6, 135.8, 134.0, 134.0, 131.1, 129.8, 129.7, 127.8, 127.8 114.0, 
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110.1, 76.3, 72.8, 72.5, 71.6, 69.5, 67.8, 60.5, 55.4, 46.6, 42.4, 41.8, 41.6, 41.5, 37.5, 
27.1, 27.1, 19.3, -1.2. 
 
Preparation of (9S,11R,12R,E)-methyl-12-(benzyloxymethoxy)-9-(tert-butyl 
dimethylsilyloxy)-11-(4-methoxybenzyloxy)-4,4-dimethyl-5-oxotridec-2-enoate 
2.42.22 To a stirring solution of alkene 2.23 (1.48 g, 2.41 mmol, 1.0 equiv) in 5% 
MeOH/EtOAc (50 mL, 0.05 M) in a 100 mL round-bottom flask at -78 °C was added 
NaHCO3 (2 g, 24.1 mmol, 10.0 equiv).  A steady stream of O3 was bubbled through the 
reaction mixture until a light blue color developed.  The excess O3 was removed by 
bubbling O2 through the mixture for 15 min until the light blue color faded.  PPh3 (945 
mg, 3.60 mmol, 1.5 equiv) was added in one portion, and the reaction mixture was slowly 
warmed to rt, and stirred for 12 h.  The solids were removed via filtration, and the filtrate 
was concentrated under reduced pressure. The resulting yellow oil was taken up in 10% 
Et2O/ pentane (200 mL) in a 500 mL round-bottom flask, and placed in a -20 °C freezer 
for 6 h.  The triphenylphosphine oxide precipitate was removed via filtration, and rinsed 
with 100 mL of ice cold 1% Et2O/pentane. The solvent was removed under reduced 
pressure to yield the crude aldehyde as light yellow oil, which was taken on to the next 
step without further purification.   
 To a stirring solution of methyl diethylphosphonoacetate 2.41 (960 µL, 5.30 
mmol, 2.2 equiv) in THF (12 mL, 0.2 M) in a 50 mL round-bottom flask at 0 °C was 








mixture was stirred at 0 °C for 30 min, and then a solution of the aforementioned crude 
aldehyde in THF (5 mL) was added to the mixture slowly via cannula.  The transfer was 
completed with two 2.5 mL rinses using THF.  The reaction mixture was stirred at 0 °C 
for an additional 2 h, then quenched by the addition of saturated aqueous NH4Cl solution 
(15 mL).  The phases were separated and the aqueous phase was extracted with CH2Cl2 
(3 × 50 mL).  The combined organic phases were dried with Na2SO4, filtered, and then 
concentrated under reduced pressure.  Purification was accomplished using flash 
chromatography on a 3 × 21 cm silica gel column, eluting with 10% EtOAc/hexanes (800 
mL), collecting 9 mL fractions.  The fractions containing product (17-43) were combined 
and concentrated under reduced pressure to give the product 2.42 (1.50 g, 92% over 2 
steps) as a colorless oil: Rf = 0.50 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 
7.38-7.34 (m, 4H), 7.31-7.28 (m, 1H), 7.25 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 15.4 Hz, 1H), 
6.86 (d, J = 8.8 Hz, 2H), 5.90 (d, J = 15.4 Hz, 1H), 4.81 (ddd, J = 7.3, 6.8, 6.4 Hz, 2H), 
4.64 (q, J = 11.7 Hz, 2H), 4.58 (d, J = 11.2 Hz, 1H), 4.45 (d, J = 10.7 Hz, 1H), 4.02 (dd, J 
= 16.4, 14.9 Hz, 1H), 3.89 (dddd, J = 8.8, 8.8, 5.4 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 
3.64 (ddd, J = 9.4, 4.4, 2.4 Hz, 1H), 2.42 (ddd, J = 7.3, 7.3, 2.0 Hz, 2H), 1.69 (ddd, J = 
14.2, 8.8, 2.4 Hz, 1H), 1.62-1.54 (m, 3H), 1.47-1.40 (m, 2H), 1.27 (s, 6H), 1.18 (d, J = 
6.4 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H);  125 MHz 13C NMR (CDCl3) 210.8, 166.9, 159.2, 
152.0, 138.1, 131.1, 129.3, 128.6, 128.0, 127.8, 120.5, 113.9, 93.4, 78.2, 73.0, 72.1, 69.6, 










Preparation of (E)-methyl 4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-me 
thoxybenzyloxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-enoate 2.21.22 To 
a stirring solution of silyl ether 2.42 (1.42 g, 2.12 mmol, 1.0 equiv) in 20:1 CH3CN/ H2O 
(42 mL, 0.05 M) in a 100 mL plastic bottle at 0 °C were added pyridine (7 mL) and a 
48% aqueous HF solution (500 µL).  The solution was stirred at 0 °C for 30 min, and then 
warmed to rt.  After 30 min of stirring at rt, additional 500 µL of aqueous HF solution 
(48%) was added every hour until TLC analysis indicated complete consumption of the 
starting material.  The reaction mixture was quenched by slowly pipetting the solution 
into a mixture of saturated aqueous NaHCO3 solution (50 mL) and EtOAc (50 mL).  
Then solid NaHCO3 was added until effervescence was complete.  The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 20 mL).  The combined 
organic phases were washed with water (100 mL), saturated aqueous CuSO4 solution (2 
× 20 mL), and brine (2 × 20 mL).  The solution was dried over Na2SO4, filtered, and 
concentrated under reduced pressure to give the crude intermediate alcohol as light 
yellow oil.  This intermediate was carried on to the next step without further purification. 
 To a stirring solution of the aforementioned crude alcohol (assumed to be 2.12 
mmol) in benzene (42 mL, 0.05 M) in a 50 mL round-bottom flask equipped with a 
condenser and a Dean-Stark apparatus was added CSA (24.5 mg, 0.106 mmol, 0.05 
equiv).  The solution was heated at reflux for 1.5 h, and then cooled to rt.  The reaction 
mixture was quenched by the addition of pyridine (0.1 mL), and the solvent was removed 
under reduced pressure.  Purification was accomplished using flash chromatography on a 
3.0 × 21 cm silica gel column, eluting with 10% EtOAc/hexanes (1000 mL), collecting 9 
mL fractions.  The fractions containing product (24-65) were combined and concentrated 
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under reduced pressure to give the product dihydropyran 2.21  (823.2 mg, 73% over 2 
steps) as a colorless oil: Rf = 0.42 (20% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 
7.37-7.35 (m, 4H), 7.33-7.29 (m, 1H), 7.27 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 15.6 Hz, 1H), 
6.86 (d, J = 8.8 Hz, 2H), 5.84 (d, J = 15.4 Hz, 1H), 4.83 (ABq, J = 8.8 Hz, Δν = 11.7 Hz, 
2H), 4.65 (ABq, J = 11.7 Hz, Δν = 14.2 Hz, 2H), 4.62 (d, J = 10.7 Hz, 1H), 4.63-4.63 (m, 
1H), 4.50 (d, J = 10.3 Hz, 1H), 4.01-3.97 (m, 1H), 3.97 (dd, J = 6.5, 5.4 Hz, 1H), 3.82 
(dd, J = 5.4, 2.0 Hz, 1H), 3.80 (s, 3H), 3.64 (s, 3H), 2.14-2.06 (m, 1H), 2.04-1.96 (m, 
1H), 1.84-1.74 (m, 2H), 1.62 (ddd, J = 14.2,10.7, 2.4 Hz, 1H), 1.52 (dddd, J = 13.2, 9.8, 
9.8, 5.9 Hz, 1H), 1.24 (s, 3H), 1.22 (s, 3H), 1.21 (d, J = 6.4 Hz, 3H); 125 MHz 13C NMR 
(CDCl3) 167.6, 159.3, 157.2, 156.4, 138.2, 131.1, 129.6, 128.6, 128.0, 127.8, 117.9, 
114.0, 94.5, 93.6, 77.7, 73.9, 73.6, 72.0, 69.5, 55.5, 51.5, 41.4, 36.2, 28.2, 25.3, 25.2, 
20.5, 15.6. 
 
Preparation of (E)-4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy 
benzyloxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-en-1-ol 2.43.22 To a 
stirring solution of ester 2.21 (794 mg, 1.47 mmol, 1.0 equiv) in CH2Cl2 (15 mL, 0.1 M) 
at -78 °C was added a solution of DIBAL-H (2.1 mL, 1.5 M in toluene, 3.10 mmol, 2.1 
equiv) slowly via syringe. The solution was stirred at -78 °C for 2 h, then warmed to 0 °C 
and stirred for 0.5 h. The reaction was quenched by the addition of EtOAc (0.5 mL) and 
the mixture was stirred at 0 °C for 10 min. A saturated Rochelle salt solution (10 mL) 
was added. Then the aqueous phase was separated and extracted with CH2Cl2 (3 × 25 
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mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished using flash chromatography on a 
3 × 21 cm silica gel column, eluting with 20% EtOAc/hexanes (500mL), collecting 9 mL 
fractions. The fractions containing product (19-42) were combined and concentrated 
under reduced pressure to give the product alcohol 2.43 (587.1 mg, 78%) as a clear 
colorless oil: Rf = 0.30 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.34-7.30 
(m, 4H), 7.28-7.25 (m, 1H), 7.23 (d, J = 8.3 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 5.74 (d, J 
= 16.1 Hz, 1H), 5.58 (ddd, J = 15.6, 5.9, 5.9 Hz, 1H), 4.80 (s, 2H), 4.61 (s, 2H), 4.62 (d, J 
= 10.6 Hz, 1H), 4.57 (d, J = 3.7 Hz, 1H), 4.53 (d, J = 10.7 Hz, 1H), 4.06 (m, 2H), 4.03-
3.94 (m, 2H), 3.85 (ddd, J = 10.3, 4.9, 2.4 Hz, 1H), 3.80 (s, 3H), 2.09 (m, 1H), 2.03-1.96 
(m, 1H), 1.83-1.77 (m, 2H), 1.60-1.46 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H), 1.14 (s, 6H); 
125 MHz 13C NMR (CDCl3) 159.4, 158.9, 140.5, 138.1, 131.2, 129.6, 128.6, 128.1, 
127.9, 125.8, 114.1, 93.6, 93.3, 78.0, 74.2, 73.4, 71.8, 69.7, 64.1, 55.5, 40.7, 36.1, 28.3, 
26.1, 26.0, 20.5, 15.7. 
 
Preparation of ((E)-4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy 
benzyloxy) butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-enyloxy)(tert-butyl) 
dimethylsilane 2.44.22 To a stirring solution of alcohol 2.43 (713.0 mg, 1.40 mmol, 1.0 
equiv) in CH2Cl2 (14 mL, 0.1M) in a 50 mL round-bottom flask at 0 °C were added 2,6-
lutidine (972 µL, 8.40 mmol, 6.0 equiv) and TBSOTf (802 µL, 3.50 mmol, 2.5 equiv) via 









methanol (1 mL). After 5 min at 0 °C, the mixture was transferred to a separatory funnel 
containing saturated NaHCO3 aqueous solution (10 mL). The aqueous phase was 
separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  Purification was 
accomplished using flash chromatography on a 3 × 21 cm silica gel column, eluting with 
5% EtOAc/hexanes (600 mL), collecting 9 mL fractions.  The fractions containing 
product (15-27) were combined and concentrated under reduced pressure to give the 
product 2.44  (768 mg, 88%) as colorless oil: Rf = 0.25 (10% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3) δ 7.34-7.31 (m, 4H), 7.30-7.25 (m, 1H), 7.23 (d, J = 8.3 Hz, 2H), 6.84 
(d, J = 8.8 Hz, 2H), 5.73 (ddd, J = 15.6, 1.5,1.5 Hz, 1H), 5.50 (ddd, J = 15.6, 5.4, 5.4 Hz, 
1H), 4.85 (ABq, J = 6.8 Hz, Δν = 9.3 Hz, 2H), 4.62 (ABq, J = 11.7 Hz, Δν = 15.6 Hz, 
2H), 4.60 (d, J = 10.8 Hz, 1H), 4.53 (dd, J = 4.4, 2.9 Hz, 1H), 4.49 (d, J = 10.7 Hz, 1H), 
4.11 (dd, J = 5.4, 1.5 Hz, 2H), 3.99 (dddd, J = 9.8, 9.8, 2.4, 2.4 Hz, 1H), 3.93 (ddd, J = 
11.2, 6.4, 6.4, Hz, 1H), 3.81 (ddd, J = 10.3, 2.0, 2.0 Hz, 1H), 3.77 (s, 3H), 2.06 (dddd, J = 
17.1, 9.8, 6.8, 2.9 Hz, 1H), 1.99-1.91 (m, 1H), 1.80 (ddd, J = 14.1, 10.7, 2.4 Hz, 1H), 
1.78 (ddd, J = 13.2, 7.4, 2.9 Hz, 1H), 1.63 (ddd, J = 14.2, 10.8, 2.4 Hz, 1H), 1.47 (dddd, J 
= 13.2, 9.8, 9.8 5.9 Hz, 1H), 1.18 (d, J = 6.3 Hz, 3H), 1.15 (s, 3H), 1.14 (s, 3H), 0.88 (s, 
9H), 0.03 (s, 6H); 125 MHz 13C NMR (CDCl3) 159.3, 159.1, 138.6, 138.1, 131.1, 129.7, 
128.6, 128.0, 127.9, 125.9, 114.0, 93.6, 93.2, 78.0, 74.1, 73.6, 71.7, 69.5, 64.6, 55.5, 40.5, 












Preparation of (2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy ben 
zyloxy)butyl)-2-((E)-5-(tert-butyldimethylsilyloxy)-2-methylpent-3-en-2-yl)-2-metho 
xydihydro-2H-pyran-3(4H)-one 2.20.22 To a stirring solution of dihydropyran 2.44 (70 
mg, 0.112 mmol, 1.0 equiv) in CH2Cl2 (1.1 mL, 0.1 M) in a 10 mL round-bottom flask at 
-15 °C was added methanol (500 µL) followed by NaHCO3 (28 mg, 0.34 mmol, 3.0 
equiv). The solution was stirred at -15 °C for 5 min, then MMPP (138 mg, 0.28 mmol, 
2.5 equiv) was added. The reaction was stirred at -15 °C for 1.5 h, and then warmed to 0 
°C and stirred for an additional 30 min. The reaction mixture was quenched by the 
addition of saturated aqueous NaHCO3 solution (1 mL) followed by saturated aqueous 
NaHSO3 solution (2 mL).  The mixture was stirred at rt for 10 min until effervescence 
was complete. The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic phases were dried with Na2SO4, filtered, and 
then concentrated under reduced pressure to provide the crude intermediate alcohol as 
colorless oil, which was carried on to the next step without further purification. 
 To a stirring solution of the aforementioned crude alcohol (assumed to be 0.112 
mmol) in CH2Cl2 (1.1 mL) in a 15 mL round-bottom flask at rt were added 4 Å molecular 
sieves (112 mg), TPAP (4 mg, 0.011 mmol, 0.1 equiv), and NMO (39 mg, 0.336 mmol, 
3.0 equiv).  The mixture was stirred at rt for 1 h. The reaction was concentrated under N2 
and then directly applied for flash column chromatography on a 3 × 12 cm flash 
chromatography, eluting with 15% EtOAc/hexanes (500 mL), collecting 9 mL fractions.  
The fractions containing product (11-17) were combined and concentrated under reduced 
pressure to give the product ketone 2.20  (54 mg, 72% over 2 steps) as colorless oil: Rf = 
0.47 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ; 7.39-7.34 (m, 4H), 7.34-7.28 
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(m, 1H), 7.22 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 5.98 (dt, J = 15.6, 1.5 Hz, 
1H), 5.51 (dt, J = 16.1, 4.9 Hz, 1H), 4.85 (ABq, J = 7.3 Hz, Δν = 7.8 Hz, 2H), 4.67 (s, 
2H), 4.63 (d, J = 10.8 Hz, 1H), 4.45 (d, J = 10.8 Hz, 1H), 4.15 (dd, J = 4.9, 1.5 Hz, 2H), 
3.89 (ddd, J = 12.2, 4.9, 2.0 Hz, 1H), 3.81-3.79 (m, 1H), 3.79 (s, 3H), 3.24 (s, 3H), 2.45 
(dd, J = 5.4, 1.0 Hz, 1H), 2.42 (d, J = 5.4 Hz, 1H), 2.00-1.86 (m, 3H), 1.66 (ddd, J = 12.9, 
10.6, 2.4 Hz, 1H), 1.22 (d, J = 6.4 Hz, 3H), 1.44 (s, 3H), 1.10 (s, 3H), 0.07 (s, 3H), 0.06 
(s, 3H); 125 MHz 13C NMR (CDCl3); 207.7, 159.6, 138.0, 136.2, 130.8, 129.4, 128.6, 
128.0, 127.9, 127.8, 114.0, 104.3, 93.6, 77.3, 72.5, 72.2, 70.3, 69.7, 64.2, 55.5, 52.3, 44.1, 
37.7, 36.4, 30.2, 26.2, 23.0, 22.2, 18.6 14.9, -5.0. 
 
Preparation of (E)-methyl 2-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-
methoxy benzyloxy)butyl)-2-((E)-5-(tert-butyldimethylsilyloxy)-2-methylpent-3-en-
2-yl)-2-methoxy-3-oxo-2H-pyran-4(3H,5H,6H)-ylidene)acetate 2.45.22 To a stirring 
solution of ketone 2.20 (1.6 g, 2.38 mmol, 1.0 equiv) in methanol (24 mL, 0.1 M) at rt 
was added K2CO3 (1.8 g, 13.0 mmol, 5.5 equiv) in one portion.  Freshly prepared and 
distilled methyl glyoxylate (3.7 mL, 47.6 mmol, 20.0 equiv) wad added via syringe. The 
mixture was stirred at rt for 1 h, and then diluted with Et2O (10 mL) and quenched by the 
addition of saturated aqueous NH4Cl solution (10 mL). The aqueous phase was separated 
and extracted with Et2O (3 × 25 mL ). The combined organic phases were dried over 












accomplished using flash chromatography on a 3 × 21 cm column, eluting with 10% 
EtOAc/hexanes (500 mL), collecting 9 mL fractions.  The fractions containing product 
(12-29) were combined and concentrated under reduced pressure to give the product 2.45  
(1.43 g, 81%) as bright yellow oil:  Rf = 0.55 (4:5:1 of hexanes/EtOAc/Et2O); 500 MHz 
1H NMR (CDCl3) δ; 7.40-7.34 (m, 4H), 7.33-7.29 (m, 1H), 7.18 (d, J = 8.8 Hz, 2H), 6.82 
(d, J = 8.8 Hz, 2H), 6.54 (dd, J = 3.4, 2.0 Hz, 1H), 5.81 (ddd, J = 15.6, 1.5, 1.5 Hz, 1H), 
5.41 (ddd, J = 16.1, 5.4, 5.4 Hz, 1H), 4.85 (ABq, J = 6.8 Hz, Δν = 12.2 Hz, 2H), 4.67 (s, 
2H), 4.61 (d, J = 10. 7 Hz, 1H), 4.41 (d, J = 10.7 Hz, 1h), 4.17-4.08 (m, 2H), 4.06 (dd, J 
= 9.3, 2.0 Hz, 1H), 3.90 (ddd, J = 10.3, 4.4, 2.0 Hz, 1H), 3.78 (s, 3H), 3.75 (s, 3H), 3.31 
(ddd, J = 18.6, 2.0, 2.0 Hz, 1H), 3.20 (s, 3H),  2.86 (ddd, J = 18.6, 12.2, 3.4 Hz, 1H), 1.97 
(ddd, J = 14.7, 9.3, 2.0 Hz, 1H), 1.75 (ddd, J = 14.7, 9.8, 2.4 Hz, 1H), 1.21 (d, J = 6.4 Hz, 
3H), 1.10 (s, 3H), 1.04 (s, 3H), 0.90 (s, 9H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCl3); 
197.7, 166.2, 159.3, 148.2, 138.0, 134.8, 130.6, 129.3, 128.7, 128.6,  128.0, 127.9, 122.7, 
114.0, 93.6, 76.9, 72.3, 71.7, 69.7, 69.5, 64.1, 55.4, 52.2, 51.9, 44.6, 36.1, 36.1, 26.1, 
22.5, 22.0, 14.7,  -5.0. 
 
Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methox 
ybenzyl)oxy)butyl)-2-((E)-5-((tert-butyldimethylsilyl)oxy)-2-methylpent-3-en-2-yl)-2 
-methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yloctanoate 2.48.22 













mL, 0.01M) in a 100 mL round-bottom flask at rt was added CeCl3·7H2O (1.64 g, 4.40 
mmol, 8 equiv). The reaction mixture was stirred at rt until most of the CeCl3·7H2O 
crystals had dissolved, then cooled to -40 °C and stirred for 15 min. NaBH4 (83 mg, 2.20 
mmol, 4.0 equiv) was then added in one portion. The mixture was stirred at -40 °C for 1.5 
h, and then diluted with 40% EtOAc/hexanes (10 mL), and quenched by the addition of 
saturated aqueous NH4Cl solution (5.0 mL). The mixture was poured into a separatory 
funnel containing 40% EtOAc/hexanes (50 mL). The organic phase was separated, 
washed with water (10 mL) and brine (10 mL), then dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting crude product was used in the next 
step without further purification. 
To a stirring solution of the aforementioned crude alcohol (assumed to be 0.552 
mmol) in CH2Cl2 (5.0 mL, 0.1 M) in a 25 mL round-bottom flask at rt, were added 
pyridine (446 µL, 5.52 mmol, 10 equiv), DMAP (134 mg, 1.10 mmol, 2.0 equiv), and 
octanoic anhydride (795 µL, 2.76 mmol, 5.0 equiv). The reaction mixture was stirred at rt 
overnight, then quenched by the addition of methanol (1.0 mL). The mixture was stirred 
for another 10 min and 10 mL of CH2Cl2 was added. The mixture was poured into a 
separatory funnel containing 10 mL of saturated aqueous NaHCO3 solution.  The aqueous 
phase was separated and extracted with CH2Cl2 (3 × 25 mL). The organic phases were 
combined, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a 3 × 21 cm silica gel 
column, eluting with 10% EtOAc/hexanes (1000 mL), collecting 9 mL fractions. The 
fractions containing product (23-59) were combined and concentrated under reduced 
pressure to give the product 2.48 (388.6 mg, 81%) as colorless oil. Rf = 0.52 (30% 
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EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.39-7.28 (m, 5H), 7.21 (d, J = 8.8 Hz, 
2H), 6.84 (d, J = 8.8 Hz, 2H), 5.98 (d, J = 15.6 Hz, 1H), 5.88 (s, 1H), 5.43 (s, 1H), 5.40 
(ddd, J = 16.1, 5.3, 5.3 Hz, 1H), 4.86 (ABq, J = 6.8 Hz, Δν = 7.0 Hz, 2H), 4.67 (ABq, J = 
12.2 Hz, Δν = 7.2 Hz, 2H), 4.62 (d, J = 10.7 Hz, 1H0, 4.43 (d, J = 10.8 Hz, 1H), 4.15-
4.03 (m, 3H), 3.90 (ddd, J = 10.3, 4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.51 (dd, J 
= 15.6, 2.4 Hz, 1H), 3.23 (s, 3H), 2.36 (t, J = 7.3 Hz, 2H), 2.29 (ddd, J = 7.3, 2.9, 2.9 Hz, 
2H), 1.91 (ddd, J = 14.2, 9.8, 2.0 Hz, 1H), 1.73 (ddd, J = 13.7, 10.3, 2.4 Hz, 1H), 1.64 (d, 
J = 7.3 Hz, 2H), 1.62-1.57 (m, 1H), 1.37-1.26 (m, 10H), 1.23 (d, J = 6.3 Hz, 3H), 1.11 (s, 
6H), 0.91 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 13C NMR 
(CDCl3) δ 179.8, 172.3, 166.7, 159.4, 152.7, 138.2, 130.7, 129.5, 128.7, 128.0, 127.9, 
124.9, 117.5, 114.0, 102.8, 93.5, 77.0, 72.6, 72.1, 72.0, 69.6, 68.4, 64.7, 55.5, 51.7, 51.3, 




methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate 2.49. 
To a solution of the PMB ether 2.48 (290 mg, 0.335 mmol, 1 equiv) in CH2Cl2 (16 mL, 
0.02 M) was added tBuOH (670 µL) followed by pH 7 buffer (7 mL). The reaction was 
cooled to 0 oC. DDQ (228 mg, 1.005 mmol) was then added to the reaction and 













NaHCO3 solution. The phases separated and the organic layer was extracted with CH2Cl2 
(3 × 20 mL) and washed with brine (50 mL). The combined organic layer was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography on a 3 × 21 cm silica gel column, eluting 
with 10% EtOAc/hexanes (200 mL), 25% EtOAc/hexanes (400 mL), collecting 9 mL 
fractions. The fractions containing product (48-65) were combined and concentrated 
under reduced pressure to give the product 2.49 (218 mg, 87%) as colorless oil. Rf = 0.42 
(30% EtOAc/hexanes); [α]20D = -3.2 (c = 0.120, CHCl3); 500 MHz 1H NMR (CDCl3) δ 
7.37-7.34 (m, 4H), 7.33-7.28 (m, 1H), 6.01 (d, J = 15.6 Hz, 1H), 5.88 (s, 1H), 5.42 (s, 
1H), 5.36 (ddd, J = 16.1, 5.4, 5.4 Hz, 1H), 4.87 (ABq, J = 6.8 Hz, Δν = 26.7 Hz, 2H), 
4.66 (ABq, J = 11.7 Hz, Δν = 19.5 Hz, 2H), 4.16 (ddd, J = 8.8, 8.8, 2.9 Hz, 1H), 4.12 (dd, 
J = 4.9, 1.5 Hz, 2H), 3.87 (m, 1H), 3.68 (s, 3H), 3.63 (m, 1H), 3.50 (m, 1H), 3.36 (s, 3H), 
2.69 (m, 1H), 2.36-2.24 (m, 3H), 1.72 (m, 2H), 1.59 (m, 2H), 1.32-1.22 (m, 12H), 1.12 (s, 
3H), 1.11 (s, 3H), 0.91 (s, 9H), 0.88 (t, J = 6.8 Hz, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 125 
MHz 13C NMR (CDCl3) δ 172.2, 166.7, 152.8, 138.2, 137.6, 128.6, 128.0, 128.0, 124.4, 
117.3, 102.8, 93.9, 78.1, 72.2, 71.2, 70.0, 68.3, 64.5, 51.6, 51.3, 45.9, 39.8, 34.5, 32.6, 
31.9, 31.8, 29.2, 26.2, 24.8, 24.6, 23.6, 22.8, 18.6, 18.6, 16.9, 14.3, -4.9; IR (neat) 2951, 
2928, 2845, 1746, 1722, 1627, 1512, 1453, 1435, 1380, 1310, 1247, 1228, 1151, 1110, 
1071, 1039, 902, 836, 690 cm-1; HRMS (ESI/TOF) calcd for C41H68O10SiNa (M + Na+) 







octanoate 2.50. A solution of the alcohol 2.49 (154.8 mg, 0.207 mmol, 1 equiv) in 
CH2Cl2 (4 mL, 0.05 M) in a 15 mL round-bottom flask was cooled to 0 oC. To this 
solution was added 2,6-lutidine (144 µL, 1.24 mmol, 6 equiv) followed by TBSOTf (119 
µL, 0.516 mmol, 2.5 equiv) via syringe. The reaction was stirred for 45 min, after which 
the reaction was quenched by addition of saturated aqueous NaHCO3 solution (2 mL). 
The phases separated and the organic layer was extracted with CH2Cl2 (3 × 20 mL), then 
washed with brine (20 mL). The combined organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography on a 1 × 10 cm silica gel column, eluting with 5% 
EtOAc/hexanes (200 mL), collecting 9 mL fractions. The fractions containing product 
(12-20) were combined and concentrated under reduced pressure to give the product 2.50 
(164.1 mg, 92%) as colorless oil: Rf = 0.62 (30% EtOAc/hexanes); [α]20D = -13.2 (c = 
0.200, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.39-7.32 (m, 4H), 7.32-7.25 (m, 1H), 5.95 
(d, J = 16.1 Hz, 1H), 5.90 (s, 1H), 5.50 (s, 1H), 5.40 (ddd, J = 16.1, 5.4, 5.4 Hz, 1H), 4.80 
(s, 2H), 4.64 (ABq, J = 11.7 Hz, Δν = 13.6 Hz, 2H), 4.10 (dd, J = 5.4, 1.4 Hz, 2H), 4.05 













(dd, J = 15.6, 2.4 Hz, 1H), 3.32 (s, 3H), 2.30 (m, 3H), 1.99 (ddd, J = 11.2, 8.8, 1.9 Hz, 
1H), 1.60 (s, 3H), 1.29 (m, 9H), 1.17 (d, J = 6.3 Hz, 3H), 1.11 (s, 3H), 0.90 (s, 9H), 0.88 
(s, 9H), 0.08 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 172.3, 
166.6, 152.9, 138.0, 137.9, 128.6, 127.9, 127.8, 125.3, 117.3, 102.6, 93.2, 75.0, 71.6, 
70.2, 69.5, 68.5, 64.7, 51.9, 51.3, 45.9, 38.7, 34.6, 33.0, 31.9, 29.2, 29.1, 26.2, 26.1, 24.9, 
24.6, 23.7, 22.8, 18.6, 18.3, 14.3, 13.9, -3.9, -4.5, -4.9; IR (neat) 2951, 2943, 2928, 2845, 
1746, 1722, 1627, 1512, 1453, 1443, 1381, 1247, 1228, 1151, 1110, 1071, 1039, 902, 





4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate 2.51. To a 
solution of the TBS ether 2.50 (27 mg, 0.031 mmol, 1 equiv) in THF (156 µL, 0.2 M) in a 
10 mL plastic centrifuge vial was added pyridine (31 µL) followed by HFPy (28 µL, 
20% HF basis, 0.312 mmol, 10 equiv) via plastic pipette. The reaction was stirred for 4 h 
at rt, after which the reaction was quenched by addition of saturated aqueous NaHCO3 
solution (2 mL). The phases separated and the organic layer was extracted with CH2Cl2 
(3 × 10 mL), then washed with brine (10 mL). The combined organic layer was dried 













accomplished by flash column chromatography on a 1 × 10 cm silica gel column, eluting 
with 25% EtOAc/hexanes (200 mL), collecting 9 mL fractions. The fractions containing 
product (8-12) were combined and concentrated under reduced pressure to give the 
product 2.51 (20.4 mg, 87%) as colorless oil. Rf = 0.32 (30% EtOAc/hexanes); [α]20D = -
1.2 (c = 0.120, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.38-7.33 (m, 4H), 7.38-7.28 (m, 
1H), 5.97 (d, J = Hz, 1H), 5.89 (s, 1H), 5.57 (s, 1H), 5.51 (ddd, J = 16.1, 5.4, 5.4 Hz, 1H), 
4.81 (s, 2H), 4.65 (s, 2H), 4.15-4.10 (m, 4H), 3.86 (ddd, J = 8.8, 8.8, 2.9 Hz, 2H), 3.70 (s, 
3H), 3.46 (dd, J = 16.1, 1.9 Hz, 1H), 3.34 (s, 3H), 2.42-2.33 (m, 1H), 2.34-2.27 (ddd, J = 
7.8, 7.8, 3.9 Hz, 2H), 1.99 (ddd, J = 11.2, 8.8, 1.9 Hz, 1H), 1.67-1.56 (m, 4H), 1.29 (m, 
9H), 1.17 (d, J = 6.3 Hz, 3H), 1.13 (s, 3H), 1.11 (s, 3H), 0.90 (s, 9H), 0.09 (s, 3H), 0.08 
(s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 172.5, 166.8, 152.9, 139.7, 138.0, 
128.6, 128.0, 127.9, 125.5, 117.1, 102.6, 93.3, 75.1, 71.5, 70.3, 69.5, 68.6, 64.3, 51.7, 
51.4, 46.2, 38.7, 34.7, 33.4, 31.9, 29.2, 29.1, 26.1, 24.2, 24.1, 22.8, 18.3, 14.3, 13.9, -3.8, 
-4.5; IR (neat) 2933, 2940, 2857, 1746, 1722, 1689, 1627, 1512, 1463, 1442, 1437, 1380, 
1300, 1243, 1228, 1156, 1110, 1071, 1043, 912, 836, 773, 736, 698, 505 cm-1; HRMS 


















solution of the alcohol 2.51 (17.1 mg, 0.023 mmol, 1.0 equiv) in CH2Cl2 (226 µL, 0.1 M) 
and tBuOH (2.5 µL) in a 5 mL vial at 0 oC was added pyridine (5.5 µL, 0.068 mmol, 3 
equiv) followed by DMP (14 mg, 0.034 mmol, 1.5 equiv). Stirring was continued at 0 °C 
for 2 h. The reaction mixture was then quenched by the addition of saturated aqueous 
Na2S2O3 solution (2 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash chromatography on a 1 × 10 cm silica gel column, eluting with 
10% EtOAc/hexanes (500 mL), collecting 9 mL fractions. The fractions containing 
product (10-14) were combined and concentrated under reduced pressure to provide the 
product aldehyde 2.11 (16.1 mg, 95%) as colorless oil: Rf  = 0.63 (30% EtOAc/hexanes); 
500 MHz 1H NMR (CDCl3) δ 9.45 (d, J = 7.8 Hz, 1H), 7.30-7.20 (m, 5H), 5.87 (dd, J = 
16.1, 7.8 Hz, 1H), 5.84 (s, 1H), 5.48 (s, 1H), 4.74 (ABq, J = 6.8 Hz, Δν = 6.3 Hz, 2H), 
4.57 (s, 2H), 4.15-4.08 (m, 2H), 3.87 (dd, J = 6.4, 4.4 Hz, 1H), 3.64 (s, 3H), 3.49 (dd, J = 
16.1, 2.0 Hz, 1H), 3.30 (s, 3H), 2.30 (dd, J = 14.2, 13.7 Hz, 1H), 2.13 (ddd, J = 16.1, 7.3, 
7.3 Hz, 1H), 2.04 (ddd, J = 16.1, 7.3, 7.3 Hz, 1H), 1.98 (ddd, J = 14.2, 8.8, 2.4 Hz, 1H), 
1.59 (ddd, J = 14.2, 8.8, 2.9 Hz, 1H), 1.51-1.44 (m, 1H), 1.25-1.15 (m, 10H), 1.12 (d, J = 
6.4 Hz, 3H), 1.11 (s, 3H), 1.08 (s, 3H), 0.82 (s, 9H), 0.80 (t, J = 6.8 Hz, 3H), 0.03 (s, 3H), 
0.0 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 194.8, 172.1, 167.1, 166.4, 151.8, 137.9, 
128.7, 128.0, 127.3, 117.9, 102.6, 93.3, 75.1, 70.8, 70.3, 69.6, 69.2, 51.9, 51.5, 47.6, 38.7, 









2.52.22 To a stirring solution of hydroxyallylsilane 2.12 (13 mg, 0.018 mmol, 1.3 equiv) 
and aldehyde 2.11 (10.5 mg, 0.014 mmol, 1.0 equiv) in Et2O (3 mL, 0.005 M) in a 15 mL 
round-bottom flask at -78 ºC was added a solution of TMSOTf in Et2O (18 µL, 1.0 M in 
Et2O, 0.018 mmol, 1.3 equiv) dropwise via syringe. After 1 h at -78 ºC, the mixture was 
slowly warmed to -40 ºC and stirred for 2 h, and then quenched by the addition of 
saturated aqueous NaHCO3 solution (2 mL). The mixture was warmed to rt, and then the 
phases were separated, and the aqueous phase was extracted with Et2O (3 × 10 mL). The 
organic phases were combined, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  Purification was accomplished by flash chromatography on a 0.5 × 10 
cm silica gel column, eluting with 30% EtOAc/hexanes, collecting 5 mL fractions. The 
fractions containing product (8-13) were combined and concentrated under reduced 
pressure to give the product 2.52 (12.9 mg, 67% yield) as colorless oil. Rf = 0.49 (50% 
















7.18 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.3 Hz, 2H), 5.94 (s, 1H), 5.90 (d, J = 16.1 Hz, 1H), 
5.61 (s, 1H), 5.42 (dd, J = 16.1, 5.9 Hz, 1H), 4.79 (s, 2H), 4.66-4.59 (m, 2H), 4.64 (s, 
2H), 4.40 (ABq, J = 10.7 Hz, Δν = 37.6 Hz, 2H), 4.12-4.06 (m, 2H), 3.93-3.89 (m, 1H), 
3.88 -3.72 (m, 5H), 3.80 (s, 3H), 3.68 (s, 3H), 3.60-3.47 (m, 4H), 3.31 (s, 3H), 2.40-2.28 
(m, 3H), 2.24 (d, J = 13.2 Hz, 1H), 2.16 (d, J = 13.7 Hz, 1H), 2.02-1.85 (m, 6H), 1.84 -
1.73 (m, 3H), 1.67-1.50 (m, 6H), 1.32-1.22 (m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.12 (s, 
3H), 1.11 (s, 3H), 1.06 (s, 9H), 0.90-0.85 (m, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 
13C NMR 125 MHz (CDCl3) δ 172.3, 166.6, 159.3, 153,3, 144.4, 138.0, 137.9, 135.8, 
134.1, 134.0, 131.2, 129.8, 129.5, 128.6, 128.0, 127.8, 127.6, 116.6, 114.0, 109.0, 102.6, 
93.2, 79.2, 75.0, 72.7, 72.0, 71.9, 71.5, 70.2, 69.5, 68.4, 60.6, 55.5, 51.5, 51.3, 46.2, 42.5, 
42.4, 41.8, 41.3, 41.0, 40.5, 38.7, 37.9, 34.6, 33.8, 31.9, 29.3, 29.2, 27.2, 26.1, 25.0, 24.4, 






methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate 2.53.22 To a stirring 
















a 25 mL round-bottom flask at rt were added pyridine (573 µL, 7.08 mmol, 50 equiv), 
DMAP (173 mg, 1.42 mmol, 10 equiv) and Ac2O (401 µL, 4.25 mmol, 30 equiv). The 
mixture was stirred at rt overnight, and then quenched by the addition of saturated 
aqueous NaHCO3 solution (5 mL). The aqueous phase was separated and extracted with 
CH2Cl2 (3 × 20 mL). The combined organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification was accomplished using flash 
chromatography with a 3 × 21 cm silica gel column, eluting with 20% EtOAc/hexanes, 
collecting 9 mL fractions.  The fractions containing product (14-23) were combined and 
concentrated under reduced pressure to provide the product 2.53 (170.8 mg, 85%) as a 
colorless oil: Rf = 0.49 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.72-7.64 
(m, 4H), 7.46-7.26 (m, 11H), 7.18 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.93 (d, J 
= 16.1 Hz, 1H), 5.90 (s, 1H), 5.58 (s, 1H), 5.42 (dd, J = 16.1, 5.4 Hz, 1H), 4.80 (s, 2H), 
4.65-4.59 (m, 3H), 4.53 (bs, 1H), 4.44 (d, J = 10.7 Hz, 1H), 4.34 (d, J = 10.7 Hz, 1H), 
4.11-4.05 (m, 2H), 3.91-3.82 9m, 2H), 3.80 (s, 3H), 3.79-3.72 (m, 2h), 3.68 (s, 3H), 3.67-
3.60 (m, 2H), 3.58-3.45 (m, 3H), 3.30 (s, 3H), 2.38-2.30 (m, 3H), 2.26 (d, J = 12.7 Hz, 
1H), 2.17 (d, J = 14.7 Hz, 1H), 2.04 (s, 3H), 2.06-1.95 (m, 3H), 1.92-1.85 (m, 2H), 1.81-
1.73 (m, 3H), 1.66-1.54 (m, 6H), 1.33-1.23 (m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.11 (s, 
6H), 1.05 (s, 9H), 0.90-0.85 (m, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR 
125 MHz (CDCl3) δ 172.4, 170.6, 166.7, 159.4, 153,1, 144.2, 138.1, 138.1, 135.8, 134.1, 
134.0, 131.2, 129.8, 129.5, 128.6, 128.0, 127.9, 127.3, 117.0, 114.1, 109.1, 102.6, 93.3, 
79.0, 75.0, 74.9, 72.8, 72.0, 71.8, 71., 70.7, 70.3, 69.5, 68.4, 60.6, 55.5, 51.6, 51.3, 46.1, 
42.8, 42.3, 40.8, 40.4, 38.7, 37.9, 37.9, 37.8, 34.6, 33.5, 31.9, 29.3, 29.2, 27.1, 26.1, 24.9, 








dene)tetrahydro-2H-pyran-3-yl octanoate 2.54.22 To a stirring solution of BPS ether 
2.53 (32.2 mg, 0.023 mmol, 1.0 equiv) in DMF (2 mL, 0.01 M) in a 15 mL round-bottom 
flask were added a solution of TBAF solution in THF (45 µL, 1.0 M in THF, 0.045 
mmol, 2.0 equiv) and AcOH (45 µL, 1.0 M in DMF, 0.045 mmol, 2.0 equiv). The 
solution was stirred at rt for 2 days, and then diluted with 40% EtOAc/hexanes (100 mL) 
and water (5 mL). The phases were separated and the organic phase was washed with 
water (3 × 10 mL). The organic phases were dried over Na2SO4, filtered, and then 
concentrated under reduced pressure. Purification was accomplished using flash 
chromatography on a 2 × 15 cm silica gel column, eluting with 30% EtOAc/hexanes (500 
mL), collecting 9 mL fractions. The fractions containing product (26-41) were combined 
and concentrated under reduced pressure to provide the alcohol 2.54 (22.2 mg, 83%) as 
colorless oil. Rf = 0.33 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 7.38-7.28 
(m, 5H), 7.26 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.94 (d, J = 15.6 Hz, 1H), 
















2H), 4.68-4.57 (m, 2H), 4.64 (s, 2H), 4.47 (ABq, J = 10.7 Hz, Δν = 33.5 Hz, 2H), 4.12-
4.05 (m, 3H), 3.90-3.83 (m, 3H), 3.81 (s, 3H), 3.76-3.70 (m, 2H), 3.69 (s, 3H), 3.62-3.45 
(m, 4H), 3.30 (s, 3H), 2.39-2.30 (m, 1H), 2.34 (td, J = 7.3, 2.4 Hz, 2H), 2.25 (d, J = 13.2 
Hz, 1H), 2.18 (d, J = 12.7 Hz, 1H), 2.04 (s, 3H), 2.04-1.88 (m, 7H), 1.80-1.70 (m, 2H), 
1.70-1.52 (m, 6H), 1.33-1.23 (m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.10 (s, 6H), 0.90-0.85 
(m, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR 125 MHz (CDCl3) δ 172.4, 
170.7, 166.7, 159.6, 153.1, 144.2, 138.4, 138.1, 130.5, 129.7, 128.6, 128.0, 127.9, 127.2, 
117.0, 114.2, 109.1, 102.6, 93.2, 79.3, 75.2, 75.0, 75.0, 72.4, 72.2, 72.0, 71.5, 70.5, 70.2, 
69.5, 68.4, 60.3, 55.5, 51.6, 51.3, 46.1, 42.7, 41.6, 40.8, 40.3, 38.6, 38.0, 37.6, 36.8, 34.6, 
33.5, 31.9, 29.3, 29.2, 26.1, 24.9, 24.2, 24.1, 22.8, 21.5, 18.3, 14.3, 14.0, -3.8, -4.5. 
 




an-2-yl)-3-((4-methoxybenzyl)oxy)butanoic acid 2.56.22 To a stirring solution of 
alcohol 2.54 (89.7 mg, 0.076 mmol, 1.0 equiv) in CH2Cl2 (7.6 mL, 0.01M) in a 25 mL 
round-bottom flask at -10 °C were added diisopropylethylamine (185 µL, 1.065 mmol, 
















was stirred at -10 °C for 5 min and SO3·Py (97 mg, 0.608 mmol, 8.0 equiv) was added in 
one portion.  Stirring was continued at -10 °C for 1 h and then warmed up to 0 oC and 
stirred for another 30 min, after which the reaction mixture was diluted with CH2Cl2 (1 
mL) and quenched by the addition of saturated aqueous NaHCO3 solution (1 mL). The 
mixture was stirred at rt for 10 min until effervescence was complete.  The reaction 
mixture was partitioned between CH2Cl2 (10 mL) and saturated aqueous NaHCO3 
solution (20 mL) and the phases were separated.  The aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL), and the combined organic phases were dried over Na2SO4, filtered, 
and concentrated under reduced pressure.  The resulting residue was washed through a 
small plug of silica gel with 20% EtOAc/hexanes (100 mL), and the solvent was removed 
under reduced pressure to provide the aldehyde, which was used in the next step without 
further purification.  
To a stirring solution of the aforementioned aldehyde (assumed to be 0.076 
mmol) in 2-methyl-2-butene (2 mL, 0.04 M) and tBuOH (4 mL) in a 25 round-bottom 
flask at rt was added aqueous solution of KH2PO4 (762 µL, 1.0 M in H2O).  The mixture 
was cooled to 0 °C, and NaClO2 (70.0 mg, 0.760 mmol, 20.0 equiv) was added in one 
portion.  The reaction mixture was stirred vigorously at 0 °C for 1.5 h, and then quenched 
by the addition of aqueous pH 4 buffer solution (5 mL).  The resulting mixture was 
partitioned between CH2Cl2 (25 mL) and aqueous pH 4 buffer solution (5 mL).  The 
phases were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 10 mL).  
The combined organic phases were dried over Na2SO4, and concentrated under reduced 
pressure.  Purification was accomplished using flash chromatography with a 1 × 10 cm 
silica gel column, eluting with 5% MeOH/20% EtOAc/75% hexanes, collecting 9 mL 
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fractions.  The fractions containing product (23-45) were combined and concentrated 
under reduced pressure to provide the product carboxylic acid 2.56 (73.5 mg, 81% over 2 
steps) as colorless oil: Rf = 0.12 (5% MeOH/20% EtOAc/75% hexanes); 500 MHz 1H 
NMR (CDCl3) δ 7.37-7.28 (m, 5H), 7.24 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 
5.96 (d, J = 16.1 Hz, 1H), 5.89 (s, 1H), 5.58 (s, 1H), 5.45 (dd, J = 15.6, 6.3 Hz, 1H), 4.90 
(m, 1H), 4.83-4.74 (m, 1H), 4.81 (s, 2H), 4.70-4.59 (m, 4H), 4.59-4.40 (m, 2H), 4.10 (m, 
5H), 3.89-3.82 (m, 2H), 3.88-3.83 (m, 6H), 3.80 (s, 3H), 3.80-3.70 (m, 2H), 3.69 (s, 3H), 
3.63-3.44 (m, 4H), 3.31 (s, 3H), 2.61 (d, J = 5.9 Hz, 2H), 2.40-2.30 (m, 2H), 2.25 (d, J = 
12.7 Hz, 1H), 2.17 (d, J = 13.2 Hz, 1H), 2.07-1.90 (m, 7H), 2.03 (s, 3H), 1.77-1.55 (m, 
7H), 1.34-1.22 (m, 10H), 1.16 (d, J = 6.8 Hz, 3H), 1.11 (s, 6H), 0.90-0.85 (m, 3H), 0.88 
(s, 3H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (CDCl3) δ 174.7, 172.4, 170.6, 166.7, 159.6, 
153.1, 144.2, 138.5, 138.0, 137.4, 130.3, 129.6, 128.6, 127.9, 127.2, 116.7, 114.1, 109.1, 
102.6, 93.1, 79.4, 75.1, 72.9, 72.4, 72.0, 71.6, 70.4, 70.4, 70.2, 69.5, 68.4, 55.5, 51.6, 
51.3, 51.0, 46.1, 42.7, 41.9, 40.4, 40.1, 38.6, 37.8, 37.6, 34.6, 31.9, 31.8, 29.2, 26.1, 26.0, 
24.9, 24.3, 24.0, 22.8, 21.5, 18.3, 14.3, 13.9, -3.8, -4.3, -4.5; 125 MHz DEPT NMR 
(CDCl3) CH3 δ 55.5, 51.4, 51.0, 26.1, 24.3, 24.0, 21.5, 14.3, 14.0, -3.8, -4.5; CH2 δ  
108.9, 92.9, 72.2, 69.3, 41.7, 41.6, 40.6, 40.2, 40.1, 38.6, 37.8, 37.6, 34.6, 34.3, 31.7, 
29.0, 28.9, 24.7, 22.6, 22.5; CH δ  138.7, 129.7, 128.6, 128.1, 127.9, 127.2, 116.9, 113.9, 







tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.57. To a stirring 
solution of TBS ether 2.56 (88.7 mg, 0.074 mmol, 1.0 equiv) in 9:1 THF/pyridine (7.5 
mL, 0.01 M) in a 25 mL plastic vial were added methanol (743 µL) and HF·Py (3.9 mL, 
20% HF basis). The solution was stirred at rt for 2 d, and then diluted with 50% 
EtOAc/hexanes (10 mL), and washed with brine (2 × 10 mL). The solution was dried 
over Na2SO4 and concentrated under reduced pressure. The crude seco acid was taken on 
to the next step without purification.  
To a stirring solution of aforementioned seco acid (assumed to be 0.074 mmol) in 
THF (2.5 mL) in a 50 mL round-bottom flask at 0 °C were added Et3N (61.7 µL, 0.444 
mmol, 6.0 equiv) and 2,4,6-trichlorobenzoyl chloride (34.7 µL, 0.222 mmol, 3.0 equiv). 
After 5 min, the mixture was warmed to rt and stirring was continued for an additional 3 
h. The reaction mixture was diluted with 3:1 toluene/THF (29.6 mL, 0.0025 M) and 
placed into a 25 mL gas-tight syringe. This solution was added by syringe pump to a 
stirring solution of DMAP (181 mg, 1.48 mmol, 20.0 equiv) in toluene (49.3 mL, 0.0015 
















over another 5 h. The residual contents of the syringe were rinsed into the flask with 
toluene (2 × 1.0 mL) and stirring was continued for an additional 2 h. The reaction 
mixture was then cooled to rt, diluted with 40% EtOAc/hexanes (100 mL), and washed 
with water (3 × 30 mL) and with brine (50 mL). The organic phase was dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash chromatography with a 1 × 10 cm silica gel column, eluting 
with 20% EtOAc/hexanes, collecting 9 mL fractions. The fractions containing product 
(23-47) were combined and concentrated under reduced pressure to provide pure 
macrolactone 2.57 (48.9 mg, 62% over 2 steps) as colorless oil: Rf = 0.49 (40% 
EtOAc/hexanes); [α]20D = +16.5 (c = 2.2, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.41-
7.28 (m, 5H), 7.21 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.22 (d, J = 15.6 Hz, 
1H), 5.95 (d, J = 1.5 Hz, 1H), 5.61-5.55 (m, 1H), 5.34 (dd, J = 15.6, 8.8 Hz, 1H), 5.18 (s, 
1H), 4.81-4.71 (m, 6H), 4.64 (ABq, J = 11.7, Δν = 14.4 Hz, 2H), 4.49 (ABq, J = 11.2 Hz, 
, Δν = 7.0 Hz, 2H), 4.19 (m, 1H), 3.99-3.91 (m, 2H), 3.80-3.73 (m, 1H), 3.76 (s, 3H), 
3.73-3.63 (m, 3H), 3.69 (s, 3H), 3.52-3.40 (m, 2H), 3.18 (m, 1H), 3.08 (m, 3H), Hz, 1H), 
2.5 (m, 2H), 2.35-2.18 (m, 4H), 2.14-1.83 (m, 10H), 2.03 (s, 3H), 1.80 (m, 2H), 1.75-1.47 
(m, 2H), 1.46-1.19 (m, 6H), 1.13-1.04 (m, 3H), 0.88 (t, J = 6.8 Hz, 3H); 125 MHz 13C 
NMR (CDCl3) δ 172.2, 172.1, 170.7, 166.9, 159.3, 151.5, 144.4, 141.7, 138.0, 130.9, 
129.6, 128.6, 128.5, 128.0, 127.8, 125.7, 119.4, 113.9, 109.1, 103.3, 93.7, 81.4, 76.3, 
74.8, 73.7, 73.5, 73.3, 73.2, 72.2, 70.8, 70.4, 69.8, 67.3, 55.5, 52.7, 51.3, 51.3, 45.2, 43.9, 
42.9, 41.9, 41.4, 40.9, 37.6, 34.8, 34.8, 31.8, 31.0, 29.2, 29.0, 26.4, 24.8, 22.8, 21.5, 20.1, 
15.3, 14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 52.7, 51.4, 26.4, 21.5, 20.1, 15.4, 
14.3; CH2 δ  93.7, 71.8, 69.9, 48.9, 48.2, 43.9, 42.9, 41.4, 37.6, 35.0, 34.8, 31.8, 31.0, 
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29.2 (×2), 29.1, 24.9, 22.8; CH δ  141.7, 129.6, 128.6, 128.0, 127.8, 125.7, 119.4, 113.9, 
81.4, 76.3, 74.8, 73.7, 73.5, 73.3, 73.2, 72.5, 70.8, 70.4, 67.3; IR (neat): 2930, 2361, 
2339, 1736, 1719, 1654, 1514, 1436, 1175, 1042, 902, 812, 505; HRMS (ESI/TOF) calcd 





tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.58.22 A 100 ml 
flask containing 50 mL of CH2Cl2 was cooled to -78 °C, and a stream of O3 was passed in 
for 3 min. The color of the solution changed to light blue. The flask was sealed and kept 
at -78 °C for immediate use. This O3 solution was added in 100 µL portion via a plastic 
syringe to a stirring solution of olefin 2.57 (39.0 mg, 0.037 mmol, 1.0 equiv) at -78 °C. 
The reaction was monitored by TLC and the addition of the O3 solution was continued 
every 10 min until the starting material was fully consumed. DMS (1.2 mL) was then 
added and the mixture was warmed to rt. The solution was stirred at rt for 12 h, after 
which the solvent was removed under reduced pressure. Purification was accomplished 
using flash chromatography on a 1 × 10 cm silica gel column, eluting with 25% 
















(36-64) were combined and concentrated under reduced pressure to provide ketone 2.58 
(29.3 mg, 75%) as colorless oil: Rf = 0.49 (40% EtOAc/hexanes); 500 MHz 1H NMR 
(CDCl3) δ 7.41-7.29 (m, 5H), 7.21 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.27 (d, J 
= 15.6 Hz, 1H), 5.95 (d, J = 1.5 Hz, 1H), 5.59-5.53 (m, 1H), 5.33 (dd, J = 15.6, 8.8 Hz, 
1H), 5.19 (s, 1H), 4.80 (s, 2H), 4.62 (ABq, J = 11.7, Δν = 14.4 Hz, 2H), 4.42 (ABq, J = 
11.2 Hz, Δν = 7.0 Hz, 2H), 42.9-4.22 (m, 1H), 4.16-4.10 (m, 1H), 3.90 (dd, J = 6.4, 4.4 
Hz, 1H), 3.77-3.74 (m, 1H), 3.76 (s, 3H), 3.70-3.65 (m, 3H), 3.67 (s, 3H), 3.48-3.40 (m, 
1H), 3.14-3.08 (m, 1H), 3.06 (s, 3H), 2.50-2.40 (m, 2H), 2.35-2.18 (m, 4H), 2.16-2.06 
(m, 2H), 2.02 (s, 3H), 1.96-1.76 (m, 5H), 1.64-1.50 (m, 6H), 1.34-1.22 (m, 10H), 1.10-
1.06 (m, 9H), 0.86 (t, J = 6.3 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 206.8, 172.3, 
172.2, 170.7, 167.0, 159.5, 151.3, 142.7, 138.1, 130.6, 129.8, 128.7, 128.0, 127.9, 124.3, 
119.6, 114.0, 103.3, 93.7, 79.8, 77.4, 74.5, 74.4, 73.6, 73.4, 72.7, 71.8, 70.9, 70.2, 69.9, 
67.3, 55.5, 52.7, 51.4, 48.9, 48.2, 45.3, 43.9, 42.9, 41.4, 37.6, 35.0, 34.8, 31.8, 31.0, 29.2, 
29.2, 29.1, 26.4, 24.9, 22.8, 21.5, 20.1, 15.4, 14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 
55.5, 52.7, 51.4, 26.4, 21.5, 20.1, 15.4, 14.3; CH2 δ  93.7, 71.8, 69.9, 48.9, 48.2, 43.9, 
42.9, 41.4, 37.6, 35.0, 34.8, 31.8, 31.0, 29.2, 29.2, 29.1, 24.9, 22.8; CH δ  142.7, 129.8, 





















18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.59. To 
a solution of the ketone 2.58 (7.7 mg, 0.007 mmol, 1 equiv) in MeOH (724 µL, 0.01 M) 
at -40 oC was added NaBH4 (1 mg, 0.029 mmol, 4 equiv). The reaction mixture was 
stirred for 1.5 h and then quenched by the addition of acetone (100 µL). The reaction was 
diluted with CH2Cl2 (5 mL) and then washed with a saturated NH4Cl solution (10 mL). 
The organic phase was dried over Na2SO4 and concentrated under reduced pressure.  
Purification was accomplished using flash chromatography with a 0.5 × 10 cm silica gel 
column, eluting with 50% EtOAc/hexanes, collecting 5 mL fractions.  The fractions 
containing product (25-30) were combined and concentrated under reduced pressure to 
provide the product 2.59 (6.0 mg, 78%) as colorless oil: Rf = 0.12 (5% methanol/20% 
EtOAc/75% hexanes); [α]20D = +19.0 (c = 0.510, CHCl3); 500 MHz 1H NMR (CDCl3) δ 
7.39-7.28 (m, 5H), 7.22 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.21 (d, J = 15.6 
Hz, 1H), 5.95 (d, J = 1.9 Hz, 1H), 5.57 (ddd, J = 11.7, 4.4, 2.4 Hz, 1H), 5.32 (dd, J = 
15.6, 8.8 Hz, 1H), 5.18 (s, 1H), 4.89-4.78 (m, 1H), 4.83 (ABq, J = 6.8 Hz, Δν = 11.2 Hz, 
2H), 4.65 (ABq, J = 11.7 Hz, Δν = 18.6 Hz, 2H), 4.48 (ABq, J = 10.7, Δν = 13.7 Hz 2H), 
4.20-4.13 (m, 1H), 4.00-3.83 (m, 4H), 3.78-3.75 (m, 1H), 3.76 (s, 3H), 3.73-3.71 (m, 
1H), 3.71-3.65 (m, 2H), 3.69 (s, 3H), 3.52-3.44 (m, 3H), 3.18 (m, 1H), 3.06 (s, 3H), 2.55-
2.44 (m, 2H), 2.38-2.21 (m, 2H), 2.15-1.96 (m, 5H), 2.03 (s, 3H), 1.96-1.79 (m, 7H), 
1.76-1.67 (m, 3H), 1.67-1.50 (m, 7H), 1.33-1.19 (m, 12H), 1.08 (m, 6H), 0.88 (t, J = 6.8 
Hz, 3H); 13C NMR (CDCl3) δ 172.3, 172.2, 170.7, 166.9, 159.4, 151.5, 141.8, 138.0, 
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130.7, 129.7, 128.0, 127.9, 125.2, 119.5, 113.9, 103.3, 93.7, 78.9, 74.7, 73.6, 73.5, 73.4, 
73.2, 71.9, 70.8, 70.3, 69.8, 68.3, 67.2, 55.5, 52.7, 51.4, 45.1, 43.6, 42.9, 42.3, 41.5, 41.2, 
37.6, 37.5, 34.8, 34.7, 31.8, 31.0,  29.9, 29.2, 29.0, 26.5, 24.9, 22.8, 21.5, 20.1, 15.3, 
14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 52.7, 51.3, 26.5, 21.5, 20.1, 15.3, 14.3; 
CH2 δ 93.7, 71.9, 69.8, 43.6, 42.9, 42.3, 41.5, 41.2, 37.6, 37.5, 34.8, 34.7, 31.8, 31.0, 
29.2, 29.1, 24.9, 22.8; CH δ  141.8, 129.7, 128.6, 128.0, 127.9, 125.2, 119.5, 113.9, 78.9, 
74.7, 73.6, 73.5, 73.4, 73.2, 70.8, 70.3, 68.3, 67.2; IR (neat): 3530, 2325, 2239, 1740, 
1644, 1523, 1486, 1175, 1039, 886, 712 cm-1; HRMS (ESI/TOF) calcd for C60H84O16Na 





18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.60. To 
a solution of the alcohol 2.59 (8 mg, 0.007 mmol, 1 equiv) in CH2Cl2 (750 µL, 0.01 M) 
was added pyridine (30 µL, 0.375 mmol, 50 equiv) followed by DMAP (9 mg, 0.075 
mmol, 10 equiv) at rt. To this solution was added octanoic anhydride (28.5 µL, 0.225 
mmol, 30 equiv) via syringe. The reaction mixture was stirred for 2 h and then quenched 


















the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic phase 
was dried over Na2SO4, and concentrated under reduced pressure.  Purification was 
accomplished using flash chromatography with a 0.5 × 10 cm silica gel column, eluting 
with 30% EtOAc/hexanes, collecting 5 mL fractions.  The fractions containing product 
(5-9) were combined and concentrated under reduced pressure to provide the product 
2.60 (7.7 mg, 92%) as colorless oil: Rf = 0.50 (50% EtOAc/hexanes); [α]20D = +29.0 (c = 
1.20, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.40-7.28 (m, 5H), 7.24 (d, J = 8.5 Hz, 2H), 
6.85 (d, J = 8.8 Hz, 2H), 6.22 (d, J = 15.6 Hz, 1H), 5.93 (d, J = 1.6 Hz, 1H), 5.56 (ddd, J 
= 11.9, 6.1, 2.4 Hz, 1H), 5.29 (dd, J = 15.6, 8.5 Hz, 1H), 5.18 (s, 1H), 5.03 (ddd, J = 15.9, 
11.0, 4.6 Hz, 1H), 4.86-4.77 (m, 1H), 4.83 (ABq, J = 7.1 Hz, Δν = 12.5 Hz, 2H), 4.65 
(ABq, J = 11.9 Hz, Δν = 16.1 Hz, 2H), 4.48 (s, 2H), 4.21-4.15 (ddd, J = 13.2, 6.6, 3.7 Hz, 
1H), 4.13 (m, 2 H), 4.03 (m, 1H), 3.95 (m, 1H), 3.75 (s, 3H), 3.72-3.65 (m, 2H), 3.61-
3.53 (m, 1H), 3.69 (s, 3H), 3.60-3.53 (m, 1H), 3.52-3.44 (m, 4H), 3.16 (m, 1H), 3.06 (s, 
3H), 2.55-2.44 (m, 2H), 2.34-2.23 (m, 2H), 2.15-1.96 (m, 5H), 2.03 (s, 3H), 1.96-1.79 
(m, 7H), 1.76-1.67 (m, 3H), 1.67-1.50 (m, 7H), 1.33-1.19 (m, 12H), 1.08 (m, 6H), 0.88 (t, 
J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 174.0, 172.2, 172.2, 170.6, 166.9, 159.4, 
151.5, 142.3, 138.1, 130.8, 129.7, 128.6, 128.0, 127.8, 124.9, 119.4, 113.9, 103.3, 93.8, 
78.7, 75.1, 73.7, 73.5, 73.3, 73.3, 73.2, 71.9, 70.8, 70.4, 70.3, 69.8, 67.3, 66.0, 60.6, 55.5, 
52.8, 51.3, 45.1, 43.7, 43.0, 41.2, 38.5, 37.6, 37.5, 34.8, 34.7, 31.8, 31.0, 29.9, 29.2, 29.0, 
28.1, 26.4, 24.8, 22.7, 21.4, 21.2, 20.1, 15.5, 15.2, 14.4, 14.2, 9.4; 125 MHz DEPT NMR 
(CDCl3) CH3 δ 55.2, 52.5, 51.1, 26.1, 21.2, 19.8, 15.2, 14.2, 14.0; CH2 δ 93.6, 71.7, 69.6, 
65.8, 60.3, 43.4, 42.8, 40.9, 38.3, 37.4, 37.3, 34.6, 34.5, 31.6, 30.8, 29.7, 28.9, 28.8, 27.8, 
24.6, 22.5; CH δ  142.0, 129.5, 128.4, 127.8, 127.6, 124.6, 119.2, 113.7, 78.5, 74.9, 73.4, 
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73.3, 73.1, 73.0, 72.9, 70.5, 70.1, 70.0, 67.0; IR (neat): 3430, 2225, 2139, 1746, 1654, 
1519, 1485, 1175, 1001, 909, 886, 712 cm-1; HRMS (ESI/TOF) calcd for C62H88O18Na 





tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.9 (Merle 34). To a 
solution of the alcohol 2.60 (3.5 mg, 0.003 mmol, 1 equiv) in CH2Cl2 (624 µL, 0.005 M) 
was added tBuOH (6 µL) followed by pH 7 buffer (62 µL) at 0 oC. To this solution was 
added DDQ (3 mg, 0.012 mmol, 4 equiv). The reaction mixture was stirred for 1.5 h and 
then quenched by the addition of saturated aqueous NaHCO3 solution (1 mL). The phases 
were separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phase was dried over Na2SO4 and concentrated under reduced 
pressure.  The crude product was passed through a plug of 0.25 × 8 cm silica gel column, 
eluting with 30% EtOAc/hexanes, collecting 1 mL fractions.  The fractions containing 
product (5-9) were combined and concentrated under reduced pressure and directly taken 


















To the crude product from the previous step (assumed to be 0.003 mmol) in a 5 
mL vial was added LiBF4 (540 µL, 0.25 M in 25:1 CH3CN/H2O, 0.135 mmol, 45 equiv) 
and heated to 80 oC for 10 h, after which the reaction mixture was cooled to rt. The 
solvent was evaporated under N2 and then directly loaded to a 0.25 × 6 cm silica gel 
column. Purification was done by eluting with 5% MeOH/30% EtOAc/65% hexanes and 
collecting in 1 mL fractions. The fractions containing product (20-23) were combined 
and evaporated under reduced pressure to provide Merle 34 2.9 (1.7 mg, 65% over 2 
steps) as white foam: Rf = 0.1 (50% EtOAc/hexanes); [α]20D = +25.6 (c = 0.100, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 5.98 (d, J = 1.7 Hz, 1H), 5.80 (d, J = 15.8 Hz, 1H), 5.29 
(dd, J = 15.8, 8.4 1H), 5.24-5.18 (m, 1H), 5.19 (s, 1H), 5.14 (s, 1H), 4.98 (ddd, J = 15.9, 
11, 4.8 Hz, 1H), 4.84 (m, 1H), 4.39 (d, J = 12.1 Hz, 1H), 4.21 (m, 2H), 4.05 (m, 1H), 
3.89-3.79 (m, 2H), 3.72-3.58 (m, 2H), 3.69 (s, 3H), 3.65-3.56 (m, 2H), 3.52 (m, 2H), 3.36 
(m, 1H), 3.26 (m, 1H), 2.53 (dd, J = 12.3, 2.2 Hz, 1H), 2.48-2.40 (m, 1H), 2.35-2.24 (m, 
2H), 2.11-1.98 (m, 4H), 2.04 (s, 3H), 1.96-1.78 (m, 8H), 1.68-1.48 (m, 4H), 1.36-1.18 
(m, 10H), 1.13 (m, 3H), 0.99 (s, 3H), 0.89 (m, 6H); 125 MHz 13C NMR (CDCl3) δ 173.9, 
172.3, 172.1, 170.6, 167.2, 152.0, 139.5, 136.0, 129.1, 125.7, 119.9, 99.1, 74.9, 74.4, 
73.9, 73.6, 70.4, 69.7, 69.6, 68.7, 64.8, 51.2, 45.0, 42.9, 42.7, 40.0, 38.9, 38.2, 37.4, 36.1, 
34.9, 34.5, 32.5, 31.9, 31.5, 30.6, 29.9, 29.5, 29.3, 29.0, 28.0, 27.5, 26.6, 24.9, 23.6, 22.8, 
21.4, 20.0, 19.9, 14.3; 125 MHz, 13C DEPT (CDCl3) CH3: δ 50.9, 30.3, 24.7, 21.1, 19.8, 
19.7, 14.0; CH2: δ 42.7, 42.5, 39.7, 38.7, 37.9, 37.2, 35.8, 34.6, 31.6, 31.2, 29.7, 28.9, 
28.8, 27.8, 24.7, 22.5; CH δ 139.2, 128.9, 125.4, 119.6, 77.2, 77.1, 76.6, 74.7, 74.1, 73.6, 
73.4, 70.2, 69.5, 69.3, 68.5, 64.5; IR (neat): 3395, 2924, 2852, 1746, 1655, 1426, 1275, 
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1110, 827, 660 cm-1; HRMS (ESI/TOF) calcd for  C45H70O16Na (M + Na+) 889.4556. 





tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 2.10 (Merle 38). To 
a solution of the alcohol 2.59 (3.1 mg, 0.003 mmol, 1 equiv) in CH2Cl2 (582 µL, 0.005 
M) was added tBuOH (5.8 µL) followed by pH 7 buffer (58 µL) at 0 oC. To this solution 
was added DDQ (2.6 mg, 0.012 mmol, 4 equiv). The reaction mixture was stirred for 1.5 
h and then quenched by the addition of saturated aqueous NaHCO3 solution (1 mL). The 
phases separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phase was dried over Na2SO4 and concentrated under reduced 
pressure.  The crude product was passed through a plug of 0.25 × 8 cm silica gel column, 
eluting with 50% EtOAc/hexanes, collecting 1 mL fractions.  The fractions containing 
product (15-19) were combined and concentrated under reduced pressure and directly 
taken for the next step.  
To the crude product from the previous step (assumed to be 0.003 mmol) in a 5 
















and heated to 80 oC for 10 h, after which the reaction mixture was cooled to rt. The 
solvent was evaporated under N2 and then directly loaded to a 0.25 × 6 cm silica gel 
column. Purification was done by eluting with 5% MeOH/15% EtOAc/80% hexanes and 
collecting in 1 mL fractions. The fractions containing product (24-40) were combined 
and evaporated under reduced pressure to provide Merle 38 2.10 (1.2 mg, 70% over 2 
steps) as white foam: Rf = 0.46 (10% MeOH/30% EtOAc/60% hexanes); [α]20D = +18.2 
(c = 0.120, CHCl3); 500 MHz 1H NMR (CDCl3) δ 5.98 (d, J = 1.7 Hz, 1H), 5.78 (d, J = 
15.8 Hz, 1H), 5.30 (dd, J = 15.8, 8.4 1H), 5.24-5.18 (m, 1H), 5.22 (s, 1H), 5.14 (s, 1H), 
4.84 (ddd, J = 15.9, 11, 4.8 Hz, 1H), 4.42 (d, J = 12.1 Hz, 1H), 4.21 (m, 2H), 4.05 (m, 
3H), 3.93-3.78 (m, 3H), 3.73-3.66 (m, 1H), 3.69 (s, 3H), 3.65-3.56 (m, 2H), 3.51 (m, 2H), 
2.53 (dd, J = 12.3, 2.2 Hz, 1H), 2.49-2.40 (m, 1H), 2.31 (ddd, J = 11.4, 7.7, 4.0 Hz, 2H), 
2.11-1.98 (m, 4H), 2.04 (s, 3H), 1.96-1.78 (m, 8H), 1.68-1.48 (m, 4H), 1.36-1.18 (m, 
10H), 1.13 (s, 3H), 1.00 (s, 3H), 0.88 (m, 6H); 125 MHz 13C NMR (CDCl3) δ 172.4, 
170.7, 167.2, 152.0, 139.1, 129.4, 119.9, 99.1, 75.2, 74.3, 74.0, 73.6, 70.5, 69.6, 68.7, 
67.6, 64.7, 51.3, 45.0, 42.9, 42.8, 42.6, 42.2, 39.9, 37.4, 36.0, 34.9, 31.9, 31.5, 29.9, 29.2, 
29.1, 24.9, 24.9, 22.8, 21.4, 20.0, 19.9, 14.3; 125 MHz, 13C DEPT (CDCl3) CH3: δ 51.0, 
24.7, 21.2, 19.8, 19.7, 14.0; CH2: δ 42.7, 42.6, 42.4, 41.9, 39.8, 37.2, 37.1, 35.8, 34.6, 
31.6, 31.2, 29.7, 29.0, 28.9, 24.7, 22.5; CH δ 138.9, 129.2, 119.7, 77.3, 77.2, 76.7, 74.9, 
74.1, 73.8, 73.4, 70.3, 69.4, 68.5, 67.4, 64.5; IR (neat): 3455, 2924, 2852, 1736, 1655, 
1426, 1245, 1110, 827 cm-1; HRMS (ESI/TOF) calcd for  C42H66O15Na (M + Na+) 
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  CHAPTER 3 
 




The bryostatins are an important class of antitumor natural products that bind to 
the C1 domain of PKC isozymes with very high binding affinity.1 Bryostatin 1 is the 
most thoroughly studied member of this family and has been subjected to numerous 
phase I and II clinical trials for cancer chemotherapy.2 Additionally, it has been shown to 
reverse multidrug resistance in cancer cells, synergize with other anticancer agents like 
Taxol®, stimulate the immune system, improve learning and memory in animal models, 
and reduce the formation of β-amyloid plaques. It is also going through a clinical trial for 
Alzheimer’s disease. Recently, it has also been shown to activate latent HIV in 
lymphocytes.3  
The unique biological profile of bryostatin 1 has been attributed to the fact that 
bryostatin 1 binds to PKC with exceptionally high affinity.3e Our group has endeavored 
to find out the exact structural features of bryostatin 1 for its unique biological profile via 
rational design of synthetic analogues. With the syntheses of Merle 23, 27, 28, 30, 32, 33, 
34, and 38, we developed considerable insight on the structural features of bryostatin 
behind its responses towards various biological endpoints.4 The biological results with
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Merle 23 refuted the concept that the northern hemisphere of bryostatin 1 is a mere 
spacer domain and holds together the key pharmacophoric elements C1 carbonyl oxygen, 
C19 hydroxy oxygen, and C26 hydroxy oxygen. Merle 23 lacked all the functional 
groups at the northern hemisphere of bryostatin 1 and Merle 28 reintroduced all the 
functional groups except the C30 carbomethoxy group. Merle 28 showed close 
resemblance to bryostatin while Merle 23 was similar to PMA in proliferation and 
attachment assays with U937 cells. With the biological evaluation of Merle 27, 30, and 
32, we came to the conclusion that C7 acetate, C9 hydroxy; C8 gem-dimethyl groups are 
not solely responsible towards bryostatin’s biology. However, it became clear that 
combinations of these groups are necessary for the unique biology. 
To explore the idea we proposed that incorporation of two polar functional groups 
in the bryopyran, making it similar in hydrophilicity to that of bryostatin 1, should be 
capable of retaining bryostatin biology. This polarity-based hypothesis has been 
explained in Chapter 2 and will not be further discussed here. However, the conclusion of 
the biological studies with Merle 34 and 38 has shed some light on the crucial fact that 
the C13-C30 olefinic functionality with the carbomethoxy group appears to have some 
role when in combination with the C7 acetate. The specific role is not clear but the 
relatively lower binding affinities with PKC for Merle 27 (Ki = 3.00 ± 0.6 nM) compared 
to Merle 30 (Ki = 0.38 nM) and 33 (Ki = 0.68 nM) was the first indication in that 
direction. This specific effect is likely to get overshadowed by the presence of other 
functional groups such as in Merle 28 (Ki = 0.52 ± 0.06 nM). The presence of an ester 
moiety or a free hydroxy group at C13 dramatically lowered the binding affinity from 
that of Merle 33 to those of Merle 34 (Ki = 16.3 nM) and 38 (Ki = 13.21 nM). This 
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forced us to further investigate the role of the C13-C30 olefin with the carbomethoxy 
group. In line with this strategy, we proposed the synthesis of an analogue, which will 
delete both the C7 and C9 hydroxy groups and retain only the C13-C30 carbomethoxy 
enoate functionality. This will enable us to directly compare this analogue (Merle 40) 
with Merle 30 and 32 and will lead to a better understanding of the individual role of this 
functionality. 
 
1st-generation retrosynthetic analysis of Merle 40 
  With the synthesis of Merle 30 and 32, we developed a route where we could 
selectively hydrolyze the C7 acetate in the presence of the macrolactone ester linkage at 
C1. We realized that the intermediate 3.2 (Figure 3.1) in the synthetic route to Merle 32 
could also be used for the synthesis of Merle 40. Barton-McCombie deoxygenation could  
 
 





































































be utilized to delete the C7 hydroxyl of 3.2.5 Merle 32 can be obtained from the known 
precursor intermediate 3.3. The advanced intermediate 3.3 was synthesized earlier from 
the A-ring aldehyde 3.4 and the β-hydroxyallyl silane 3.5. However, before pursuing this 
route any further, we wanted to study the methods to delete the C7 oxygenated 
functionality in model substrates. The methods developed from this strategy could then 
be utilized on the alcohol 3.2 to delete the C7 hydroxyl. 
 
Model studies for the Barton-McCombie deoxygenation 
 The A-ring alcohol 3.6, an intermediate en route Merle 32, was protected as the 
TBS ether to give 3.7. Attempts were then made to hydrolyze the C7 acetate in the 
presence of the thioester to provide the free alcohol (Figure 3.2). Various attempts failed 
to hydrolyze the acetate selectively without affecting the thioester. Eventually, we settled  
 
 





















































with a compromise in that the transesterification of the thioester occurred along with 
hydrolysis of the C7 acetate. K2CO3/MeOH conditions targeted both the acetate and the 
thioester and TLC analysis showed the formation of two new spots. The reaction was 
continued until the spots merged to a single spot after 2-3 h. The free hydroxy at C7 was 
then converted to the thionoester 3.9. With the thionoester 3.9 in hand, we attempted the 
Barton-McCombie deoxygenation and to our delight, we observed the deoxygenation 
went smoothly to give the C7 deoxy compound 3.10.   
 However, at this point of time, a 2nd-generation synthetic route for the total 
synthesis of bryostatin 1 was being explored where a more convergent coupling with a 
fully functionalized C-ring aldehyde and an A-ring β-hydroxyallyl silane was utilized. 
With the successful application of this 2nd-generation route, we decided to utilize a 
similar route with the fully functionalized C-ring aldehyde and thus avoid various side 
reactions that occurred with the late-stage functionalization of C-ring. 
 
2nd-generation retrosynthesis of Merle 40 
The 2nd-generation retrosynthetic analysis of Merle 40 followed the same strategy 
as for bryostatin 1, Merle 34, and 38 (Figure 3.3). A disconnection at the C1 ester bond 
keeping late-stage Yamaguchi macrolactonization in mind and the second disconnection 
at the B-ring pyran ring across C15 carbon led to the two equally complex synthetic 
intermediates β-hydroxyallyl silane 3.12 and the C-ring aldehyde 3.11. The aldehyde 3.11 
could arise from some protecting group manipulation of a previously known aldehyde 
with PMB ether at C25. The β-hydroxyallyl silane 3.12 was envisaged to form via Corey-




































































































3.14 could arise from the ethyl ester 3.15 via a DIBAL-H half reduction. The ester 3.15 
was envisioned to arise from an addition of ethyl acetate onto the lactone 3.16 followed 
by reduction of the hemiketal at C9 of the adduct. The lactone 3.16 could arise from a 
ring-closing metathesis of the ester 3.17 followed by hydrogenation of the resulting 
alkene. Although there are very few examples of a ring-closing metathesis next to a gem-
dimethyl group, we anticipated that free energy of the formation of six-membered ring 
from the tethered alkenes would drive the reaction.7 The ester 3.17 could then arise from 
esterification of the alcohol 3.19 with the known 3,3-dimethyl-2-butenoic acid 3.18. The 
known carboxylic acid 3.18 could be obtained from tiglic acid via a known procedure.8 
The alcohol 3.19 was disconnected at the C5 stereocenter, which could arise from a 
chelation-controlled stereoselective vinylation of the previously synthesized aldehyde 
3.20. 
 
Synthesis of Merle 40 
Synthesis of the β-hydroxyallyl silane 3.12 
 The synthesis of the A-ring β-hydroxyallyl silane 3.12 began with the 
monoprotection of 1,3-propanediol 3.21 followed by Swern oxidation to provide the 
aldehyde 3.23. Using catalytic asymmetric allylation (CAA) developed in our group with 
(R)-BITIP catalyst, we were able to convert the aldehyde to the homoallylic alcohol 3.24. 
Protection of the alcohol as the PMB ether followed by ozonolysis of the terminal alkene 
provided the aldehyde 3.20. With the aldehyde 3.20 in hand, we attempted various Lewis 
acid-mediated 1,3 chelation-controlled addition of a vinyl Grignard reagent. Strong Lewis 
acids such as SnCl4, TiCl4 mostly decomposed the aldehyde with only traces of the 
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desired product formed. Mild Lewis acids such as triflates of the lanthanide metals (Sm, 
Ln), on the other hand, did not provide any selectivity possibly due to a lack of strong co-
ordination with the aldehyde. When we switched our Lewis acid to dimethyl aluminum 
chloride, we found it to realize diastereoselectivity (2:1), albeit low. At this point, we 
realized that commercially available vinyl magnesium bromide is in a co-ordinating 
solvent THF, which could potentially disrupt the chelation required for higher 
diastereoselectivity. Dr. Merritt Andrus from our group previously observed that removal 
of THF in vacuo and replacing the solvent with CH2Cl2 provided a 50-100-fold increase 
in diastereoselectivity in such reactions.9 In our case, as the Lewis acid dimethyl 
aluminum chloride is in toluene, we decided to replace THF with toluene. To our delight, 
we observed an increase in diastereoselectivity to 10:1 under these conditions. However, 
attempts at further optimization with these conditions did not yield any increase in 
diastereoselectivity. We then focused on proving the stereochemistry of the C5 hydroxy. 
Under the chelation control, we anticipated 10:1 diastereoselectivity favoring the desired 
1,3-anti relative configuration between C3 and C5. Protection of the free alcohol 3.26 as 
the acetate, removal of the PMB group, followed by revealing the C5 hydroxy group 
provided the diol, which was then converted to the acetonide 3.27. To our utter surprise, 
NMR analysis of the acetonide using Rychnovsky’s method revealed that the major 
diastereomer was of the 1,3-syn relative configurations between C3 and C5.10 The minor 
diastereomer was the desired product and NMR analysis again supported that (Figure 
3.4). The mechanism of this outcome is not understood at this point as a second chelation 
with sterically hindered BPS ether seemed too far-fetched to explain the stereochemistry. 
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outcome did not jeopardize our synthetic route as we decided to utilize Mitsunobu 
esterification with the carboxylic acid 3.18 to switch the C5 stereocenter to the desired 
1,3-anti relative configuration with C3.11 The 3,3-dimethyl-2-butenoic acid 3.18 was 
prepared in one step from commercially available tiglic acid in moderate yield via 
enolization of one of the protons on β-methyl group followed by capturing the enolate 
with an electrophilic methyl source (Me2SO4) at the α position. With 3.17 in hand, we 
wished to ensure that the stereocenter at C5 had indeed switched to the desired one. 
Following similar steps as before, we converted 3.17 to the acetonide 3.28 and NMR 
analysis proved the stereocenter had indeed switched to the desired one.    
 With the ester 3.17 in hand, we then attempted ring-closing metathesis reaction 
with Grubbs’ 1st- and 2nd-generation catalysts. However, we did not detect any product 
formation even using a stoichiometric amount of catalyst under reflux conditions at 110 
oC. We considered that the strong co-ordination of the catalyst with multiple oxygenated 
functionalities on the substrate could be the reason behind the complete inactivity of the 
catalysts. Literature precedence for the use of Ti(OiPr)4 under similar circumstances 
prompted us to reflux the substrate in CH2Cl2 in the presence of 5 equivalent of Ti(OiPr)4 
and then add the Grubbs’ 2nd-generation catalyst 3.30.12 To our delight, the reaction went 
to completion cleanly after refluxing overnight at 45 oC (Figure 3.5). With the ring-closed 
alkene 3.31 in hand, we then attempted to hydrogenate the alkene without affecting the 
PMB ether. Various hydrogenating agents such as Pd/H2 in charcoal, Pd(OAc)2/H2, tosyl 
hydrazine, and Ru(PPh3)2Cl2/H2 resulted in complex mixture of products including 
hydrogenation of C6-C7 bond and cleavage of PMB ether at C3. Finally, Adams’ catalyst 













































































PtO2•H2O, H2, 0 °C
(74%)
1. EtOAc, LDA, THF;
    3.16 
2. Et3SiH, TMSOTf





































product 3.16. It proved necessary to monitor the reaction closely and remove the 
hydrogen atmosphere after about 1 h to prevent the cleavage of the PMB ether linkage. 
The next step was to add an enolate nucleophile onto the ester carbonyl at C9 to form the 
hemiketal. However, this apparently straightforward reaction proved challenging as the 
enolate of ethyl acetate could not be added onto the ester 3.16 under various conditions. 
We anticipated that the presence of any trace amount of Ru complex carried over from 
the previous metathesis reaction might be deleterious for the enolate to survive under the 
reaction condition. Therefore, our focus shifted towards getting rid of any trace amount 
of Ru from the substrate. Stirring the reaction mixture with charcoal overnight got rid of 
most of the Ru complexes. Although column chromatography on the crude reaction 
mixture was able to purify the product, it still retained a faint brownish color of Ru 
complexes. NMR analysis could not detect this trace amount of Ru complex. Fortunately, 
under oxidative work-up condition when a CH2Cl2 solution of the product was treated 
with H2O2, the brownish color disappeared after effervescence, indicating complete 
destruction of Ru complexes to Ru oxides.13 After complete removal of any trace amount 
of Ru, the lactone 3.16 was reacted with the enolate of ethyl acetate and the reaction went 
smoothly to give the intermediate hemiketal. This hemiketal was subsequently subjected 
to reductive etherification condition with Et3SiH and TMSOTf to produce the A-ring 
substituted pyran 3.15. The reaction can be expected to proceed through a half-chair 
reactive intermediate 3.32 where the hydride source approaches the oxocarbenium ion 
from the bottom face to achieve relatively stable chair-like transition state and avoid a 
high energy twist boat type transition state in case of top face attack. The stereochemistry 
of C9 was proven by nOe experiments in NMR analysis. Interestingly, during nOe 
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experiments, we observed that the C9 hydrogen correlated with the protons of one of the 
C8 gem-dimethyl groups that were upfield. One would expect a nOe enhancement of the 
signal for the C8 equatorial methyl protons, which are usually downfield. A gradient 
homonuclear correlation spectroscopy (gCOSY) NMR experiment and a gradient 
heteronuclear multiple quantum coherence (gHMQC) NMR experiment revealed that the 
upfield protons were indeed those of the C8 equatorial methyl group. The original 
assignment of these protons by George Pettit was erroneous and later revised by 
Schaufelberger.14  
 DIBAL-H reduction of the ethyl ester 3.15 provided the half-reduction product 
aldehyde 3.14. With this aldehyde in hand, we attempted Williams modified Corey 
allylation using the 2-substituted allyl silane 3.13. In 1989, Corey reported an asymmetric 
allylation with tosylated (S,S)-1,2-diamino-1,2-diphenylethane (also known as 
stilbenediamine, stien) as the ligand, BBr3 as the Lewis acid, and allyl stannane as the 
transmetalating agent.6c, 6d Williams modified this procedure with 2-substituted allyl 
stannane reagents.6a, 6b, 6e The ligand had to be moisture free as traces of water often 
decomposed the boron-ligand adduct. It was also necessary to remove all the residual 
volatile brominated compounds for a successful reaction. The presence of 2,6-di-tert-4-
methyl pyridine was used to sequester any acidic protons from hydrogen bromide formed 
as the by-product. The active allyl borane reagent 3.13 was generated via transmetalation 
by the allyl stannane reagent 3.34, which successfully converted the aldehyde 3.14 to the 
β-hydroxy allyl silane 3.12. The stereo induction of the C11 of 3.12 can be explained by 
considering a favored transition state like 3.36 where the Si face of the aldehyde is 
attacked by the allyl borane reagent. The tosyl groups on the nitrogen atoms of the ligand 
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are oriented so as to decrease the steric repulsion with the phenyl groups. The absence of 
the steric hindrance between the aldehyde carbonyl proton and one of the tosyl group 
makes 3.36 favored over the other transition state 3.35 for Re face attack. The 
stereochemistry of the C11 alcohol was proved by Mosher ester analysis of the alcohol 
3.12.15 Both (R) and (S) Mosher esters were prepared and compared for the ΔδS-R.  The 
most stable conformations are indicated as 3.37 and 3.38 for (R) and (S) MTPA, 
respectively. For (R)-MTPA ester, the portion colored in green (Figure 3.6), denoted as 
R2, gets shielded by the phenyl group whereas for (S)-MTPA ester, the orange colored 
portion of the molecule R1 gets shielded by the phenyl group. Therefore, the ΔδS-R 
 
 




































































is positive for R2, whereas it is negative for R1. R1 and R2 were then placed according to 
the prescribed suggestion of Mosher. The analysis (Figure 3.6) indicated the absolute 
stereochemistry of C11 to be (S) as expected. 
 
Completion of the synthesis of Merle 40 
 With the β-hydroxyallyl silane 3.12 in hand, we then attempted to couple with the 
fully functionalized C-ring 3.11 using the key reaction of pyran annulation. The standard 
conditions of pyran annulation, however, could not achieve the annulation and only trace 
amount of the desired product 3.40 was isolated (Figure 3.7). The major side products 
were the protodesilylation of the β-hydroxyallyl silane 3.12, TMS protection of the free 
alcohol at C11, and elimination of the methoxy ketal at C19. The lack of reactivity of the 
aldehyde 3.11 towards the silane 3.12 was unexpected considering its success in the total 
syntheses of bryostatin 1 and 7 and hence is not fully understood. However, isolation of 
TMS protected silane prompted us to introduce a free hydroxyl group in the substrates. In 
the total syntheses of Merle 33, 34, and 38, it had been observed that free hydroxy  
 
 






































groups on the substrates are well tolerated in this reaction. Therefore, we decided to use a 
synthetic equivalent of the C-ring aldehyde 3.11 with a free hydroxyl at C25 (Figure 
3.8).16 Deprotection of the C25 TBS group of 3.11 gave the aldehyde 3.41. To our 
delight, the pyran annulation of 3.41 with 3.12 went smoothly in about 2 h to provide 
3.42. Protection of the C25 free alcohol provided the compound 3.40. Next, removal of 
the BPS group followed by Parikh-Doering oxidation and Lindgren oxidation provided 
the carboxylic acid at C1.17 Removal of the TBS ether of C25 gave the seco-acid, which 
was then subjected to Yamaguchi macrolactonization to provide the macrolactone 3.44.18 
Using a saturated solution of ozone at -78 oC, we were able to selectively cleave the 
olefin at C13-C30. All that is left is to convert the ketone to the carbomethoxy enoate 
3.45 using Fuji’s chiral phosphonate 3.4719 followed by removal of the PMB ether at C3 
and global deprotection to provide the analogue Merle 40 (Figure 3.9). 
 
Conclusion 
 Development of a synthetic strategy towards the analogue Merle 40 was 
accomplished. This synthetic route also demonstrated the scope of pyran annulation 
under different circumstances. Along with the total syntheses of Merle 33, 34, and 38, 
this synthetic route established the fact that pyran annulation can in certain circumstances 
go smoothly in presence of free hydroxyl groups. A new stereochemical outcome was 
observed during a chelation-controlled addition with vinyl Grignard reagent. A sterically 
demanding metathesis reaction was achieved in presence of various other co-ordinating 
groups. Additionally, Williams modified Corey allylation elegantly installed the C11 

























































































Et2O, -78 °C, 2 h
(75%)
O
1. TBAF, AcOH, DMF, 2 d
2. iPr2EtN, SO3•Py, DMSO, 
    CH2Cl2, -10 °C
    [78% (2 steps)]
1. KH2PO4, NaClO2,
    tBuOH, isoamylene, 
    H2O
2. HF•Py, MeOH, THF/Py
3. 2,4,6-TCBC, Et3N, 
    THF/tol; DMAP, 






















Figure 3.9. Completion of the synthesis of Merle 40 
 
11 steps would accomplish the synthesis of Merle 40 taking the longest linear steps to 
just 33.  
 The biological studies with Merle 40 should reveal the role of the C13-C30 
carbomethoxy enoate group compared to merle 30, 32. Additionally, these studies should 
also provide further insights into our current understanding of the interaction of the 



























































General experimental procedures, materials, and instrumentation  
Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals.20 Diisopropylamine, triethylamine, pyridine, Hünig’s base, 
EtOAc, and CH2Cl2 were distilled from CaH2 under an atmosphere of dry N2. THF, Et2O, 
and toluene were distilled from Na under an atmosphere of dry N2. Ti(OiPr)4 and TiCl4 
were distilled prior to use. A stock solution of Ti(OiPr)4 (1.0 M in CH2Cl2) was prepared 
and used for the BITIP catalyst preparations. The titer of n-butyllithium was determined 
by the method of Eastham and Watson.21 All other reagents were used without further 
purification. Yields were calculated for material judged homogeneous by thin layer 
chromatography and nuclear magnetic resonance (NMR) spectroscopy. Thin layer 
chromatography was performed on Merck Kieselgel 60 F254 plates eluting with the 
solvent indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic 
solution of 12-molybdophosphoric acid. Glassware for reactions was oven dried at 125 
oC and cooled under a dry atmosphere prior to use. Liquid reagents and solvents were 
introduced by oven-dried syringes through septum-sealed flasks under a nitrogen 
atmosphere. Column flash chromatography was performed with Silicycle Grade 70 – 230 
mesh, 60 – 200 µm, 60 Å silica gel, slurry packed with 1% EtOAc/hexanes in glass 
columns. Preparative thin layer chromatography was performed on Analtech Inc. Silica 
Gel GF 20 cm × 20 cm × 2000 µm plates or on Merck Kieselgel 60 F254 20 cm × 20 cm × 
250 µm plates. Nuclear magnetic resonance spectra were acquired on Varian VXR-500, 
Varian Inova-500 spectrometer 500 MHz for 1H and 125 MHz for 13C. Prior to use, 
CDCl3 was filtered through a plug of Fischer Scientific 80 – 200 mesh Alumina 
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Adsorption stored at 110 oC. Chemical shifts for proton nuclear magnetic resonance (1H 
NMR) spectra are reported in parts per million relative to the signal of trimethylsilane at 
0 ppm, relative to the signal of residual CHCl3 at 7.27 ppm, or relative to the signal of 
residual C6D5H at 7.16 ppm. Chemical shifts for carbon nuclear magnetic resonance (13C 
and DEPT) spectra are reported in parts per million relative to the signal of 
trimethylsilane at 0 ppm, relative to the center line of the CDCl3 triplet at 77.23 ppm, or 
relative to the center line of the C6D6 triplet at 128.62 ppm. Chemical shifts of the 
unprotonated carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C 
NMR spectrum. The abbreviations s, bs, d, dd, ddd, dddd, t, td, tt, q, dq, dqd, ddq, ABq, 
quin, and m stand for the resonance multiplicity singlet, broad singlet, doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, triplet, 
triplet of doublets, triplet of triplets, quartet, doublet of quartets, doublet of quartet of 
doublets, doublet of doublet of quartets, AB quartet, quintet, and multiplet, respectively. 
IR spectra were obtained from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer. 
Melting points were obtained using a Mel-Temp electrochemical melting point apparatus 
and are uncorrected. Optical rotations were obtained on a Perkin Elmer model 343 
polarimeter (Na D line) using a microcell with 1 dm path length. Specific rotations 
([α]20D, Unit: ocm2/g) are based on the equation α = (100. α)/(l.c) and are reported as 
unitless numbers where the concentration c is in g/100 mL and the path length l is in 
decimeters. Mass spectrometry was performed at the mass spectrometry facility of the 
Department of Chemistry at the University of Utah on a Finnigan MAT 95 double 




Experimental procedures and analytical data 
 
Preparation of methyl (R)-4-((2S,4S,6S)-6-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-4-hydroxy-6-methoxy-5,5-dimethyltetrahydro-2H-
pyran-2-yl)-3-((tert-butyldiphenylsilyl)oxy)butanoate 3.8. To a stirring solution of the 
acetate 3.7 (103.8 mg, 0.134 mmol, 1.00 equiv) in MeOH (2.7 mL, 0.05 M) in a 10 mL 
round-bottom flask under an atmosphere of N2 was added K2CO3 (92.7 mg, 0.671 mmol, 
5.00 equiv) in one portion. The mixture was stirred for 6 h and then quenched by the 
addition of saturated aqueous NH4Cl solution (5 mL). The phases were separated and the 
organic phase was extracted with 30% EtOAc/ hexanes (3 × 15 mL). The organic phases 
were combined, washed once with brine (50 mL), dried over Na2SO4, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
on a 1.5 × 15 cm silica gel column, eluting with 30% EtOAc/ hexanes (250 mL), 
collecting 5 mL fractions. The fractions containing product (13 - 17) were combined and 
concentrated under reduced pressure to give the alcohol 3.8 (72.2 mg, 80%) as colorless 
oil: Rf 0.26  (30% EtOAc/ hexanes); [α]D20 = +25.5 (c = 0.88, CHCl3); 400 MHz 1H NMR 
(CDCl3) δ 7.71 – 7.64 (m, 4H), 7.46 – 7.35 (m, 6H), 4.28 – 4.22 (m, 1H), 3.78 – 3.64 (m, 
2H), 3.59 (s, 3H), 3.60 – 3.54 (m, 1H), 3.20 (ddd, J = 11.5, 7.1, 3.8 Hz, 1H), 2.93 (s, 3H), 
2.67 (dd, J = 14.7, 4.2 Hz, 1H), 2.55 (dd, J = 14.8, 7.8 Hz, 1H), 1.94 – 1.69 (m, 3H), 1.52 
(td, J = 14.0, 3.9 Hz, 1H), 1.26 (m, 1H), 1.18 (m, 1H), 1.02 (s, 9H), 0.93 (s, 3H), 0.89 (s, 










129.9, 129.8, 127.8, 127.7, 104.1, 70.9, 69.9, 66.5, 59.6, 51.5, 48.3, 43.9, 43.5, 42.8, 36.3, 
36.1, 27.0, 26.2, 20.5, 19.5, 18.5, 16.1, -5.00, -5.01; 125 MHz DEPT (CDCl3) d CH3: 
51.5, 48.3, 27.0, 26.2, 20.5, 19.5, -5.00, -5.01, CH2: 59.6, 43.9, 43.5, 36.3, 36.1, CH: 
136.1, 129.9, 129.8, 127.8, 127.7, 70.9, 69.9, 66.5; IR (thin film) 3462, 2987, 2961, 2859, 
1741, 1682, 1473, 1425, 1386, 1335, 1255, 1111, 735 cm–1; HRMS (ESI/TOF) Calcd for 
C37H60O7Si2Na m/z (M + Na+): 695.3770. Found: 695.3793. 
 
Preparation of methyl (R)-4-((2S,4S,6S)-6-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-6-methoxy-5,5-dimethyl-4-((phenoxycarbonothioyl) 
oxy)tetrahydro-2H-pyran-2-yl)-3-((tert-butyldiphenylsilyl)oxy)butanoate 3.9. To a 
stirring solution of alcohol 3.8 (45.1 mg, 0.067 mmol, 1.00 equiv), DMAP (1.60 mg, 
0.013 mmol, 0.20 equiv), pyridine (67 µL) in CH2Cl2 (134 µL, 0.05 M) in a 5 mL 
reaction vial in an atmosphere of N2, at 0 oC, was added phenyl thionocarbonyl chloride 
(46 µL, 0.34 mmol, 5.00 equiv) via syringe. The cold bath was removed and the reaction 
was stirred for 30 h. The reaction was poured into a separatory funnel containing CH2Cl2 
(20 mL) and then the organic phase was washed with H2O (2 × 10 mL), with brine (5 
mL), dried over Na2SO4, filtered, and then concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a silica gel column (1 
× 10 cm), eluting with 5% EtOAc/hexanes (100 mL), collecting 5 mL fractions. The 
fractions containing product (9-14) were combined and concentrated under reduced 











EtOAc/ hexanes); [α]D20 =  +23.9 (c = 0.90, CHCl3); 400 MHz 1H NMR (CDCl3) δ 7.72 – 
7.64 (m, 4H), 7.47 – 7.36 (m, 8H), 7.32 – 7.28 (m, 1H), 7.10 – 7.08 (m, 2H), 5.41 (dd, J 
= 11.7, 5.0 Hz, 1H), 4.23 (m, 1H), 3.71 – 3.56 (m, 2H), 3.60 (s, 3H), 3.21 (m, 1H), 2.96 
(s, 3H), 2.68 (dd, J = 14.8, 4.2 Hz, 1H), 2.57 (dd, J = 14.8, 7.7 Hz, 1H), 1.96 – 1.67 (m, 
4H), 1.53 (td, J = 14.1, 3.6 Hz, 1H), 1.27 – 1.17 (m, 1H), 1.03 (s, 9H), 0.96 (s, 3H), 0.95 
(s, 3H), 0.89 (s, 9H), 0.82 (s, 3H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 194.6, 
172.0, 153.5, 136.1, 136.0, 134.2, 133.8, 130.0, 130.0, 129.7, 127.8, 127.8, 126.7, 122.1, 
104.3, 85.3, 70.9, 69.9, 66.2, 59.4, 51.6, 48.6, 43.8, 43.6, 42.4, 35.9, 31.7, 29.9, 27.1, 
27.0, 26.1, 20.4, 19.4, 18.5, 17.8, -5.11, -5.13; 125 MHz DEPT (CDCl3) d CH3: 51.6, 
48.6, 27.0, 26.1, 20.4, 17.8, -5.11, -5.13, CH2: 59.4, 43.8, 43.6, 35.9, 31.7, CH: 136.1, 
136.0, 130.0, 130.0, 129.7, 127.8, 127.8, 126.7, 122.1, 85.3, 69.9, 66.2; IR (thin film) 
3458, 2985, 2961, 2859, 1741, 1678, 1473, 1425, 1386, 1241, 1111, 701 cm–1; HRMS 
(ESI/TOF) Calcd for C44H64O8SSi2Na (M + Na+): 831.3752. Found: 831.3746. 
 
Preparation of methyl (R)-4-((2S,6S)-6-(2-((tert-butyldimethylsilyl)oxy)ethyl)-
6-methoxy-5,5-dimethyltetrahydro-2H-pyran-2-yl)-3-((tert-butyldiphenylsilyl)oxy) 
butanoate 3.10. Thionocarbonate 3.9 (25 mg, 0.031 mmol, 1 equiv) was dissolved in 
benzene (310 µL, 0.1 M) in a 5 mL round-bottom flask. In another 5 mL round-bottom 
flask containing benzene (500 µL) were added Bu3SnH (42 µL, 0.154 mmol, 5 equiv) via 
syringe and AIBN (2.5 mg, 0.015 mmol, 0.5 equiv) in one portion. A portion of this 









heated to 90 oC. The rest of the AIBN/Bu3SnH solution was added slowly to the reaction 
mixture via syringe pump (0.5 mL/h). After 1.5 h, the reaction was cooled to rt and then 
quenched by the addition of water. The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic phases were washed with 
brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a silica gel column (1 × 10 
cm), eluting with 15% EtOAc/hexanes (400 mL) collecting in 5 mL fractions. The 
fractions containing product (18-25) were combined and concentrated under reduced 
pressure to give the product 3.10 (19 mg, 94%) as colorless oil: Rf = 0.53 (30% 
EtOAc/hexanes); [α]20D = +18.2 (c = 0.120, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.76-
7.61 (m, 4H), 7.48-7.33 (m, 6H), 4.24 (ddd, J = 12.2, 8.3, 3.9 Hz, 1H), 3.67 (dd, J = 18.1, 
9.8 Hz, 1H), 3.59 (s, 3H), 3.55 (dd, J = 15.6, 8.3 Hz, 1H), 3.13 (m, 1H), 2.96 (s, 3H), 
2.71 (dd, J = 14.6, 3.9 Hz, 1H), 2.54 (dd, J = 14.6, 8.3 Hz, 1H), 1.82 (m, 2H), 1.7 (m, 
2H), 1.49 (m, 1H), 1.40-1.18 (m, 3H), 1.02 (s, 9H), 0.92 (s, 3H), 0.89 (s, 9H), 0.80 (s, 
3H), 0.04 (s, 6H); 125 MHZ 13C NMR (CDCl3) δ 172.3, 136.0, 129.8, 129.8, 127.7, 
102.7, 70.1, 67.7, 59.7, 51.6, 48.3, 44.2, 43.6, 36.5, 36.3, 34.8, 27.8, 27.0, 26.2, 25.8, 
23.9, 19.5, 18.5, -5.0, -5.1; 125 MHz DEPT (CDCl3) CH3 δ 51.6, 48.3, 27.0, 26.2, 25.8, 
24.0, -5.0; CH2 δ 59.7, 44.2, 43.6, 36.3, 34.8, 27.8; CH δ 136.0, 129.8, 127.7, 70.1, 67.7; 
IR (neat) 3069, 2928, 2840, 1611, 1523, 1455, 1370, 1352, 1246, 1118, 1001, 900, 819 
cm-1; HRMS (ESI/TOF) Calcd for C37H60O6Si2Na (M + Na+): 679.382. Found: 679.3834. 








methoxybenzyl)oxy)hept-1-en-3-ol 3.26 and (3R,5S)-7-((tert-butyldiphenylsilyl)oxy)-
5-((4-methoxybenzyl)oxy)hept-1-en-3-ol 3.19. Aldehyde 3.20 (313 mg, 0.656 mmol, 
1.0 equiv) was dissolved in toluene (6.50 mL, 0.1 M) in a 15 mL round-bottom flask and 
cooled to -78 oC. After stirring for 10 min, a solution of Me2AlCl (1.10 mL, 3.00 M in 
toluene, 3.28 mmol, 5.0 equiv) was added to the solution at -78 oC. In the meantime, a 
separate 5 mL round-bottom flask was charged with vinyl magnesium bromide (2.00 mL, 
1.00 M in THF, 1.97 mmol, 3.0 equiv); the solvent was evaporated to near dryness under 
vacuum (0.1 mm of Hg) over about 30 min (complete dryness is avoided), and replaced 
with 2 mL of toluene. After 15 min at -78 oC, the vinyl magnesium bromide solution in 
toluene was added to the reaction mixture via cannula, dropwise over 5 min. The reaction 
mixture was allowed to stir for 2 h at -78 oC and then quenched by the addition of a 
saturated Rochelle’s salt solution (3 mL). The cold bath was removed and the reaction 
mixture was then allowed to slowly reach rt. The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 × 10 mL). The combined organic phases were 
washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished by flash chromatography on a 3 × 20 cm silica 
gel column, eluting with 15% EtOAc/hexanes (200 mL), then 20% EtOAc/hexanes (600 
mL), collecting 5 mL fractions. The minor fractions containing product (35-40) were 
combined and concentrated under reduced pressure to give the minor diastereomer 3.19 
(30 mg, 9%) as colorless oil. The major fractions containing product (45-85) were 
combined and concentrated under reduced pressure to give the major product 3.26 (258 
mg, 78%) as colorless oil. Analytical data for the major diastereomer 3.26: Rf = 0.33 
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(30% EtOAc/hexanes); [α]20D = +2.2 (c = 0.700, CHCl3); 500 MHz 1H NMR (CDCl3) δ 
7.70-7.64 (m, 4H), 7.47- 7.36 (m, 6H), 7.21 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 
5.81 (ddd, J = 16.6, 10.4, 5.7 Hz, 1H), 5.23 (d, J = 17.1 Hz, 1H), 5.07 (d, J = 10.4 Hz, 
1H), 4.55-4.33 (ABq, J = 10.9 Hz, Δν = 76.3 Hz, 2H), 4.25 (m, 1H), 3.91-3.84 (m, 1H), 
3.80 (s, 3H), 3.80 (m, 1H), 3.78-3.71 (m, 1H), 3.32 (s, 1H), 2.01-1.92 (m, 1H), 1.81-1.65 
(m, 3H), 1.07 (s, 9H); 125 MHZ 13C NMR (CDCl3) δ 159.6, 141.1, 136.2, 135.9, 135.6, 
135.3, 133.9, 130.3, 130.1, 129.7, 129.6, 128.3, 127.6, 114.8, 114.2, 113.9, 113.5, 76.6, 
73.9, 69.9, 60.5, 55.5, 41.9, 41.8, 36.9, 27.2, 27.0, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 
55.5, 27.0; CH2 δ 113.9, 69.9, 60.5, 41.8, 36.9; CH δ 141.1, 135.6, 129.6, 129.7, 127.6, 
113.9, 73.9, 69.9; IR (neat) 3069, 2928, 2840, 1611, 1523, 1455, 1370, 1352, 1246, 1118, 
1001, 900, 819 cm-1; HRMS (EI) Calcd for C31H40O4SiNa (M + Na+): 527.2588. Found: 
527.2601. Analytical data for the minor diastereomer 3.19: Rf = 0.35 (30% 
EtOAc/hexanes); [α]20D = +9.8 (c = 0.680, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-
7.65 (m, 4H), 7.48- 7.37 (m, 6H), 7.22 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.87 
(ddd, J = 16.9, 10.5, 5.3 Hz, 1H), 5.27 (d, J = 17.2 Hz, 1H), 5.11 (d, J = 10.5 Hz, 1H), 
4.46 (ABq, J = 11.0 Hz, Δν = 16.9 Hz, 2H), 4.38 (m, 1H), 4.00-3.94 (m, 1H), 3.81 (s, 
3H), 3.80-3.72 (m, 2H), 2.91 (s, 1H), 2.03-1.93 (m, 1H), 1.84-1.70 (m, 3H), 1.08 (s, 9H); 
125 MHZ 13C NMR (CDCl3) δ 159.5, 141.2, 135.8, 134.0, 134.0, 133.9, 130.5, 129.9, 
129.8, 129.7, 128.0, 127.9, 114.1, 114.1, 77.4, 74.1, 71.2, 70.1, 60.7, 55.5, 40.4, 36.8, 
27.3, 27.1, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.3, 26.8; CH2 δ 113.9, 71.0, 60.5, 
40.2, 36.6; CH δ 141.2, 135.8, 129.6, 129.5, 127.7, 113.9, 73.9, 69.9; IR (neat) 3069, 
2928, 2840, 1611, 1523, 1455, 1370, 1352, 1246, 1118, 1001, 900, 819 cm-1; HRMS (EI) 




 Preparation of tert-butyl(2-((4S,6S)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-
yl)ethoxy)diphenylsilane 3.27. To a solution of the major diastereomer 3.26 (30.0 mg, 
0.059 mmol, 1.0 equiv) in CH2Cl2 (600 µL, 0.1 M) in a 5 mL round-bottom flask was 
added pyridine (24 µL, 0.295 mmol, 5.0 equiv), DMAP (~1 mg, 0.006 mmol, 0.1 equiv), 
and Ac2O (17 µL, 0.178 mmol, 3.0 equiv) sequentially at rt. The mixture was stirred for 2 
h and then quenched by the addition of saturated NaHCO3 solution (2 ml). The phases 
were separated and the aqueous phase was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The crude mixture was purified using a silica 
gel column (1 × 10 cm), eluting with 10% EtOAc/hexanes (200 mL), then 15% 
EtOAc/hexanes (400 mL), collecting 5 mL fractions. The fractions containing product 
(25-45) were combined and concentrated under reduced pressure to give the acetate 
product as colorless oil. The acetate was taken forward for the next step.  
The acetate (assumed to be 0.059 mmol) was taken up in CH2Cl2 (5.9 mL, 0.01 
M) in a 15 mL round-bottom flask. tBuOH (118 µL, 0.5 M) and pH 7 buffer (1.2 mL, 0.1 
M, 0.118 mmol, 2 equiv) were added to the reaction mixture at rt. DDQ (53 mg, 0.236 
mmol, 4 equiv) was added in one portion and the reaction was stirred vigorously for 1.5 h 
and then quenched by the addition of saturated aqueous NaHCO3 solution (3 ml). The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (3 × 10 mL). 





filtered, and concentrated under reduced pressure. This alcohol was carried forward 
directly for the next step.  
  The acetate (assumed to be 0.059 mmol) was dissolved in MeOH (5.00 mL, 0.1 
M) in a 15 mL round-bottom flask at rt. K2CO3 (41 mg, 0.295 mmol, 5 equiv) was then 
added in one portion. The reaction mixture was stirred vigorously for 1.5 h and then 
quenched by the addition of saturated NaHCO3 solution (3 ml). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 1 × 10 cm silica gel column, eluting with 25% EtOAc/hexanes (400 
mL), collecting 9 mL fractions. The fractions containing product (20-32) were combined 
and concentrated under reduced pressure to give the acetate product as colorless oil. This 
oil was then directly taken to the next step. 
The diol (assumed to be 0.059 mmol) was taken up in CH2Cl2 (1.2 mL, 0.05 M) in 
a 10 mL round-bottom flask at rt. 2-methoxypropene (28 µL, 0.295 mmol, 5 equiv) was 
then added dropwise via a syringe followed by PPTS (~1 crystal) in one portion. The 
reaction was stirred for 1 h and then quenched by the addition of saturated NaHCO3 
solution (3 ml). The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL). The combined organic phases were washed with brine (10 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a silica gel column (1 × 10 cm), eluting with 
5% EtOAc/hexanes (400 mL) collecting 5 mL fractions. The fractions containing product 
(12-16) was combined and concentrated under reduced pressure to give the acetate 
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product as colorless oil: Rf = 0.58 (30% EtOAc/hexanes); [α]20D = +3.8 (c = 0.210, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.71-7.66 (m, 4H), 7.46- 7.36 (m, 6H), 5.83 (ddd, 
J = 16.6, 10.5, 5.9 Hz, 1H), 5.26 (d, J = 17.1 Hz, 1H), 5.13 (d, J = 10.5 Hz, 1H), 4.35 (m, 
1H), 4.18 (m, 1H), 3.86 (m, 1H), 3.73 (m, 1H), 1.72 (m, 2H), 1.49 (s, 3H), 1.43 (m, 4H), 
1.07 (s, 9H); 125 MHZ 13C NMR (CDCl3) δ 139.1, 135.8, 134.2, 134.1, 129.8, 129.8, 
127.8, 127.8, 115.4, 98.8, 70.5, 65.6, 59.8, 39.5, 37.2, 30.5, 27.1, 20.0, 19.4; 125 MHz 
DEPT (CDCl3) CH3 δ 30.5, 26.8, 20.0; CH2 δ 115.1, 59.6, 39.3, 36.9; CH δ 138.8, 135.5, 
135.5, 129.6, 129.5, 127.6, 127.5, 70.2, 65.3; IR (neat) 3069, 2928, 2840, 1611, 1452, 
1305, 1348, 1122, 989, 889, 823 cm-1; HRMS (ESI/TOF) Calcd for C26H36O3SiNa (M + 
Na+): 447.2326. Found: 447.2340. 
 
Preparation of tert-butyl(2-((4S,6R)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-
yl)ethoxy)diphenylsilane 3.19. Same procedure as 3.26: Rf = 0.58 (30% 
EtOAc/hexanes); [α]20D = +5.6 (c = 0.210, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-
7.65 (m, 4H), 7.46- 7.36 (m, 6H), 5.91 (ddd, J = 17.1, 10.5, 5.9 Hz, 1H), 5.23 (d, J = 17.1 
Hz, 1H), 5.14 (d, J = 10.5 Hz, 1H), 4.35 (m, 1H), 4.16 (m, 1H), 3.82 (m, 1H), 3.73 (m, 
1H), 1.84-1.65 (m, 2H), 1.40 (s, 3H), 1.38 (m, 4H), 1.06 (s, 9H); 125 MHZ 13C NMR 
(CDCl3) δ 139.1, 135.8, 135.8, 134.2, 134.1, 129.8, 129.8, 127.8, 115.2, 100.5, 68.2, 
63.4, 60.2, 39.2, 37.7, 27.1, 25.8, 25.1, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 27.1, 25.8, 
25.1; CH2 δ 115.3, 60.3, 39.2, 37.8; CH δ 139.1, 135.8, 129.8, 127.9, 68.2, 63.4; IR (neat) 
3069, 2928, 2840, 1611, 1452, 1305, 1348, 1122, 989, 889, 823 cm-1; HRMS (ESI/TOF) 






Preparation of 2,2-dimethylbut-3-enoic acid 3.18. A solution of nBuLi (88 mL, 
2.5 M in hexanes, 220.6 mmol, 2.2 equiv) in THF (88 mL, 2.5 M) was cooled to -78 oC 
under nitrogen atmosphere. Diethylamine (21.8 mL, 210.6 mmol, 2.1 equiv) was added to 
the solution and the solution was stirred for 15 min at 0 oC, and then cooled to -78 oC 
again. The tiglic acid (10.0 g, 100.3 mmol, 1.0 equiv) was then added slowly during 5 
min to the stirring solution and the resulting yellow solution was stirred for 30 min at 0 
oC, and then cooled down again to -78 oC. Me2SO4 (9.5 mL, 100.3 mmol, 1.0 equiv) in 
THF (200 mL, 0.5 M) was added slowly and the solution was stirred for another 30 min 
at 0 oC and then slowly warmed up to rt over 1 h. The reaction was then quenched with 
water (100 mL) and the reaction mixture was extracted with Et2O (3 × 50 mL). The 
aqueous layer was acidified with ice-cold solution of conc. HCl and then extracted with 
EtOAc (3 × 20 mL), and the combined organic layer was dried with Na2SO4 and 
evaporation of the solvent gave the crude acid reaction mixture. Purification was 
accomplished by flash chromatography on a silica gel column (3 × 25 cm), eluting with 
40-50% EtOAc/hexanes (1000 mL) collecting 9 mL fractions. The fractions containing 
product (19-40) were combined and concentrated under reduced pressure to give the 
acetate product (6.0 g, 53%) as colorless oil: Rf = 0.40 (50% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3) δ 6.06 (dd, J = 17.4, 10.8 Hz, 1H), 5.16 (d, J = 17.6 Hz, 1H), 5.11 (d, J 









methoxybenzyl)oxy)hept-1-en-3-yl 2,2-dimethylbut-3-enoate 3.17. To a solution of the 
alcohol 3.26 (324 mg, 0.642 mmol, 1.0 equiv) in THF (13 mL, 0.05 M) in a 25 mL round-
bottom flask at rt was added PPh3 (842 mg, 3.21 mmol, 5 equiv) and DEAD (505 µL, 
3.21 mmol, 5 equiv). The acid 3.18 (293 mg, 2.57 mmol, 4 equiv) was dissolved in THF 
(1 mL) in a separate flask and added to the reaction mixture via cannula. The reaction 
mixture was allowed to stir for 2 h at rt and then quenched by the addition of saturated 
NaHCO3 solution (3 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic phases were washed with 
brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a silica gel column (3 × 15 
cm), eluting with 10% EtOAc/hexanes (400 mL), collecting 5 mL fractions. The fractions 
containing product (15-25) were combined and concentrated under reduced pressure to 
give the ester 3.17 (323 mg, 84%) as colorless oil: Rf = 0.53 (30% EtOAc/hexanes); 
[α]20D = +8.2 (c = 0.630, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.75-7.65 (m, 4H), 7.48- 
7.36 (m, 6H), 7.21 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 6.06 (dd, J = 17.5, 10.6 
Hz, 1H), 5.79 (ddd, J = 16.9, 10.6, 5.9 Hz, 1H), 5.51 (m, 1H), 5.24 (d, J = 17.2 Hz, 1H), 
5.10 (m, 4H), 4.44-4.29 (ABq, J = 10.6 Hz, Δν = 51.0 Hz, 2H), 3.87-3.65 (m, 3H), 3.80 
(s, 3H), 1.90-1.74 (m, 1H), 1.33 (s, 3H), 1.32 (s, 3H), 1.08 (s, 9H); 125 MHZ 13C NMR 








116.1, 114.0, 113.9, 113.2, 72.6, 71.9, 71.8, 60.6, 55.5, 45.2, 40.5, 37.8, 27.1, 24.8, 24.7, 
19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.1, 24.8, 24.7; CH2 δ 116.1, 114.0, 72.6, 
71.8, 41.8, 36.9; CH δ 142.5, 137.0, 129.8, 129.5, 127.9, 127.9, 113.9, 72.6, 71.9; IR 
(neat) 3056, 2936, 2834, 1736, 1619, 1447, 1370, 1354, 1246, 1224, 1118, 823 cm-1; 
HRMS (ESI/TOF) Calcd for C37H48O5SiNa (M + Na+): 623.3163. Found: 623.3174. 
 
Preparation of (R)-6-((S)-4-((tert-butyldiphenylsilyl)oxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,3-dimethyl-3,6-dihydro-2H-pyran-2-one 3.31. The ester 
3.17 (450 mg, 0.749 mmol, 1 equiv) was dissolved in degassed CH2Cl2 (150 mL, 0.005 
M). CH2Cl2 was degassed with a steady flow of N2 for 30 min prior to use. Ti(OiPr)4 
solution (3.7 mL, 1 M in CH2Cl2, 3.74 mmol, 5 equiv) was then added dropwise to the 
reaction mixture. It was then heated at reflux for 1 h under N2 atmosphere. Grubbs’ 2nd-
generation catalyst 3.30 (127 mg, 0.150 mmol, 0.20 equiv) was then added in one portion 
and heated at reflux for another 12 h. The reaction mixture was then passed through a 
plug of Celite®, and then the solution was stirred in an open Erlenmeyer flask with 
activated charcoal overnight. The solution was then filtered through a plug of Celite® and 
then treated with H2O2 for 2 h until effervescence stopped and the solution became 
colorless. The excess H2O2 (10 mL) was then quenched by the addition of saturated 
aqueous NaS2O3 solution (10 mL). The phases were separated and the aqueous layer was 
then extracted with CH2Cl2 (3 × 25 mL). The combined organic phases were washed with 








Purification was accomplished by flash chromatography on a silica gel column (3 × 15 
cm), eluting with 10% EtOAc/hexanes (400 mL), collecting 5 mL fractions. The fractions 
containing product (15-25) were combined and concentrated under reduced pressure to 
give the ester 3.17 (412 mg, 96%) as colorless oil: Rf = 0.35 (30% EtOAc/hexanes); 
[α]20D = +10.5 (c = 0.500, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.71-7.66 (m, 4H), 
7.47- 7.36 (m, 6H), 7.21 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 5.64 (s, 1H), 5.14 
(dd, J = 6.2, 5.7 Hz, 1H), 4.54-4.40 (ABq, J = 10.8 Hz, Δν = 40.9 Hz, 2H), 4.14 (dd, J = 
14.4, 7.2 Hz, 1H), 4.0 (m, 1H), 3.80 (s, 3H), 3.80 (m, 2H), 1.92-1.78 (m, 4H), 1.35 (s, 
3H), 1.32 (s, 3H), 1.08 (s, 9H); 125 MHZ 13C NMR (CDCl3) δ 175.3, 159.4, 135.8, 
133.9, 133.9, 132.7, 130.9, 129.8, 129.7, 127.9, 125.0, 114.0, 76.3, 72.8, 72.0, 60.5, 55.5, 
42.9, 38.0, 37.6, 28.1, 27.1, 26.9, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 27.1, 24.8, 
24.7; CH2 δ 116.1, 114.0, 72.6, 71.8, 41.8, 36.9; CH δ 135.8, 132.7, 129.8, 129.7, 125.0, 
114.0, 76.3, 72.8; IR (neat) 3056, 2936, 1735, 1615, 1455, 1370, 1354, 1246, 1112, 816 
cm-1; HRMS (ESI/TOF) Calcd for C35H44O5SiNa (M + Na+): 595.2848. Found: 
595.2856.   
 
Preparation of (S)-6-((S)-4-((tert-butyldiphenylsilyl)oxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,3-dimethyltetrahydro-2H-pyran-2-one 3.16. To a 
solution of the olefin 3.31 (46 mg, 0.080 mmol, 1 equiv) in EtOAc (800 µL, 0.1 M) under 
an atmosphere of H2 (balloon) at 0 oC was added Adams’ catalyst (2 mg, 10 wt%) quickly 








balloon was removed as soon as the starting material was consumed. The mixture was 
then filtered through a plug of Celite®, washed with EtOAc (3 × 10 mL), and then 
evaporated under reduced pressure. The crude mixture was purified by flash 
chromatography on a silica gel column (1 × 10 cm), eluting with 15-20% EtOAc/hexanes 
(400 mL), collecting 5 mL fractions. The fractions containing product (13-17) were 
combined and concentrated under reduced pressure to give the lactone 3.16 (34 mg, 74%) 
as colorless oil: Rf = 0.30 (25% EtOAc/hexanes); [α]20D = +8.3 (c = 0.100, CHCl3); 500 
MHz 1H NMR (CDCl3) δ 7.70-7.64 (m, 4H), 7.47- 7.36 (m, 6H), 7.19 (d, J = 8.8 Hz, 2H), 
6.85 (d, J = 8.8 Hz, 2H), 4.45-4.35 (ABq, J = 11.2 Hz, Δν = 39.9 Hz, 2H), 3.86-3.73 (m, 
3H), 3.80 (s, 3H), 2.02 (ddd, J = 13.7, 6.8, 6.8 Hz, 1H), 1.89 (ddd, J = 14.2, 6.4, 6.4 Hz, 
1H), 1.80 (m, 1H), 1.73 (m, 1H), 1.70-1.55 (m, 4H), 1.30 (s, 3H), 1.26 (s, 3H), 1.07 (s, 
9H); 125 MHZ 13C NMR (CDCl3) δ 177.5, 159.4, 135.8, 133.9, 130.8, 129.9, 129.7, 
127.9, 127.9, 113.9, 79.0, 72.0, 70.6, 60.5, 55.5, 40.8, 38.3, 36.8, 34.7, 28.1, 28.0, 27.1, 
26.2, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 28.1, 28.0, 27.1; CH2 δ 70.6, 60.5, 40.8, 
36.8, 34.7, 26.2; CH δ 135.8, 129.9, 129.7, 127.9, 127.9, 114.0, 79.0, 72.0; IR (neat) 
3065, 2936, 1736, 1612, 1455, 1370, 1352, 1246, 1112, 816 cm-1; HRMS (ESI/TOF) 
Calcd for C35H46O5SiNa (M + Na+): 597.3007. Found: 597.3022.  
 
Preparation of ethyl 2-((2S,6S)-6-((S)-4-((tert-butyldiphenylsilyl)oxy)-2-((4-
methoxybenzyl)oxy)butyl)-3,3-dimethyltetrahydro-2H-pyran-2-yl)acetate 3.15. A 









to -78 oC. nBuLi (472 µL, 2.5 M in hexanes, 1.18 mmol, 25 equiv) was then added 
dropwise via syringe. The solution was then warmed to 0 oC and stirred for 30 min. The 
solution was then cooled again to -78 oC. EtOAc (116 µL, 1.18 mmol, 25 equiv) was then 
added dropwise via syringe slowly over 2 min. The reaction mixture was then stirred for 
another 45 min. To this solution was added lactone 3.16 (27.2 mg, 0.047 mmol, 1 equiv) 
in THF (1 mL) slowly down the side of the flask via cannula. Another 1 mL of THF was 
used to wash the flask and then transferred to the reaction mixture. The reaction was 
allowed to stir for 1 h and then quenched by the addition of saturated NH4Cl solution (10 
mL). The phases were separated and the aqueous phase was extracted with CH2Cl2 (3 × 
10 mL). The combined organic phases were washed with brine (10 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure. This crude mixture was then 
taken directly to the next step. 
The hemiketal (assumed to be 0.047 mmol) was dissolved in CH2Cl2 and cooled 
to -78 oC. Et3SiH (151 µL, 0.946, 20 equiv) was added to the reaction mixture and stirred 
for 10 min. To this solution was added TMSOTf (52 µL, 0.052, 1.1 equiv) dropwise over 
2 min. The reaction mixture was stirred at -78 oC for 1.5 h and then quenched by the 
addition of saturated aqueous NaHCO3 solution. The phases were separated and the 
aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The organic layers were 
combined, dried over Na2SO4 and the solvent was evaporated under reduced pressure. 
Purification was accomplished by flash chromatography on a 1 × 10 cm silica gel 
column, eluting with 10% EtOAc/hexanes (400 mL), collecting 5 mL fractions. The 
fractions containing product (13-24) were combined and concentrated under reduced 
pressure to give the ester 3.17 (25 mg, 84%) as colorless oil: Rf = 0.52 (25% 
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EtOAc/hexanes); [α]20D = +6.5 (c = 0.500, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-
7.65 (m, 4H), 7.48- 7.35 (m, 6H), 7.24 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 4.40 
(ABq, J = 10.9 Hz, Δν = 17.3 Hz, 2H), 4.09 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 3.80 (m, 
3H), 3.65 (dd, J = 9.8, 1.7 Hz, 1H), 3.55 (m, 1H), 2.46 (m, 1H), 2.36 (m, 1H), 1.79 (ddd, 
J = 6.2, 6.2, 6.2 Hz, 2H), 1.59 (m, 2H), 1.52-1.34 (m, 4H), 1.20 (m, 3H), 1.07 (s, 9H), 
0.93 (s, 3H), 0.88 (s, 3H); 125 MHZ 13C NMR (CDCl3) δ 172.6, 159.3, 135.8, 134.2, 
134.2, 131.6, 129.8, 129.7, 127.8, 113.9, 82.0, 75.0, 73.2, 72.3, 60.9, 60.5, 55.5, 42.6, 
39.5, 38.3, 36.3, 32.4, 29.2, 27.5, 27.1, 19.4, 19.4, 14.5; 125 MHz DEPT (CDCl3) CH3 δ 
55.5, 27.5, 27.1, 19.4, 14.5; CH2 δ 72.3, 60.9, 60.5, 42.6, 39.5, 38.3, 36.3, 29.2; CH δ 
135.8, 129.7, 129.7, 127.8, 113.9, 82.0, 75.0, 73.2; IR (neat) 3056, 2936, 1750, 1615, 
1455, 1370, 1354, 1246, 1050, 816 cm-1; HRMS (EI) Calcd for C39H54O6Si (M + Na+): 




3.14. The ester 3.17 (300 mg, 0.464 mmol, 1 equiv) was dissolved in CH2Cl2 (5 mL, 0.1 
M) in a 15 mL round-bottom flask. The solution was then cooled to -78 oC and stirred for 
10-15 min. DIBAL-H (650 µL, 1.5 M in toluene, 0.974, 2.1 equiv) was added slowly 
down the side of the flask over 20 min by means of syringe pump. The reaction mixture 
was stirred for 1.5 h and then quenched by the addition of acetone (1 mL) and then stirred 









mixture was slowly warmed up to rt. The phases were separated and the aqueous layer 
was extracted by CH2Cl2 (3 × 10 mL). The organic layers were combined, dried over 
Na2SO4, and the solvent was removed under reduced pressure. Purification was 
accomplished by flash chromatography on a silica gel column (3 × 15 cm), eluting with 
5-15% EtOAc/hexanes (800 mL), collecting 5 mL fractions. The fractions containing 
product (31-43) were combined and concentrated under reduced pressure to give the ester 
3.14 (243 mg, 87%) as colorless oil: Rf = 0.45 (20% EtOAc/hexanes); [α]20D = +4.1 (c = 
0.500, CHCl3); 500 MHz 1H NMR (CDCl3) δ 9.68 (t, J = 2.0 Hz, 1H), 7.71-7.64 (m, 4H), 
7.46- 7.35 (m, 6H), 7.21 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.46-4.31 (ABq, J 
= 11.2 Hz, Δν = 51.3 Hz, 2H), 3.81-3.71 (m, 2H), 3.80 (s, 3H), 3.56 (dd, J = 10.3, 2.9 Hz, 
1H), 3.53 (m, 1H), 3.49 (m, 1H), 2.39 (m, 2H), 1.78 (m, 2H), 1.66-1.35 (m, 6H), 1.06 (s, 
9H), 0.93 (s, 3H), 0.84 (s, 3H); 125 MHZ 13C NMR (CDCl3) δ 202.6, 159.3, 135.8, 
134.1, 131.4, 129.8, 129.6, 127.9, 127.8, 114.0, 80.7, 75.1, 72.8, 71.8, 66.0, 60.7, 55.5, 
44.4, 42.4, 39.3, 37.9, 32.4, 29.1, 27.4, 27.1, 19.4, 19.4, 15.5; 125 MHz DEPT (CDCl3) 
CH3 δ 55.5, 27.4, 27.1, 19.4; CH2 δ 71.8, 60.7, 44.4, 42.4, 39.3, 37.9, 29.1; CH δ 202.6, 
135.8, 129.8, 129.7, 129.6, 127.8, 114.0, 80.7, 75.1, 72.8; IR (neat) 3056, 2826, 2730, 
1734, 1615, 1455, 1370, 1354, 1246, 1050, 816 cm-1; HRMS (EI) Calcd for 












((trimethylsilyl)methyl)pent-4-en-2-ol 3.12. A 50 mL round-bottom flask was charged 
with N,N'-((1S,2S)-1,2-diphenylethane-1,2-diyl)bis(4-methylbenzenesulfonamide) 3.33 
(100 mg, 0.192 mmol, 3 equiv) and a stir bar. The flask was heated for 18 h at 100 oC 
under vacuum (0.1 mm of Hg). The dry powder was then cooled to rt and flushed with Ar 
from Schlenk line. CH2Cl2 (274 µL, 0.7 M) was added to the flask via syringe and stirred 
for 1 h. The suspension was then cooled down to 0 oC. BBr3 (18 µL, 0.192 mmol, 3 
equiv) was added dropwise via syringe, and then the solution was stirred for another 1 h 
at rt. Next, the flask was connected to the vacuum line and the solvent was removed 
under vacuum for about 30 min This should also remove volatile bromine from the 
reaction mixture. A separate 25 mL pear shaped flask was charged with 2,6-di-tert-butyl-
4-methylpyridine (39.4 mg, 0.192 mmol, 3 equiv) followed by trimethyl(2-
((tributylstannyl)methyl)allyl)silane 3.34 (77 µL, 0.192 mmol, 3 equiv) and was flushed 
with Ar 2-3 times and then left connected with Ar Schlenk line. CH2Cl2 (2 mL, 0.1 M) 
was added to the mixture via syringe and cannulated into the reaction mixture. This 
mixture was then stirred for another 16 h at rt. After 16 h, the solution was cooled down 
to -78 oC.  
The aldehyde 3.14 (271 mg, 0.449 mmol, 1 equiv) was dissolved in CH2Cl2 (9 
mL, 0.05 M) in a 15 mL round-bottom flask. This solution was then cooled down to -78 
oC and then cannulated to the flask containing the reagent over 15 min The reaction 
mixture was then stirred for another 2 h before being quenched by the addition of 
aqueous pH 7 buffer solution (10 mL, 0.1 M) and warmed to rt. The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The organic 
layers were combined, dried over Na2SO4, and the solvent was evaporated under reduced 
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pressure to about ⅓ of the original volume. A mixture of Et2O/hexanes (2:1, 20 mL) was 
added and the N,N'-((1S,2S)-1,2-diphenylethane-1,2-diyl)bis(4-
methylbenzenesulfonamide) precipitated and was recovered by filtration. The filtrate was 
concentrated under reduced pressure.  Purification was accomplished by flash 
chromatography on a silica gel column (1 × 10 cm), eluting with 5% EtOAc/hexanes 
(400 mL), collecting 5 mL fractions. The fractions containing product (23-41) were 
combined and concentrated under reduced pressure to give the ester 3.12 (35.5 mg, 76%) 
as colorless oil: Rf = 0.55 (20% EtOAc/hexanes); [α]20D = +17.1 (c = 0.500, CHCl3); 500 
MHz 1H NMR (CDCl3) δ 7.71-7.64 (m, 4H), 7.45- 7.35 (m, 6H), 7.21 (d, J = 8.3 Hz, 2H), 
6.84 (d, J = 8.8 Hz, 2H), 4.66 (s, 1H), 4.62 (s, 1H), 4.41 (ABq, J = 10.8 Hz, Δν = 18.1 
Hz, 2H), 4.00-3.92 (m, 2H), 3.80 (s, 3H), 3.81-3.69 (m, 1H), 3.54 (m, 1H), 3.27 (m, 1H), 
2.23 (dd, J = 14.2, 6.4 Hz, 1H), 2.04 (dd, J = 14.2, 6.8 Hz, 1H), 1.85-1.75 (m, 2H), 1.74-
1.60 (m, 4H), 1.50-1.34 (m, 5H), 1.33-1.22 (m, 2H), 1.06 (s, 9H), 0.92 (s, 3H), 0.82 (s, 
3H), 0.03 (s, 9H); IR (neat) 3056, 2826, 2730, 1734, 1615, 1455, 1370, 1354, 1246, 1050, 














equiv) in CH2Cl2 (171 µL, 0.1 M) in a 5 mL vial was added DMAP (1 mg, 0.007 mmol, 
0.4 equiv), EDCIHCl (9.8 mg, 0.051 mmol, 3 equiv) and (S)-MTPA (8 mg, 0.034 mmol, 
2 equiv) at rt. The reaction mixture was stirred for 9 d and then quenched by the addition 
of saturated NaHCO3 solution (2 mL). The phases were separated and the aqueous layer 
was extracted by CH2Cl2 (3 × 5 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. Purification was 
accomplished by flash chromatography on a silica gel column (1 × 10 cm), eluting with 
2.5-5% EtOAc/hexanes (200 mL), collecting 5 mL fractions. The fractions containing 
product (15-19) were combined and concentrated under reduced pressure to give the ester 
3.38 (12.6 mg, 78%) as colorless oil: Rf = 0.55 (20% EtOAc/hexanes); [α]20D = +12.5 (c 
= 0.200, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-7.65 (m, 4H), 7.59-7.53 (m, 2H), 
7.44- 7.33 (m, 9H), 7.16 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.52 (m, 1H), 4.56 
(s, 1H), 4.50 (s, 1H), 4.38 (s, 2H), 3.83-3.75 (m, 3H), 3.79 (s, 3H), 3.54 (s, 3H), 3.42 (m, 
1H), 3.13 (dd, J = 9.8, 1.5 Hz, 1H), 2.28 (m, 2H), 2.06 (m, 1H), 1.90-1.62 (m, 7H), 1.56 
(m, 2H), 1.53-1.33 (m, 7H), 1.05 (s, 9H), 0.89 (s, 3H), 0.80 (s, 3H), -0.05 (s, 9H); 125 
MHZ 13C NMR (CDCl3) δ 165.8, 159.2, 142.6, 135.8, 134.2, 134.2, 132.7, 131.4, 129.7, 
129.6, 129.4, 128.4, 127.8, 113.9, 111.0, 82.0, 75.4, 74.2, 73.5, 71.4, 60.8, 55.6, 55.5, 
42.5, 42.2, 39.7, 37.8, 34.6, 32.6, 29.9, 29.0, 27.5, 27.1, 26.8, 19.4, 19.2, -1.3; 125 MHz 
DEPT (CDCl3) CH3 δ 55.6, 55.5, 27.5, 27.1, 27.1, 19.2, -1.3; CH2 δ 111.0, 71.3, 60.7, 
42.4, 42.2, 39.6, 37.8, 34.6, 29.0, 26.8; CH δ 135.8, 129.7, 129.6, 129.4, 128.4, 127.8, 
127.8, 113.9, 82.0, 75.4, 74.1, 73.5; IR (neat) 3056, 2936, 2859, 1765, 1615, 1590, 1473, 
1370, 1354, 1246, 1050, 824, 816 cm-1; HRMS (EI) Calcd for C54H73F3O7Si2Na m/z (M + 







phenylpropanoate 3.37. Same procedure as 3.38 with (R)-MTPA: Rf = 0.55 (20% 
EtOAc/hexanes); [α]20D = +2.5 (c = 0.020, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.70-
7.64 (m, 4H), 7.59-7.53 (m, 2H), 7.45-7.32 (m, 9H), 7.16 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 
8.8 Hz, 2H), 5.54 (m, 1H), 4.66 (s, 1H), 4.60 (s, 1H), 4.38 (s, 2H), 3.85-3.74 (m, 3H), 
3.79 (s, 3H), 3.53 (s, 3H), 3.38 (m, 1H), 3.07 (dd, J = 9.8, 1.5 Hz, 1H), 2.41-2.30 (m, 
2H), 1.81-1.71 (m, 4H), 1.71-1.61 (m, 3H), 1.57-1.19 (m, 13H), 1.05 (s, 9H), 0.86 (s, 
6H), 0.73 (s, 3H), -0.02 (s, 9H); 125 MHZ 13C NMR (CDCl3) δ 166.0, 159.2, 143.0, 
135.8, 134.2, 134.2, 132.7, 131.4, 129.7, 129.6, 129.5, 129.4, 128.4, 127.8, 113.9, 110.8, 
81.4, 75.2, 74.2, 73.5, 71.3, 60.8, 55.7, 55.5, 42.3, 42.2, 39.6, 37.9, 34.5, 32.6, 31.8, 29.9, 
29.0, 27.4, 27.1, 26.9, 22.9, 19.4, 19.1, 14.3, 1.2; 125 MHz DEPT (CDCl3) CH3 δ 55.4, 
55.2, 27.5, 27.2, 26.9, 18.9, 1.4; CH2 δ 110.6, 71.0, 60.6, 42.0, 41.9, 39.4, 37.6, 34.2, 
29.7, 28.7, 26.6; CH δ 135.6, 129.5, 129.4, 129.4, 129.2, 129.1, 128.2, 127.6, 113.7, 81.2, 
74.9, 73.9, 73.2; IR (neat) 3056, 2936, 2859, 1765, 1615, 1590, 1455, 1370, 1354, 1246, 
1050, 824, 816 cm-1; HRMS (ESI/TOF) Calcd for C54H73F3O7Si2Na m/z (M + Na+): 












oxopent-3-en-2-yl)tetrahydro-2H-pyran-3-yl octanoate 3.41. The TBS ether 3.11 (34.2 
mg, 0.046 mmol, 1 equiv) was dissolved in THF/Py (9:1, 4.6 mL, 0.01 M) in a 10 mL 
plastic vial at rt. MeOH (500 µL), followed by 2.5 mL of HFPy (20% of HF in Py), was 
added to the reaction mixture. After stirring for 12 h at rt, the reaction was judged 
incomplete by TLC analysis and an additional 1 mL of HFPy was added to the reaction 
mixture. After another 24 h, the reaction was complete and cooled to 0 oC. Powdered 
NaHCO3 was added slowly to the reaction mixture to quench until effervescence was 
complete. Water was added to the reaction mixture which was then warmed to rt. The 
phases were separated and the aqueous layer was extracted by CH2Cl2 (3 × 5 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. Purification was accomplished by flash chromatography on a silica gel 
column (1 × 10 cm), eluting with 15-25% EtOAc/hexanes (600 mL), collecting 9 mL 
fractions. The fractions containing product (50-55) were combined and concentrated 
under reduced pressure to give the alcohol 3.41 (26.6 mg, 92%) as colorless oil: Rf = 0.40 
(50% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3) δ 9.50 (d, J = 7.3 Hz, 1H), 7.34-7.25 
(m, 5H), 7.23 (d, J = 8.8 Hz, 2H), 5.89 (dd, J = 16.1, 7.8 Hz, 1H), 5.83 (s, 1H), 5.46 (s, 














4.62 (ABq, J = 11.7 Hz, Δν = 20.5 Hz, 2H), 4.23 (td, J = 8.8, 2.9 Hz, 1H), 3.79 (m, 1H), 
3.65 (s, 3H), 3.59 (m, 2H), 3.45 (m, 1H), 3.38 (s, 3H), 2.63 (s, 1H), 2.34 (t, J = 13.7 Hz, 
1H), 2.19-2.02 (m, 2H), 1.69 (m, 2H), 1.50 (m, 2H), 1.33-1.17 (m, 12H), 1.15 (s, 3H), 
1.11 (s, 3H), 0.83 (t, J = 7.3 Hz, 3H); 125 MHZ 13C NMR (CDCl3) δ 194.7, 171.9, 167.0, 
166.5, 151.9, 137.6, 128.7, 128.1, 128.0, 127.1, 102.6, 94.1, 71.4, 71.2, 70.2, 68.7, 51.5, 
47.7, 39.9, 34.6, 33.1, 31.8, 29.9, 29.1, 29.0, 24.8, 23.9, 22.7, 22.1, 17.0, 14.2; IR (neat) 
3056, 2936, 2859, 1735, 1615, 1590, 1473, 1370, 1354, 1246, 1050, 824, 816 cm-1; 






methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate 3.42. To a solution of 
the β-hydroxyallyl silane 3.12 (16 mg, 0.023 mmol, 1.3 equiv) in Et2O (1.1 mL, 0.02 M) 
in a 5 mL vial was added a solution of aldehyde 3.41 (11 mg, 0.017 mmol, 1 equiv) in 
Et2O (250 µL) via cannula. Another 250 µL was used to transfer all the aldehyde to the 
reaction mixture. The mixture was then cooled to -78 oC and stirred for 10 min before 
















slowly down the side of the flask. The resulting solution was stirred for 2 h and then 
quenched by addition of iPr2EtN (1 mL) and saturated aqueous NaHCO3 solution (2 mL). 
The phases were separated and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. Purification was accomplished by flash chromatography on a 
silica gel column (0.5 × 10 cm), eluting with 10-25% EtOAc/hexanes (1000 mL), 
collecting 5 mL fractions. The fractions containing product (112-123) were combined and 
concentrated under reduced pressure to give the alcohol 3.42 (16.6 mg, 75%) as colorless 
oil: Rf = 0.25 (30% EtOAc/hexanes); [α]20D = +14.5 (c = 0.120, CHCl3); 500 MHz 1H 
NMR (CDCl3) δ 7.70-7.65 (m, 4H), 7.45-7.28 (m, 11H), 7.19 (d, J = 8.8 Hz, 2H), 6.85 (d, 
J = 8.8 Hz, 2H), 5.96 (d, J = 15.1 Hz, 1H), 5.87 (s, 1H), 5.57 (m, 1H), 5.42 (dd, J = 16.1, 
5.9 Hz, 1H), 4.86 (ABq, J = 6.8 Hz, Δν = 24.5 Hz, 2H), 4.65 (ABq, J = 11.7 Hz, Δν = 
18.1 Hz, 2H), 4.63-4.44 (ABq, J = 14.7 Hz, Δν = 70.4 Hz, 2H), 4.40 (ABq, J = 10.3 Hz, 
Δν = 28.4 Hz, 2H), 4.23 (m, 1H), 3.86 (m, 2H), 3.82-2.70 (m, 3H), 3.80 (s, 3H), 3.68 (s, 
3H), 3.62 (m, 2H), 3.54-3.38 (m, 2H), 3.34 (s, 3H), 3.12 (m, 1H), 2.66 (d, J = 4.41 Hz, 
1H), 2.44-2.28 (m, 4H), 2.18 (m, 1H), 2.10-1.96 (m, 3H), 1.89-1.75 (m, 5H), 1.73-1.69 
(m, 3H), 1.66-1.51 (m, 8H), 1.51-1.34 (m, 6H), 1.34-1.19 (m, 15H), 1.11 (m, 6H), 1.06 
(s, 9H), 0.93 (s, 3H), 0.88 (t, J = 6.4 Hz, 3H), 0.84 (s, 3H); 125 MHZ 13C NMR (CDCl3) 
δ 172.3, 166.8, 159.3, 153.2, 144.4, 138.8, 137.8, 135.8, 134.1, 134.0, 131.4, 129.8, 
129.5, 129.3, 129.2, 128.7, 128.0, 128.0, 127.9, 126.8, 114.0, 113.9, 108.9, 102.8, 94.0, 
81.4, 81.4, 81.3, 79.2, 78.2, 75.9, 74.8, 73.4, 72.3, 72.0, 71.9, 71.2, 70.1, 68.1, 60.7, 55.5, 
51.3, 51.2, 46.3, 42.8, 41.0, 39.9, 39.9, 39.8, 38.0, 36.9, 34.6, 32.5, 31.9, 29.9, 29.3, 29.3, 
29.2, 27.6, 27.2, 27.1, 24.9, 24.2, 24.0, 22.8, 19.4, 17.0, 14.3; 125 MHz DEPT (CDCl3) 
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CH3 δ 55.2, 51.1, 51.0, 27.4, 26.9, 26.9, 23.9, 23.8, 19.1, 16.8, 14.0; CH2 δ 108.7, 93.8, 
72.0, 71.8, 69.8, 60.4, 42.5, 40.8, 39.6, 39.6, 37.8, 36.7, 34.3, 31.6, 29.1, 29.0, 28.9, 24.7, 
22.5; CH δ 138.6, 135.6, 129.5, 129.2, 129.0, 129.0, 128.5, 127.8, 127.6, 126.6, 113.8, 
113.7, 81.1, 81.0, 79.0, 77.9, 77.9, 75.6, 74.6, 74.5, 73.2, 72.1, 71.6, 70.9, 69.9, 67.9; IR 
(neat) 3215, 3056, 2936, 2859, 1746, 1735, 1615, 1590, 1473, 1370, 1354, 1246, 1050, 







2-methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate 3.40. 
The alcohol 3.42 (37.7 mg, 0.029 mmol, 1 equiv) was dissolved in CH2Cl2 (1.5 mL, 0.02 
M) in a 10 mL round-bottom flask and cooled to 0 oC, then 2,6-lutidine (42 µL, 0.354 
mmol, 12 equiv) was added to the solution followed by TBSOTf (34 µL, 0.148 mmol, 5 
equiv) dropwise via syringe. The reaction was stirred at 0 oC for 30 min and then 
quenched by the addition of MeOH (500 µL) followed by saturated NaHCO3 solution (2 
















mL). The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. Purification was accomplished by flash 
chromatography on a silica gel column (1 × 10 cm), eluting with 5% EtOAc/hexanes 
(800 mL), collecting 5 mL fractions. The fractions containing product (30-67) were 
combined and concentrated under reduced pressure to give the alcohol 3.40 (34.9 mg, 
86%) as colorless oil: Rf = 0.61 (30% EtOAc/hexanes); [α]20D = +16.5 (c = 0.150, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.70-7.64 (m, 4H), 7.45-7.30 (m, 11H), 7.19 (d, J 
= 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.94 (d, J = 16.1 Hz, 1H), 5.88 (s, 1H), 5.59 (s, 
1H), 5.42 (dd, J = 16.1, 5.9 Hz, 1H), 4.79 (s, 2H), 4.79-4.43 (ABq, J = 18.6 Hz, Δν = 
71.4 Hz, 2H), 4.63 (s, 2H), 4.40 (ABq, J = 10.3 Hz, Δν = 28.4 Hz, 2H), 4.09 (m, 2H), 
3.90-3.70 (m, 3H), 3.80 (s, 3H), 3.68 (s, 3H), 3.60 (m, 1H), 3.54-3.43 (m, 2H), 3.30 (s, 
3H), 3.12 (m, 1H), 2.34 (m, 3H), 2.16 (m, 1H), 2.04-1.95 (m, 2H), 1.87-1.75 (m, 4H), 
1.69-1.51 (m, 6H), 1.49-1.34 (m, 4H), 1.33-1.22 (m, 12H), 1.16 (m, 5H), 1.10 (m, 6H), 
1.06 (s, 9H), 0.92 (s, 3H), 0.87 (s, 9H), 0.83 (s, 3H), 0.08 (s, 3H), 0.06 (s, 3H); 125 MHZ 
13C NMR (CDCl3) δ 167.6, 166.6, 159.3, 144.3, 138.3, 138.2, 135.8, 134.1, 134.1, 131.4, 
129.8, 129.5, 129.5, 128.6, 128.0, 128.0, 127.9, 127.3, 114.0, 102.7, 93.3, 81.3, 79.1, 
78.7, 75.9, 75.1, 74.7, 73.4, 72.3, 71.5, 70.4, 69.6, 68.5, 60.7, 55.5, 51.6, 51.3, 51.0, 46.1, 
42.7, 41.6, 39.9, 38.8, 37.9, 36.9, 34.6, 32.5, 32.1, 31.9, 29.9, 29.3, 29.3, 27.6, 27.1, 26.1, 
24.9, 24.2, 22.8, 19.4, 18.3, 14.3, 14.0, -3.8, -4.4; 125 MHz DEPT (CDCl3) CH3 δ 55.2, 
50.9, 50.8, 50.8, 27.4, 26.9, 26.9, 25.9, 25.8, 19.1, 14.0, -4.5; CH2 δ 108.9, 93.0, 72.0, 
69.3, 60.4, 55.4, 42.5, 39.6, 37.8, 36.7, 34.2, 31.7, 31.6, 29.7, 29.2, 29.0, 24.6, 22.6; CH δ 
135.6, 129.5, 129.2, 128.4, 127.8, 127.6, 113.8, 81.0, 78.5, 75.7, 74.5, 73.2; IR (neat) 
3056, 2936, 2859, 1736, 17.45, 1615, 1590, 1473, 1370, 1354, 1146, 1050, 906, 824, 816 
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2-methylbut-3-en-2-yl)tetrahydro-2H-pyran-3-yl octanoate 3.43. The BPS ether 3.40 
(31.3 mg, 0.023 mmol, 1 equiv) was dissolved in DMF (2.3 mL, 0.01 M) in a 10 mL 
round-bottom flask at rt. To this solution were added TBAF (46 µL, 1 M in THF, 0.046 
mmol, 2 equiv) and a solution of AcOH (46 µL, 1 M in DMF, 0.046 mmol, 2 equiv). The 
solution was stirred for 2 d and then diluted with 50% EtOAc/hexanes (2 mL) and 
quenched with water (2 mL). The phases were separated and the aqueous phase was 
extracted with 40% EtOAc/hexanes (3 × 5 mL). The combined organic phases were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. This material was then 
taken to the next step without further purification. 
To a stirring solution of alcohol (assumed to be 0.023 mmol, 1.0 equiv) in CH2Cl2 
(250 µL, 0.1 M), in a 5 mL reaction vial at 0 °C, were added diisopropylethylamine (31 
















was stirred at -10 °C for 5 min and SO3·Py (16 mg, 0.101 mmol, 4.0 equiv) was added in 
one portion.  Stirring continued at -10 °C for 1.5 h, after which the reaction mixture was 
diluted with CH2Cl2 (1 mL) and quenched by the addition of saturated aqueous NaHCO3 
solution (1 mL). The mixture was stirred at rt for 10 min until effervescence was 
complete.  The reaction mixture was then partitioned between CH2Cl2 (5 mL) and 
saturated aqueous NaHCO3 solution (5 mL). The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash chromatography on a silica gel column (1 × 10 cm), eluting 
with 10% EtOAc/hexanes, collecting 9 mL fractions. The fractions containing product 
(45-53) were combined and concentrated under reduced pressure to provide the aldehyde 
3.43 (20 mg, 78%) as colorless oil: Rf = 0.51 (30% EtOAc/hexanes); [α]20D = +16.5 (c = 
0.500, CHCl3); 500 MHz 1H NMR (CDCl3) δ 9.79 (t, J = 2 Hz, 1H), 7.38-7.26 (m, 7H), 
7.25 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.96 (d, J = 16.1 Hz, 1H), 5.89 (s, 1H), 
5.59 (s, 1H), 5.43 (dd, J = 15.6, 5.9 Hz, 1H), 4.80 (s, 2H), 4.64 (m, 3H), 4.48 (m, 3H), 
4.17 (m, 1H), 4.10 (m, 2H), 3.89-3.78 (m, 1H), 3.81 (s, 3H), 3.75 (m, 1H), 3.68 (s, 3H), 
3.56 (m, 1H), 3.53-3.42 (m, 3H), 3.31 (s, 3H), 3.11 (m, 1H), 2.62 (m, 2H), 2.36 (m, 4H), 
2.19 (d, J = 13.7 Hz, 1H), 2.01 (m, 2H), 1.89-1.70 (m, 5H), 1.69-1.54 (m, 8H), 1.53-1.35 
(m, 6H), 1.35-1.15 (m, 8H), 0.93-0.86 (m, 15H), 0.83 (s, 3H), 0.08 (s, 3H), 0.06 (s, 3H); 
125 MHZ 13C NMR (CDCl3) δ 201.7, 172.5, 167.6, 166.7, 159.6, 144.3, 138.6, 138.1, 
137.5, 130.6, 129.5, 129.4, 128.6, 128.6, 128.0, 127.9, 127.8, 127.1, 126.9, 114.1, 109.3, 
102.7, 93.3, 93.2, 81.4, 79.4, 76.0, 75.1, 74.8, 72.4, 72.1, 70.3, 69.6, 66.0, 55.5, 51.6, 
51.3, 51.0, 49.6, 46.1, 42.6, 40.9, 39.9, 39.7, 36.9, 34.6, 32.5, 31.9, 29.9, 29.5, 29.2, 27.6, 
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26.0, 25.6, 24.9, 24.2, 23.6, 22.8, 19.3, 18.2, 15.5, 14.3, 13.9, -3.8, -4.2, -4.4; 125 MHz 
DEPT (CDCl3) CH3 δ 55.3, 50.8, 27.3, 25.8, 19.0, 14.0, -4.5; CH2 δ 109.0, 93.0, 72.1, 
69.3, 49.3, 42.3, 39.6, 39.4, 36.7, 34.3, 31.7, 29.7, 29.0, 29.0, 24.6, 22.6; CH δ 201.4, 
129.3, 129.1, 128.4, 127.8, 127.6, 113.9, 81.2, 78.8, 77.2, 75.8, 74.8, 74.5, 71.9; IR (neat) 
3059, 2936, 2859, 1737, 1612, 1473, 1368, 1355, 1243, 1050, 903, 820, 801 cm-1; HRMS 





tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 3.44. To a stirring 
solution of the aldehyde 3.43 (24.5 mg, 0.022 mmol, 1.0 equiv) in 2-methyl-2-butene 
(548 µL, 0.04 M) and tert-butyl alcohol (1 mL), in a 5 mL reaction vial at rt, was added 
aqueous KH2PO4 solution (438 µL, 1 M in H2O).  The mixture was cooled to -10 °C, and 
NaClO2 (39.6 mg, 0.438 mmol, 20.0 equiv) was added in one portion.  The reaction 
mixture stirred vigorously at -10 °C for 4 h, and was then quenched by the addition of 
aqueous pH 4 buffer solution (1 mL).  The reaction mixture was partitioned between 
CH2Cl2 (5 mL) and aqueous pH 4 buffer solution (5 mL).  The phases were separated, 
















phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The 
product was taken directly to the next step without further purification. 
To a stirring solution of TBS ether (assumed to be 0.022 mmol) in 9:1 
THF/pyridine (2.1 mL, 0.01 M) in a 5 mL plastic vial were added methanol (210 µL) and 
HF·Py (20 %, 1.1 mL). The solution was stirred at rt for 2 d, and then diluted with 50% 
EtOAc/hexanes (100 mL), and washed with brine (2 × 10 mL). The solution was dried 
over Na2SO4 and concentrated under reduced pressure. The crude seco-acid was taken on 
to the next step without purification. 
To a stirring solution of seco-acid (assumed 0.022 mmol) in THF (756 µL, 0.03 
M) at 0 °C in a 15 mL round-bottom flask were added triethylamine (19 µL, 0.136 mmol, 
6.0 equiv) and 2,4,6-trichlorobenzoyl chloride (680 µL, 0.1 M in THF, 0.068 mmol, 3.0 
equiv) by syringe. The solution was stirred at 0 °C for 5 min, then warmed to rt and 
stirred for 2 h. The reaction mixture was diluted with 1:3 THF/toluene (9 mL, 0.0025 M), 
and taken up into a 10.0 mL gas-tight syringe. The resulting solution was added into a 
stirring solution of 4-dimethylaminopyridine  (55 mg, 0.454 mmol, 20 equiv) in toluene 
(15 mL, 0.0015 M) in a 50 mL round-bottom flask at 40 °C over 12 h by means of a 
syringe pump. The vial was rinsed with toluene (2 mL) and the rinsing solution was 
added into the reaction mixture by syringe pump over 3 h. The solution was cooled to rt 
and diluted with 50 mL of 40% EtOAc/hexanes. The solution was washed with saturated 
aqueous NaHCO3 solution (10 mL) and brine (10 mL). The organic phases were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash chromatography on a 1.5 × 10 cm silica gel column, eluting 
with 5% EtOAc/hexanes, collecting 5 mL fractions.  The fractions containing product 
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(13-17) were combined and concentrated under reduced pressure to give the product 
macrolactone 3.44 (12 mg, 50%) as a colorless oil: Rf = 0.64 (30% EtOAc/hexanes); 
[α]20D = +12.5 (c = 0.250, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.44-7.26 (m, 5H), 7.21 
(d, J = 8.3 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.23 (d, J = 15.6 Hz, 1H), 5.94 (m, 1H), 
5.58 (ddd, J = 11.7, 3.9, 1.9 Hz, 1H), 5.33 (dd, J = 8.8, 6.8 Hz, 1H), 5.16 (s, 1H), 4.81 
(m, 4H), 4.64 (ABq, J = 12.2 Hz, Δν = 21.0 Hz, 2H), 4.51-4.40 (ABq, J = 10.3 Hz, Δν  = 
29.8 Hz, 2H), 4.11 (m, 1H), 3.99-3.91 (m, 2H), 3.77-3.65 (m, 2H), 3.74 (s, 3H), 3.69 (s, 
3H), 3.43 (dd, J = 9.8, 9.3 Hz, 1H), 3.31 (m, 1H), 3.08 (s, 3H), 2.78 (d, J = 10.3 Hz, 1H), 
2.63 (dd, J = 15.2, 2.5 Hz, 1 H), 2.46-2.18 (m, 6H), 2.16-1.95 (m, 4H), 1.95-1.76 (m, 
4H), 1.75-1.51 (m, 6H), 1.49-1.19 (m, 10H), 1.09 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H), 0.82 
(s, 3H), 0.79 (s, 3H); 125 MHZ 13C NMR (CDCl3) δ 172.4, 172.2, 166.9, 159.3, 151.5, 
144.6, 142.6, 138.2, 134.5, 131.1, 129.6, 128.6, 128.1, 127.8, 125.5, 119.5, 113.9, 108.9, 
103.4, 93.7, 82.9, 81.7, 73.9, 73.0, 71.9, 70.5, 69.8, 62.3, 55.5, 52.9, 51.3, 45.2, 43.3, 
41.6, 41.2, 40.8, 39.1, 38.8, 34.8, 34.4, 32.2, 31.8, 31.1, 29.9, 29.2, 29.0, 27.3, 26.2, 24.9, 
22.8, 20.0, 18.9, 14.9, 14.2; 125 MHz DEPT (CDCl3) CH3 δ 55.2, 52.6, 51.0, 27.0, 26.0, 
19.8, 18.7, 14.7, 14.0; CH2 δ 108.7, 93.5, 71.7, 69.5, 43.0, 41.3, 40.9, 40.6, 38.8, 38.6, 
34.6, 34.1, 31.6, 30.8, 29.7, 29.0, 28.9, 28.8, 24.6, 22.5; CH δ 142.3, 129.3, 128.4, 127.8, 
127.6, 125.3, 119.2, 113.6, 82.7, 81.4, 76.7, 76.5, 76.4, 73.6, 72.7, 70.3, 67.0; IR (neat) 
3046, 2936, 2859, 1737, 1615, 1590, 1473, 1370, 1354, 1246, 1050, 907, 824, 816 cm-1; 







tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate 3.45. A 100 ml flask 
containing 50 mL of CH2Cl2 was cooled to -78 °C, and a stream of O3 was passed in for 5 
min. The color of the solution changed to light blue. The flask was sealed and kept at -78 
°C for immediate use. This O3 solution was added in 100 µL portion via a plastic syringe 
to a stirring solution of olefin 3.44 (8.4 mg, 0.008 mmol, 1.0 equiv) in CH2Cl2 (1 mL, 
0.01 M) at -78 °C. The reaction was monitored by TLC and the addition of the O3 
solution was continued every 10 min until the starting material was fully consumed. 
Dimethyl sulfide (2 mL) was then added and the mixture was warmed to rt. The solution 
was stirred at rt for 12 h, after which the solvent was removed under reduced pressure. 
Purification was accomplished using flash chromatography on a silica gel column (1 × 10 
cm), eluting with 15% EtOAc/hexanes (600 mL), collecting 5 mL fractions. The fractions 
containing product (38-58) were combined and concentrated under reduced pressure to 
provide ketone 3.45 (6 mg, 78%) as colorless oil: Rf = 0.50 (30% EtOAc/hexanes); [α]20D 
= +25.5 (c = 0.200, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.39-7.28 (m, 5H), 7.21 (d, J 

















1H), 5.32 (dd, J = 15.6, 8.8 Hz, 1H), 5.17 (s, 1H), 4.80 (ABq, J = 6.8 Hz, Δν = 17.6 Hz, 
2H), 4.64 (ABq, J = 11.7 Hz, Δν = 20.0 Hz, 2H), 4.49-4.34 (ABq, J = 10.8 Hz, Δν  = 53.0 
Hz, 2H), 4.28 (ddd, J = 8.8, 8.8, 3.9 Hz, 1H), 4.05 (m, 1H), 3.91 (m, 1H), 3.81-3.62 (m, 
3H), 3.74 (s, 3H), 3.69 (s, 3H), 3.30 (m, 1H), 3.08 (s, 3H), 2.72 (m, 1H), 2.57 (m, 2H), 
2.45-2.34 (m, 4H), 2.28 (m, 2H), 2.20-1.96 (m, 5H), 1.85 (m, 3H), 1.67-1.49 (m, 4H), 
1.49-1.10 (m, 14H), 1.01 (m, 4H), 0.88 (t, J = 6.4 Hz, 3H), 0.83 (s, 3H), 0.77 (s, 3H); 125 
MHZ 13C NMR (CDCl3) δ 206.8, 172.4, 171.9, 166.7, 159.1, 151.1, 143.5, 137.9, 130.5, 
129.4, 128.4, 127.8, 127.6, 123.8, 119.3, 113.7, 103.0, 93.5, 82.0, 79.7, 75.1, 73.5, 72.8, 
71.4, 70.3, 69.5, 67.0, 55.2, 52.5, 51.1, 48.4, 47.7, 45.0, 40.6, 38.7, 34.6, 34.1, 31.8, 31.6, 
30.8, 29.7, 28.9, 28.8, 26.9, 25.9, 24.6, 22.5, 19.6, 18.6, 14.7, 14.0; 125 MHz DEPT 
(CDCl3) CH3 δ 55.2, 52.5, 26.9, 25.9, 18.6, 14.7, 14.0; CH2 δ 93.5, 71.4, 69.5, 53.5, 47.7, 
43.2, 40.7, 38.7, 34.6, 34.1, 31.6, 30.8, 29.7, 28.9, 28.8, 24.6; CH δ 143.6, 129.4, 128.4, 
127.8, 127.6, 123.8, 119.3, 113.7, 82.0, 79.7, 77.2, 76.5, 76.8, 75.1, 73.5, 72.8, 70.3, 67.0, 
28.6, 17.9; IR (neat) 2936, 2859, 2347, 1732, 1652, 1590, 1473, 1370, 1354, 1246, 1050, 
824, 716 cm-1; HRMS (ESI/TOF) Calcd for C59H84O15Na (M + Na+): 1055.5702. Found: 
1055.5714.   
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1H, AND 13C NMR SPECTRA FOR CHAPTER 1
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